DPGU

Dnyaan Prasad Global University

Dr. D. Y. Patil Unitech Society

3.3.1 – Does your university as a body have current collaborations with local, national or global health institutions to improve health & wellbeing outcomes?

Yes.

Dnyaan Prasad Global University (DPGU) is a State Private University established under the aegis of Dr. D. Y. Patil Unitech Society under the Maharashtra Private Universities (Establishment and Regulation) (Amendment) Act, 2024 (Maharashtra Act No. 20 of 2024). Building on more than four decades of educational legacy of Dr. D. Y. Patil Unitech Society, the University is committed to advancing excellence in education, research, innovation and societal development across diverse disciplines.

DPGU comprises six Schools: School of Pharmacy and Research (SPR), School of Management and Research (SMR), School of Hospitality and Tourism (SHT), School of Liberal Arts (SLA), School of Technology and Research (STR), and School of Business and Strategy (SBS). Through this multidisciplinary academic structure, the University promotes academic collaboration, research, innovation, professional development and societal engagement.

The University has current active collaborations with local, national, and global health institutions to improve health and well-being outcomes. These collaborations, particularly through the School of Pharmacy and Research (SPR), encompass pharmaceutical and healthcare research, drug discovery and development, clinical and translational research, public health awareness, healthcare innovation, skill development, internships, and knowledge exchange. Examples include collaborations with AIMST University, Malaysia; Manthan Foundation, Pune; SBM Pharma Tech; Hindustan Antibiotics Limited, Pune; Karaganda University, Kazakhstan; Leiutis Pharmaceuticals LLP, Hyderabad; Forward Life Pvt. Ltd.; Beaver Life Sciences Pvt. Ltd.; SilicoScientia Pvt. Ltd., Bengaluru and various pharmaceutical and healthcare organizations.

These partnerships contribute to SDG 3 (Good Health and Well-being) by strengthening health research, development of therapeutics, healthcare innovation, capacity building, and the skilled healthcare workforce. The University's multidisciplinary academic environment also provides scope for relevant

contributions from its other Schools through their respective academic, research and societal engagement initiatives, wherever supported by documented evidence.

Total MoUs reported: 68

The details of the collaborations, including the collaborating institutions, geographical level, activities undertaken or proposed, and intended impact or outcomes, are presented in the following table.

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
1.	**AIMST University, Malaysia** (26/08/2024 For 03 years)	International	Dr. Sanjeevani Deshkar visited as a member of scientific committee during the International Conference on Drug Discovery and Translational Medicine 2025 (ICDDTM'25), 20th - 27th November 2025. Dr. S. Parasuraman, AIMST University, Malaysia served as evaluator for the Dr. P. D. Patil National Level Award 2025 for Best Thesis in Pharmaceutical Sciences. Dr. K. Venkateskumar, AIMST University, Malaysia served as speaker at the 6th iFDP on "Advances in Biological Insights and Perspectives" (April 20–25, 2026).	Promotes **healthcare research, pharmaceutical education, and knowledge exchange**, contributing to improved **health and well-being** through innovation and capacity building.
2.	**Manthan Foundation, Pune** (22/04/2025 For 05 years)	Local	Organized an awareness session for students on Community Services Sensitization on 23rd May 2025; Organized a Session on Gender Sensitization on 22nd January 2025.	Improves **community health awareness** and supports **public health initiatives**.
3.	**SBM Pharma Tech** (20/01/2025 For 05 years)	National	Organized a webinar on pharmaceutical formulation development and commercialization by an industry expert from Novartis	Drives **innovations in drug delivery systems** and advanced

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
			Healthcare, India (February 4, 2025). Identified a guest speaker for the 6th iFDP on “Advances in Biological Insights and Perspectives” (April 20–25, 2026).	**pharmaceutical formulation**.
4.	**Hindustan Antibiotics Limited, Pimpri, Pune** (01/10/2024 For 03 Years - 30/09/2027)	Local	Working in collaboration on the project entitled Systemic intravenous injection test (IV) in mice as per IP for rubber stoppers, lipolene granules.	Ensures **safety and quality standards** for pharmaceutical products through **applied research**.
5.	**Indus Biotech Limited** (17/07/2024 For 10 Years)	National	Working in collaboration on two projects.	Fosters **innovations in healthcare products** through advanced **pharmaceutical research**.
6.	**Karaganda University, Buketov, Kazakhstan, Karaganda** (16/04/2021 for 5 years till 15/03/2026)	Global	Dr. R. P. Bhole visited E. A. Buketov Karaganda University, Kazakhstan during June 2024 for 04-week duration. Collaborative Research Publications.	Promotes **collaborative research** and knowledge exchange for global health solutions.
7.	**Leiutis Pharmaceuticals LLP, Hyderabad** (14th July 2023 5 years)	National	Project work for any API / new formulation for study of CNS activities in animal model or in vivo cell line study.	Advances the development of **new therapeutics** by researching **CNS activities**.
8.	**Venture Centre, Pune** (15th Oct 2025 for 1 year)	National	Support for mentoring and advisory clinics, Policy design and drafting for innovation management, IPR protection and data management.	Accelerates the market availability of **health innovations** by supporting IPR protection and policy.

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
9.	**Formulaite, Inc., USA** 07/07/2026 For 03Years	International	Research collaboration on herb-drug interactions using Formulaite's bioavailability simulation platform, with the intent of pursuing joint publications and joint applications for research grants	Supports **safer and effective therapeutics** through herb–drug interaction research.
10.	**ICT, Mumbai** 31/07/2026 For 05 Years	National	To promote collaborative research, strengthen exchange of scientific expertise, support student and faculty development, encourage joint grant applications and enable innovation-oriented pharmaceutical and technological research	Promotes **pharmaceutical research and healthcare innovation**.
11.	**Shriya Bhargava, Shri Vayu Wellness Labs** 01/07/2026 Valid until it is expressly terminated by either Party	National	Confidentiality Agreement for Product Development	Supports **healthcare product development and innovation**.
12.	**School of Pharmacy & Health Sciences, United States International University, Africa, Kenya** 04/02/2026 For 05 Years	International	Joint Research Projects, Publications, and Patents, Joint Submission of Research Proposals, Conduct of Joint Conferences, Symposia, and Certification Courses, Faculty Exchange, Student Internships, Sharing of Research Facilities	Promotes **global health research and healthcare innovation**.
13.	**Forward Life Pvt Ltd** 20/02/2026 For 03 Years	National	Placement-oriented interviews were conducted, and selected students were	Develops a **skilled healthcare workforce** through training and placements.

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
			offered internships based on their performance.	
14.	**Marathwada Mitra Mandal's College of Pharmacy, Pune** 15/10/2025 For 05 years	National	Sharing of Research Facilities for Analysis, Consultancy Services	Strengthens **pharmaceutical research and healthcare innovation**.
15.	**Spellbound Inc.** 19/09/2025 Valid until it is expressly terminated by either Party	National	Placement-oriented interviews were conducted, and selected students were offered internships based on their performance.	Develops **skilled professionals for the healthcare industry**.
16.	**Beaver Life Sciences Pvt. Ltd., India** 22/06/2025 Valid until it is expressly terminated by either Party	National	Guest sessions were organized to provide students with industry-oriented knowledge and career guidance. Also Placement-oriented interviews were conducted, selected students were offered internships based On their performance.	Supports **healthcare innovation and pharmaceutical skill development**.
17.	**SilicoScientia Pvt. Ltd., Bengluru** (07/05/2025 1st July 2025 till 30th June 2026)	National	Advanced Diploma Program in Artificial Intelligence and Computational Drug Discovery.	Accelerates new drug identification through training in **Artificial Intelligence and Computational Drug Discovery**.
18.	**Klyntra E-commerce Ventures Pvt. Ltd., Super Tabs Innovations Pvt. Ltd., H2h Global Media Tech Pvt. Ltd.** (13/02/2025 For 10 years)	National	For R & D, Training and Internship activities.	Supports **R&D activities** essential for **healthcare innovation** and talent development.

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
19.	**B & B IP Consortium, Pune** (19/11/2024 For 05 years)	National	IP & Pharma Regulatory related courses, Joint National / International Innovation related event / competitions / sessions / workshop, Training & Placement activities.	Ensures **legal compliance and quality** of healthcare products through **Pharma Regulatory** and IP courses.
20.	**Blue Ocean Compliance, Vadodara, Gujrat** (19/10/2024 For 05 years)	National	Joint National / International Innovation related event / competitions / sessions / workshop, Training & Placement activities, Joint courses, Train the faculty Program, etc.	Builds competence and professionalism in the **pharmaceutical/compliance** workforce.
21.	**Genexis Biotech Pvt. Ltd. Vadodara, Gujarat, India.** (19/10/2024 For 05 years)	National	Joint National / International Innovation related event / competitions / sessions / workshop, Training & Placement activities, Joint courses, Train the faculty Program, etc.	Builds competence and professionalism in the **biotech/ healthcare** workforce.
22.	**Murli Krishna Pharma Private Ltd. MIDC Ranjangaon, Shirur, Pune.** (19/10/2024 For 05 years)	National	Joint National / International Innovation related event / competitions / sessions / workshop, Training & Placement activities, Joint courses, Train the faculty Program, etc.	Builds competence and professionalism in **pharmaceutical manufacturing**.
23.	**Valeshvar Biotech Pvt. Ltd. Gujarat, India.** (19/10/2024 For 05 years)	National	Joint National / International Innovation related event / competitions / sessions / workshop, Training & Placement activities, Joint courses, Train the faculty Program, etc.	Builds competence and professionalism in the **biotech/healthcare** workforce.
24.	**Embiotic Laboratories Pvt. Ltd.**	National	Joint National / International Innovation related event / competitions / sessions /	Supports the development of a **skilled**

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
	Bengaluru, Karnataka,India. (19/10/2024 For 05 years)		workshop, Training & Placement activities, Joint courses, Train the faculty Program, etc.	**pharmaceutical workforce**.
25.	**Arobel International Pvt. Ltd., Hyderabad, Telangana, India** (19/10/2024 For 05 years)	National	Joint National / International Innovation related event / competitions / sessions / workshop, Training & Placement activities, Joint courses, Train the faculty Program, etc.	Supports the development of a **skilled pharmaceutical workforce**.
26.	**Expecto Health Science, Singapore.** (19/10/2024 For 05 years)	National	Joint National / International Innovation related event / competitions / sessions / workshop, Training & Placement activities, Joint courses, Train the faculty Program, etc.	Supports the development of a **skilled health science workforce**.
27.	**Proexp Pharma, Pvt.Ltd, Mumbai, Maharashtra, India** (19/10/2024 For 05 years)	National	Joint National / International Innovation related event / competitions / sessions / workshop, Training & Placement activities, Joint courses, Train the faculty Program, etc.	Supports the development of a **skilled pharmaceutical workforce**.
28.	**Swami Ramanand Teerth Marathwada University, Nanded** (14/10/2024 For 05 Years)	National	Joint Research Projects, Publications, and Patents, Joint Submission of Research Proposals, Conduct of Joint Conferences, Symposia, and Certification Courses, Faculty and Students Exchange/ Trainings, Student Internships, Sharing of Research Facilities.	Advances new **health knowledge** through joint research projects, publications, and patents.

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
29.	**Markians Consult Pvt Ltd, Kharadi, Pune** (06/08/2024 For 05 Years)	National	Facilitating guidance for students seeking higher education opportunities abroad.	Supports the creation of **globally educated health leaders** and professionals.
30.	**Sanovaskale Technologies Pvt. Ltd.** (17/07/2024 For 05 Years)	National	Training & Research Collaboration, Capacity Building & Internship Programs.	Drives **research collaboration** and capacity building in health technology.
31.	**Hemvati Nandan Bahuguna Garhwal University, Uttarakhand** (08/07/2024, For 5 Years)	National	Research Collaboration for students & Staff training programmes.	Advances **new health knowledge** through research collaboration and staff training.
32.	**Climed Research Solution** (27th April 2024, For 36 months till 15th March 2027.)	National	Cooperation and collaboration for job opportunities for Pharm D students.	Ensures qualified Pharm D graduates enter the **clinical research/pharmacy workforce**.
33.	**SIEC Education Pvt Ltd Pune** (16th Jan 2024 For 5 Years)	National	To organise seminars, conferences, workshops for students.	Enhances the **knowledge base and skills** of future healthcare professionals.
34.	**Bell Pharmaceutical ltd** (12th January 2024 For 5 Years)	National	Industrial Exposure in terms of jobs, training etc.	Provides essential **industrial training and job exposure** for the pharmaceutical sector.
35.	**CiRO Pharma ltd** (12th January 2024 For 5 Years)	National	To provide scientific advantages to students, Training.	Enhances student **scientific skills** necessary for the

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
				pharmaceutical industry.
36.	**Operant Pharmacy Federation Ltd** (3 years Date of MoU 12th January 2024)	National	To offer certified courses, workshops to the students.	Elevates the **competence and expertise** of the healthcare workforce through certified courses.
37.	**Orcimed Life Sciences ltd** (12th January 2024 For 5 Years)	National	Team building courses, Placements, Training to the students.	Supports the growth of a **skilled life sciences workforce** through training and placement.
38.	**PES Modern College of Pharmacy (For Ladies), Moshi, Pune.** (03rd Jan 2024 For 5 Years)	National	Collaborative research activities and publication, organization and participation of faculty and students in joint academic and scientific activities like seminars, workshops, trainings and conferences.	Advances **new health knowledge** through collaborative research and academic exchange.
39.	**Indique Life Sciences Pvt Ltd, Pune** (1st January 2024, For 5 Years)	National	To enhance educational opportunities and encourage innovation.	Fosters **innovation** and **educational advancement** in health sciences.
40.	**Pharma Fly, Mumbai** (5th Dec 2023 For 3 years)	National	To send Pharm D students abroad.	Provides **global exposure** for future pharmacists and clinical professionals.
41.	**Chandigarh College of Pharmacy Mohali** (5 Years Date of MoU 4th Oct 2023)	National	Skill based training and education and research. Discussion for Joint Collaborative Project	Focuses on **skill development and research** to enhance pharmaceutical education.

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
42.	**Thetabeta Analgorithams Pvt. Ltd.** (5 Years Date of MoU 21th June 2023)	National	Research Collaboration for product development.	Facilitates **product development research** for new health solutions.
43.	**ST. Johns Fisher University, Rochester, Newwork, USA** (3 years Date of MoU 7th Jan 2023)	International	To promote academic and translational research co-operation two institutes.	Promotes **translational research**, converting laboratory discoveries into practical health treatments.
44.	**Indira college of Pharmacy, Pune** (3 Years Date of MoU 19/12/2022)	National	Research Collaboration, Skill Based Training, Education, Placement, Industrial visit, Expert Lecture.	Supports **collaborative health research** and the development of a skilled workforce.
45.	**Renovare Healthcare Solutions. Belapur, Navi Mumbai** (26/11/2022 Valid till termination)	National	Skill based training, education, placement, internships, expert lectures, etc.	Provides essential **skill-based training and placement** for future healthcare professionals.
46.	**Institute for Tuberculosis Research Chicago, USA** (26 Oct. 2021 Valid until it is expressly terminated by either Party)	International	Research Collaboration.	Dedicated **research on Tuberculosis**, directly contributing to fighting a major global health threat.
47.	**University of Surrey** (08/06/2021 for	International	For the project on clinical evaluation of oxysterols and immunometabolism.	Generates **clinical insights** into disease

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
	the period of 05 years)			mechanisms for new treatments.
48.	**Dr. D.Y.Patil medical college, Hospital and research center, Pimpri, Pune** (w.e.f. 22th March, 2022 for the period of three years)	National	To promote academic and translational research co-operation two institutes.	Bridges drug discovery with **patient care** through academic and translational research.
49.	**Study smart Overseas Education, Pune** (12th January 2022 Valid until it is expressly terminated by either Party)	National	SkillBased Training, Education, Placement, Industrial visit, Expert Lecture.	Cultivates a **skilled global health workforce** through training and international exposure.
50.	**OPERON STRATEGIST** (26th Nov 2021 Valid until it is expressly terminated by either Party)	National	Placement-oriented interviews were conducted, and selected students were offered internships based on their performance.	Supports a **skilled workforce** in pharmaceutical strategy and operations.
51.	**Cadila Healthcare (Zydus Cadila), Ahmedabad, Gujarat** (30th October 2021 Valid until it is expressly terminated by either Party)	National	Campus recruitment activities for internships and job opportunities are currently under process.	Supports a **skilled workforce** for a major pharmaceutical company.
52.	**Advantmed India LLP,**	National	Campus recruitment activities for internships and job	Supports a **skilled workforce** in

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
	Ahmedabad, Gujarat (26 October 2021 Valid until it is expressly terminated by either Party)		opportunities are currently under process.	healthcare technology and consulting.
53.	**Piramal Pharma Solutions, Ahmadabad** (25th October 2021 Valid until it is expressly terminated by either Party)	National	Skill based training, Education, Placement, Industrial visit and Expert lectures.	Supports a **skilled workforce** for pharmaceutical solutions and development.
54.	**Asoj Soft Caps Pvt. Ltd, Vadodara** (10th October 2021 Valid until it is expressly terminated by either Party)	National	Skill based training, Education, Placement, Industrial visit and Expert lectures.	Supports a **skilled workforce** for specialized pharmaceutical manufacturing.
55.	**Solinova Life sciences Pvt Ltd** (27 Sept 2021 for the period of Five years)	National	Academic and research co-operation between the two institutions.	Advances **health research and academic knowledge** through co-operation.
56.	**Dr. D. Y. Patil Biotechnology and Bioinformatics, Tathawade, Pune** (w.e.f. 23th September 2021 for the period of five years)	National	For academic and research Collaboration.	Promotes **interdisciplinary research** critical for modern drug discovery and health data analysis.

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
57.	**Aficionado Technologies Pvt. Ltd., Bangalore** (4th Sept 2021 Valid until it is expressly terminated by either Party)	National	SkillBased Training, Education, Placement, Industrial visit, Expert Lecture.	Supports a **skilled workforce** at the intersection of technology and health.
58.	**Haffkine Biopharmaceuti cal Corporation Limited, Pimpri** (4th Sept 2021 Valid until it is expressly terminated by either Party)	National	Industrial visits and internships were organized to provide students with practical industry exposure, enhance their understanding Of pharmaceutical industry Operations, and develop their professional skills.	Supports a **skilled workforce** for biopharmaceutical production.
59.	**MPrex Healhcare, Wakad, pune** (4th Sept 2021 Valid until it is expressly terminated by either Partis)	National	Placement-oriented interviews were conducted, and selected students were offered internships based on their performance.	Supports a **skilled workforce** for healthcare services.
60.	**Aayush Healhcare, Wakad, Pune** (4th Sept 2021 Valid until it is expressly terminated by either Party)	National	SkillBased Training, Education, Placement, Industrial visit, Expert Lecture.	Supports a **skilled workforce** for healthcare services.
61.	**Cognizance Market Research, Pune, Maharashtra,**	National	SkillBased Training, Education, Placement, Industrial visit, Expert Lecture.	Supports a **skilled workforce** in health market research.

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
	India (3rd Sept 2021 Valid until it is expressly terminated by either Party)			
62.	**OpEx accelerator Pvt. Ltd.** (Valid until it is expressly terminated by either party)	National	For training, education, placement, internships, Expert lecture.	Provides essential **training and placement** for future health professionals.
63.	**Ivan Franko National University Lviv, Ukraine** (w.e.f. 16th March 2021 for the period of Five years)	International	Published joint research papers. To create a means for cooperative efforts to affect the academic and research interchange of faculty and students, and academic and research information between the two Institutions.	Promotes **academic and research exchange** to advance global health science.
64.	**College of Life Sciences, National Chiayi University, Taiwan** (w.e.f. December 2020 for the period of Five years)	International	To create a means for cooperative efforts to affect the academic and research interchange of faculty and students, and academic and research information between the two Institutions.	Promotes **academic and research exchange** to advance global health science.
65.	**DPGU School for Hospitality and Tourism – DoubleTree by Hilton Chinchwad** (10/12/2025; 3 years as stated in MoU)	National	Industry-based internships, training workshops, expert sessions and experiential learning. Health, hygiene, food safety and workplace well-being may be included where supported by documented activities	Supports the development of industry-ready hospitality professionals. Any contribution to health, hygiene, food safety and well-being will be reported based on

Sr. No.	Collaboration Institute (Date/Duration)	Level	Activity Conducted/ Purpose	Impact/ Outcome
				documented activities and outcomes.
66	**Brandtouch & Analytics Private Ltd. (11/7/2025)**	Local	To establish industry–institute collaboration through knowledge exchange, industry interactions, practical exposure and collaborative initiatives. To facilitate opportunities for students and faculty to understand industry practices, emerging trends and professional requirements.	Promotes industry–academia engagement, experiential learning and enhances students' industry readiness through practical knowledge and professional exposure.
67	**Indian Social Responsibility Network (1/10/2025)**	Local	To initiate and undertake collaborative projects, including joint research initiatives, policy briefs, workshops and knowledge-sharing activities, focusing on social responsibility and sustainable development.	Promotes collaborative research, social responsibility, policy development and knowledge dissemination, contributing to community engagement and sustainable institutional practices.
68	**Pune Management Association (10/14/2025)**	Local	To facilitate knowledge-sharing initiatives, management development programmes, expert interactions and professional learning opportunities to bridge the gap between academic knowledge and industry practices.	Strengthens industry–academia linkages, promotes management knowledge and professional development, and enhances students' understanding of contemporary industry practices.

AIMST UNIVERSITY

DYP DPU
Dr. D. Y. Patil Dnyan Prasad University

MEMORANDUM OF UNDERSTANDING

BETWEEN

AIMST UNIVERSITY
MALAYSIA

AND

DR. D.Y. PATIL DNYAN PRASAD UNIVERSITY
INDIA

Dr. D. Y. Patil Dnyan Prasad University
DYP DPU Pune

THIS MEMORANDUM OF UNDERSTANDING made on **26** day of **August** 2024 in two (2) original texts each in the English language, all texts being equally authentic.

BETWEEN

AIMST UNIVERSITY (Co.No.:496741-P), a private university of higher learning established in Malaysia under the Private Higher Education Institutions Act 1996 [Act 555] and having a license number of DU010(K) with its registered address at Batu 3 ½, Jalan Bedong-Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia (hereinafter referred to as "**AIMST**"), of the one part

AND

Dr. D. Y. Patil Unitech society's DR. D. Y. PATIL DNYAN PRASAD UNIVERSITY, (DYP-DPU) Pune, Maharashtra, India, a private university established under Maharashtra Private Universities (Establishment and regulations) (Amendment) Act 2024 (Mah. Act No. XX of 2024). The University is highly committed to providing excellence in education and research in the faculties of Engineering, Pharmaceutical Sciences, Management and allied fields. The University has six constituent units in the field of Engineering, Pharmacy, Management, Hotel management, Law and Humanities. All the constituent units are accredited and recognized by apex bodies like NAAC , NBA, NIRF (hereinafter referred to as "**DYPDPU**"), of the other part

(AIMST and DYPDPU hereinafter referred to singularly as "**the Party**" and collectively as "**the Parties**");

WHEREAS the Parties are desirous of entering this Memorandum of Understanding ("**MoU**") to decalre their respective intentions and to establish a basis of co-operation and collaboration between the Parties upon the terms as contained herein.

Sohanchitlange

Dr. D Y Patil Dnyan Prasad University
DYP DPU Pune

DESIRING to strengthen and further develop the friendly relations between the Parties in the field of academic programmes related to pharmacy coursesand other faculties;

APPRECIATING the importance of enhancing tertiary education for economic development as well as a means to further develop the ties between both Parties;

CONVINCED of the necessity for a lasting and effective cooperation in the interest of the Parties; and

BELIEVING that such cooperation would serve their common interests and contribute to the enhancement of tertiary education for the benefit of both Parties.

NOW BOTH PARTIES HAVE AGREED as follows:

ARTICLE I
OBJECTIVE

The Parties, subject to the terms of this Memorandum of Understanding and the laws, rules, regulations and national policies, of each Party from time to time in force, agree to strengthen, promote and develop cooperation in tertiary education, as well as the development of activities for the purpose of mutual recognition.

ARTICLE II
AREAS OF CO-OPERATION

1. Each Party will, subject to the laws, rules, regulations, procedures and national policies from time to time in force governing or relating to the subject matter of this Memorandum of Understanding, endeavour to take necessary steps to encourage and promote co-operation in the following areas :-

Sohan Chitlange

Dr. D.Y. Patil Dnyan Prasad University DYP DPU Pune

a) Joint Research Projects, Publications, and Patents

Collaboration on research endeavors, facilitating the development of joint research projects, publications, and the filing of patents. This initiative fosters the sharing of expertise and the generation of innovative intellectual property.

b) Joint Submission of Research Proposals

Jointly submitting research proposals to both national and international funding agencies, promoting the pursuit of collaborative research and access to additional resources for scientific exploration.

c) Conduct of Joint Conferences, Symposia, and Certification Courses

Collaborating to organize joint conferences, symposiums, and certification courses. These events serve as platforms for the exchange of knowledge and the enhancement of professional development.

d) Faculty Exchange

The exchange of faculty members between AIMST and Dr. D.Y. Patil Dnyan Prasad University, enabling cross-institutional sharing of expertise, insights, and teaching methods.

e) Student Internships

Offering opportunities for students from both institutions to undertake internships, gaining real-world experience and practical insights into the field of pharmaceutical sciences and other domains thereof.

Sohan Chitlange

Dr. D Y Patil Dnyan Prasad University
DYP DPU Pune

f) Sharing of Research Facilities

Sharing research facilities, which not only optimizes resource utilization but also promotes collaboration on scientific investigations?

Timeline to Implement the Collaboration Agenda:

a) Research activities can be initiated at any time during the memorandum of understanding (MoU) period, fostering ongoing collaboration in this vital area.

b) Joint conferences are scheduled by 2025, allowing the timely exchange of ideas and research findings.

c) Certification courses can be organized at any time during the MoU period, providing opportunities for specialized learning and skill development.

d) Exchange of learning and teaching information remains an ongoing and flexible component throughout the MoU period, ensuring the continuous exchange of knowledge and resources.

e) The Global Immersion Programme (GIP) is planned for June/December 2024 onwards, offering students the chance to immerse themselves in international pharmaceutical practices and research.

The collaboration between AIMST and DYPDPU is driven by the following objectives:

a) To expand networks for students and professionals, creating a global community of learners.

Sohan Chitlange

b) To offer opportunities for students and professionals to participate in conferences, symposiums, and certification courses, fostering their academic and professional growth.

c) To engage in collaborative research projects that promote scientific innovation and knowledge advancement.

2. This collaboration between AIMST and DYPDPU is a testament to the commitment to excellence and innovation in the field of education and research. Through the mutually beneficial initiatives outlined above, both institutions strive to enhance the learning experiences and academic achievements of their students and faculty.

3. . For the purpose of implementing the co-operation in respect of any area stated in paragraph 1, the Parties will enter into a legally binding agreement subject to terms and conditions as mutually agreed upon by the Parties.

4. The Parties will have the right to use and publish any information derived from implementing the cooperation in respect of any area stated in paragraph 1 provided that written consent is obtained from the other Party. In the event that one Party wishes to publish, disclose and/or present (in any form of disclosure) the data and/or the outcomes arising from this Memorandum of Understanding, the Party will submit a draft of each such publication or presentation to the other Party and give the right to have certain parts of the said publication or presentation to be removed or amended by the other Party itself. In any such publication, the contribution of the Parties will be acknowledged.

Dr. D. Y. Patil Dnyan Prasad University
DYP DPU Pune

ARTICLE III
PROJECT STEERING COMMITTEE

1. The Parties will establish a Project Steering Committee (hereinafter referred to as "Project Steering Committee") to review the implementation of this Memorandum of Understanding between the two Parties.

2. The Project Steering Committee will consider ways and means to promote the aforesaid objective and to ensure the proper coordination and implementation of its decisions and/or recommendations. The Project Steering Committee will also review the progress of the implementation of all understandings concluded between the Parties within the framework of this Memorandum of Understanding and take steps to ensure the active and prompt implementation of the understandings.

3. The Project Steering Committee will be chaired by the Registrar of AIMST or alternatively by the Faculty Dean of Pharmacy of AIMST and by the CEO of Dr. D. Y. Patil Unitech Society on behalf of DYPDPU, with participation by other relevant stakeholders of the Parties as appropriate and mutually agreed upon by the Parties.

4. The Project Steering Committee will meet at a date and venue convenient to and decided upon by the Parties.

5. The composition and procedure of the Project Steering Committee will be jointly decided upon by the Parties.

6. The decisions and other conclusions of the Project Steering Committee will be reflected in the minutes of the meeting and the Parties will take appropriate steps to implement these decisions and conclusions as soon as practicable.

Sohan Chitlange

Dr. D Y Patil Dnyan Prasad University
DYP DPU
Pune

ARTICLE IV
EFFECT OF MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding serves only as a record of the Parties' intentions and does not constitute or create, any legally binding or enforceable obligations, express or implies, under domestic or international law.

ARTICLEV
IMPLEMENTATION

In the implementation of this Memorandum of Understanding, AIMST and DYPDPU will arrange the details of any activities to be carried out, recognizing that the exchange of any staff or materials will not necessarily be simultaneously reciprocal.

ARTICLE VI
FINANCIAL ARRANGEMENTS

1. This Memorandum of Understanding will not give rise to any financial obligation by one Party to other.

2. However, commercials for each program mentioned above, will be worked out jointly and after the same is mutually agreed upon by both the parties concerned, they will enter into a separate agreement which will form part of this Memorandum of Understanding.

3. Each Party will bear its own cost and expenses in relation to this Memorandum of Understanding.

Sohan Chitlange

Dr. D Y Patil Dnyan Prasad University
DYP DPU Pune

ARTICLE VII
PARTICIPATION OF THIRD PARTY

Either Party may invite the participation of a third party in the joint activities and/or programmes being carried out under this Memorandum of Understanding subject to written approval of the other Party. In carrying out such joint activities and/or programmes, the third party will be subject to all conditions and provisions of this Memorandum of Understanding unless the Parties agreed otherwise.

ARTICLE VIII
PROTECTION OF INTELLECTUAL PROPERTY RIGHTS

1. The protection of intellectual property (IP) rights will be enforced in conformity with the national laws, rules and regulations of the Parties.

2. The use of the name, logo and/or official emblem of any of the Parties on any publication, document and/or paper is prohibited without the prior written approval of either Party.

3. Notwithstanding anything in paragraph 1 above, the intellectual property rights in respect of any technological development, and any products and services development, carried out :-

   (i) jointly by the Parties and obtained through the joint activity effort of the Parties, will be jointly owned by the Parties in accordance with the terms to be mutually agreed upon; and

   (ii) solely and separately by either Party and obtained through the sole and separate effort of either Party, will be solely owned by the Party concerned.

Sohan Chitlange

Dr. D Y Patil Dnyan Prasad University
DYP DPU
Pune

4. The Parties agree that if any joint projects are undertaken in the course during the active duration of the signed Memorandum of Understanding, they would follow the terms mentioned in paragraph 2 of Article II, to avoid any conflict pertaining to intellectual property (IP) ownership. Therefore, the Parties acknowledge and agree that separate contractual document(s) shall be entered into between AIMST and DYPDPU in relation to IP ownership and commercialization prior to starting any joint projects.

ARTICLE IX
CONFIDENTIALITY

1. Each Party agrees to hold strict confidence any and all **Confidential Information** concerning the Program disclosed by the other Party in connection with this Memorandum of Understanding and **shall not disclose** the same to any third party **without prior written** consent of the other Party and shall not use the same for any other purpose than the Program.
2. The obligations of confidentiality according to this Article shall not apply to such information for which it can be proved that the information:-

   (a) is at the time of disclosure **generally available to the public**;

   (b) becomes after disclosure, generally available to the public through no fault of the receiving Party,

   (c) is prior to the disclosure in the receiving Party's possession as evidenced in the documentary form,

   (d) is received from any third party with a right to disclose; or

Sohan Chitlange

Dr. D Y Patil Dnyan Prasad University
DYP DPU
Pune

(e) is **independently developed** without using information disclosed by the other Party.

3. The Parties agree that the provisions of this Article will continue to be binding between the Parties notwithstanding the termination or suspension of this Memorandum of Understanding .

ARTICLE X
SUSPENSION

Each Party reserves the right for reasons of national security, national interest, public order or public health to suspend temporarily, either in whole or in part, the implementation of this Memorandum of Understanding which suspension shall take effect immediately after written notification has been given to the other Party.

ARTICLE XI
REVISION, MODIFICATION AND AMENDMENT

1. Either Party may request in writing a revision, modification or amendment of all or any part of this Memorandum of Understanding.

2. Any revision, modification or amendment agreed to by the Parties will be reduced into writing and shall form part of this Memorandum of Understanding .

3. Such revision, modification or amendment will enter into force on such date as may be determined by the Parties.

Sohan Chitlange

Dr. D Y Patil Dnyan Prasad University
DYP DPU
Pune

4. Any revision, modification or amendment will not prejudice the rights and obligations arising from or based on this Memorandum of Understanding before or up to the date of such revision, modification or amendment.

ARTICLE XII
SETTLEMENT OF DISPUTES

Any difference or dispute between the Parties concerning the interpretation and/or implementation and/or application of any of the provisions of this Memorandum of Understanding will be settled amicably through mutual consultation and/or negotiations between the Parties, without reference to any third party or international tribunal.

ARTICLE XIII
ENTRY INTO FORCE, DURATION AND TERMINATION

1. This Memorandum of Understanding will come into force on the date of signing and will remain in force for a **period of three (3) years**.

2. Notwithstanding anything in this Article, either Party may terminate this Memorandum of Understanding by notifying the other Party **three (3)** months advance notice in writing of such termination of its intention to terminate this Memorandum of Understanding
3. The termination of this Memorandum of Understanding will not affect the implementation of on-going activities and/or programmes which have been agreed upon before the date of the termination of this Memorandum of Understanding.

Sohan Chitlange

Dr. D Y Patil Dnyan Prasad University
DYP DPU
Pune

ARTICLE XIV
APPLICABLE LAW

This Memorandum of Understanding shall be deemed to have been made and executed in Malaysia and shall be governed and construed in accordance with the laws of Malaysia.

ARTICLE XV
ASSIGNMENT

Except with the prior written approval of the other party, neither party shall assign or transfer the benefits or obligations of this Memorandum of Understandingor any part thereof.

ARTICLE XVI
STAMP DUTY

1. Each party must bear its own costs arising out of the negotiation and preparation of this Memorandum of Understanding.

2. All stamp duty chargeable on this Memorandum of Understanding, on any instrument executed under it, and in respect of any transaction evidenced by this Memorandum of Understandingshall be borne equally by the parties.

ARTICLE XVII
NOTICE

1. Any notice required to be given pursuant to this Agreement shall be in writing and may be delivered or posted by ordinary mail, postage prepaid, to the Party to which such notice is required to be given under this Agreement at the address below.

Sohan Chitlange

To DYPDPU:

Prof.Dr.S.S.Chitlange,

Vice-Chancellor (I/C)

Dr. D. Y. Patil Dnyan Prasad University, Pune &

CEO, Dr. D. Y. Patil Unitech Society,

Sant Tukaram Nagar,

Pune-411018, Maharashtra, India

Telephone: 02067116417/ 02027805292/ 02027805293

Email: vicechancellor@dypdpu.edu.in, ceo@dypvp.edu.in

To AIMST University:

Prof. Dr. Nahlah Elkudssiah Ismail

Dean, Faculty of Pharmacy

AIMST University

Jalan Bedong-Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia

Telephone no.: +604-4298108 ext. 1285

Email: nahlah@aimst.edu.my

2. The addresses referred to in the preceding sub-clause may, from time to time, be changed by written notice.

3. Any notice given under this clause by post shall be deemed to have duly served at the expiration of three (3) clear days (i.e. excluding weekends or public holidays) after the time of such posting and production of any official post office receipt showing the time and date of posting shall be conclusive evidence of the time and date of posting.

4. The Parties acknowledge and agree that the exchange of electronic or fax signature will have the same legal validity as the Parties' signatures if signed in hand copy form.

Dr. D Y Patil Dnyan Prasad University
DYP DPU Pune

ARTICLE XVIII
SUCCESSORS-IN-TITLE

This Memorandum of Understanding shall be binding on the respective heirs, personal representatives, receivers, successors-in-title and of the parties thereto.

ARTICLE XIX
PERSONAL DATA PROTECTION ACT 2010

The parties agree to comply with all data protection provisions including, without limitation, the personal data protection act 2010 and any other applicable legislation relating to data protection.

ARTICLE XX
PROHIBITION OF CORRUPT PRACTICES

Conflict of Interest

1. Neither DYPDPU nor any of its representatives shall give to, or receive from, AIMST or its representatives any commission, fee, rebate, or any gift or entertainment of value in connection with this Memorandum of Understanding.

2. DYPDPU shall:
    a. Promptly notify AIMST of any violation of this clause; and
    b. Repay or credit to AIMST any consideration received as a result of such violation.

3. In addition to the rights AIMST has under this Memorandum of Understanding, if any violation of this Article occurring prior to the date of this Memorandum of Understanding resulted directly or indirectly in AIMST entering into this

Sohan Chitlange

Memorandum of Understanding, AIMST may at its option terminate this Memorandum of Understanding at any time and (despite any other provision of this Memorandum of Understanding) pay no compensation or reimbursement to DYPDPU whatsoever after the date of termination.

4. AIMST shall:
    a. Promptly notify DYPDPU of any violation of this clause; and
    b. Repay or credit to DYPDPU any consideration received as a result of such violation.

5. In addition to the rights DYPDPU has under this Memorandum of Understanding, if any violation of this Article occurring prior to the date of this Memorandum of Understanding resulted directly or indirectly in DYPDPU entering into this Memorandum of Understanding, DYPDPU may at its option terminate this Memorandum of Understanding at any time and (despite any other provision of this Memorandum of Understanding) pay no compensation or reimbursement to AIMST whatsoever after the date of termination.

Anti-Corruption

1. Each Party shall:
    a. comply with all applicable laws relating to anti-corruption including but not limited to regulations of the Malaysian Anti-Corruption Commission Act 2009, in connection with its conduct under this Memorandum of Understanding;

    b. have and shall maintain in place throughout the term of the Memorandum of Understanding its own policies and procedures, to ensure compliance with the laws and will enforce them where appropriate; and

Dr. D Y Patil Dnyan Prasad University
DYP DPU
Pune

c. promptly report to the other Party any request or demand for any undue financial or other advantage of any kind received by it in connection with this Memorandum of Understanding.

2. Each Party shall ensure that any associate (as defined in Section 3 of the Malaysian Anti-Corruption Commission Act 2009) (hereinafter referred to as "Associate") who it involves in the performance of any obligations under this Memorandum of Understanding and/or the provision of support services does so only on the basis of a written agreement which imposes on and secures from such associate terms equivalent to those imposed on the Parties under this Article XX. The Parties shall be responsible for the observance and performance by such associate of such terms, and shall be liable to the other Parties for any breach by such associate of any such terms.

3. The Parties acknowledge and agree that any breach of this Article XX (however trivial) shall be deemed to be an irremediable material breach of this Memorandum of Understanding.

Sohan Chitlange

IN WITNESS WHEREOF, the Parties have caused this Memorandum of Understanding to be executed in their respective names by their duly authorized representatives.

FOR AIMST UNIVERSITY	FOR DR. D. Y. PATIL Unitech Society's Dr. D. Y. Patil Dnyan Prasad University, Pune
..... **PROF. CHM. DR. KATHIRESAN V SATHASIVAM,** Vice-Chancellor and Chief Executive AIMST University Malaysia Witnessed by: 8.12.24 ..... **PROFESSOR DR. KIRAN REDDY** Chief Operating Officer & Academic Advisor AIMST University, Malaysia	..... **DR. SOMNATH PATIL** Secretary Dr. D. Y. Patil Unitech Society Pimpri, Pune, Maharashtra, India Witnessed by: Dr. D. Y. Patil Dnyan Prasad University DYP DPU Pune ..... **DR. SOHAN CHITLANGE** Vice-Chancellor (I/C) Dr. D. Y. Patil Dnyan Prasad University, Pune & Chief Executive Officer Dr. D. Y. Patil Unitech Society, Pune

Malaysian Association for Cancer Research
OS Registration Number: PPM-005-10-18102017

INTERNATIONAL CONFERENCE ON DRUG DISCOVERY AND TRANSLATIONAL MEDICINE 2025 (ICDDTM'25)

"Fostering Global Interdisciplinary Collaboration for Sustainable Innovation in Drug Discovery and Translational Medicine"

Reference: MACR/ICDDTM25/APPOINTMENT/SC/16
Date: 3 March 2025

Professor Dr Sanjeevani Deshkar
Head, Department of Pharmaceutics,
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri Pune, MH state, India

Dear **Professor Dr Sanjeevani Deshkar**,

APPOINTMENT AS A MEMBER OF THE SCIENTIFIC COMMITTEE OF THE INTERNATIONAL CONFERENCE ON DRUG DISCOVERY AND TRANSLATIONAL MEDICINE 2025 (ICDDTM'25)

The Malaysian Association for Cancer Research (MACR), in partnership with local and international universities, will be organising the **International Conference on Drug Discovery and Translational Medicine 2025 (ICDDTM'25)** as follows:

Date	:	26-27 November 2025
Venue (tentative)	:	Hospital Sultan Abdul Aziz Shah, Universiti Putra Malaysia, Selangor, Malaysia

In recognition of your expertise, I am pleased to appoint you as a **Member of the Scientific Committee**. Your responsibilities are detailed in the **Appendix**.

ICDDTM is a biennial conference first launched in 2018 by MACR to provide an international platform for researchers to network and share the latest findings in precision medicine. As the fourth edition of the conference, ICDDTM'25 aims to foster specific research networks and working groups to accelerate the translation of scientific discoveries into effective healthcare solutions.

I hope you will find this appointment a rewarding experience, and I look forward to working with you to make the conference a success.

Thank you very much.

Yours sincerely,

.....
PROFESSOR DR JOHNSON STANSLAS
President, Malaysia Association for Cancer Research
Chair, ICDDTM'25 Organising Committee
Department of Medicine,
Faculty of Medicine and Health Sciences,
Universiti Putra Malaysia,
Serdang, Selangor, Malaysia

icddtm25.macr-cancer.org/

DPGU

Dnyaan Prasad Global University
Dr. D. Y. Patil Unitech Society
School of Pharmacy and Research

MoU with AIMST University, Malaysia

Period of MoU: w.e.f. 26th Aug 2024 (Valid for a total period of 03 years)

Objective of MoU: Joint Research Projects, Conduct of Joint Conferences, Symposia, and Certification Courses, Faculty Exchange, Student Internships, Sharing of Research Facilities

Summary of activities under MOU year wise

Academic year	List the actual activities under each MOU and web - links year-wise
2025-2026	Dr. S. Parasuraman, Associate Professor & Head, Pharmacology, Toxicology and Basic Health Sciences Unit, Faculty of Pharmacy, AIMST University, Malaysia contributed as evaluator for Dr. P. D. Patil National Level Award 2025 for the Best Thesis in Pharmaceutical Sciences.
2025-2026	Dr. K. Venkateskumar, Associate Professor & Unit Head, Pharmaceutical Technology Unit, Faculty of Pharmacy, AIMST University, Malaysia served as speaker during 6th International Faculty Development Program (iFDP) on *"Advances in Biological Insights and Perspectives"* held from April 20–25, 2026.

Dr. A. B. Thomas
Coordinator

Dr. M. K. Shelar
Dy. Director

School of Pharmacy and Research DPGU Pimpri, Pune-18

Dnyaan Prasad Global University
Dr. D. Y. Patil Unitech Society
School of Pharmacy and Research

Ref No.: DPGU/SPR/68/7/2026 Date: 06/04/2026

To,

Dr. S. Parasuraman

Associate Professor & Head,
Pharmacology, Toxicology and Basic Health Sciences Unit,
Faculty of Pharmacy, AIMST University, Malaysia.

Subject: Heartfelt Thanks for Serving as Expert Evaluator for Dr. P. D. Patil National Level Award 2025

Dear Sir,

Greetings from DPGU's School of Pharmacy and Research (formerly Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research)!

On behalf of our institution, we would like to express our sincere gratitude for your valuable contribution as an Expert Evaluator for the Dr. P. D. Patil National Level Award 2025 for the Best Thesis in Pharmaceutical Sciences.

We deeply appreciate your time, efforts, and expertise in evaluating the research work of participating scholars. Your insightful assessment and constructive remarks have played a significant role in maintaining the quality and integrity of this prestigious award. Your support has greatly contributed to encouraging and recognizing emerging talent in the field of pharmaceutical sciences.

It is an honour for us to have your association with this academic initiative, and we look forward to your continued guidance and support in future endeavours.

Thank you once again for your invaluable contribution.

Yours sincerely,

School of Pharmacy & Research Pimpri Pune-18

Dr. Maruti Shelar
Deputy Director

Date: 22/04/2026

Type of Program	6th International FDP on the theme "Advances in Biologicals: Insights and Perspectives"
Resource Person	**Dr. K. Venkateskumar** Associate Professor & Unit Head, Pharmaceutical Technology Unit, Faculty of Pharmacy, AIMST University Malaysia **Topic:** Management of Dry Eye Disease- A Pharmaceutical Insights
	Dr. Ankit Gangrade Research Associate, University of Colorado, Boulder **Topic:** Engineering Biomaterials to Solve Today's Most Pressing Medical Challenges
Date	22nd April 2026
Brief Report	Day 3 of the International Faculty Development Program commenced with a short recap of the previous day's sessions, setting the context for the day's discussions. The first session was delivered by **Dr. K. Venkateskumar**, Associate Professor and Unit Head, Pharmaceutical Technology Unit, Faculty of Pharmacy, AIMST University, Malaysia, on the topic *"Management of Dry Eye Disease – A Pharmaceutical Insight."* The session highlighted the increasing prevalence of dry eye disease, particularly due to prolonged screen exposure. Dr. Venkateskumar explained the role of meibomian gland dysfunction and gut-related factors in disrupting tear film stability and ocular health. He emphasized a holistic management strategy, including tear replenishment, rational use of cyclosporine, and the importance of preservative-free formulations for long-term safety. The session also introduced advanced therapeutic approaches such as tear conservation devices, moisture-retaining spectacles, IPLT, LLLT, and emerging innovations like 3D-printed microneedles, punctal plugs, and surgical interventions for severe cases. Overall, the talk provided a comprehensive pharmaceutical and technology-driven perspective on managing dry eye disease. The second session was conducted by **Dr. Ankit Gangrade**, Research Associate at the University of Colorado, Boulder, on *"Engineering Biomaterials to Solve Today's Most Pressing Medical Challenges."* His talk focused on the development of advanced biomaterials for therapeutic and regenerative applications. He discussed injectable silk-based hydrogels designed for breast tumor and gastric cancer models, enabling localized treatment and tissue regeneration. The session also covered clinically translated shear-thinning laponite–gelatin gels for hepatocellular carcinoma and PRP-based regenerative strategies using dopagelatin and laponite. Dr. Gangrade further elaborated on the theranostic potential of silk fibroin in hemorrhage control and introduced a nanoengineered adhesive hydrogel for treating enterocutaneous fistulas, highlighting its strong adhesion, hemostatic, and

	regenerative capabilities. The session concluded with innovative biomaterial approaches aimed at addressing osteoarthritis, demonstrating the potential of engineered hydrogels and nanocomposites in solving complex medical challenges. Overall, Day 3 offered valuable insights into pharmaceutical innovations and advanced biomaterials, emphasizing their critical role in modern healthcare solutions.

Dr. A. B. Thomas
(Head- R & D)

Dr. Maruti Shelar
(Deputy Director)

Management of Dry Eye Disease: Pharmaceutical Insights



Dr. K. Venkateskumar M.Pharm., PhD SFHEA
Senior Associate Professor & Unit Head
Faculty of Pharmacy
AIMST University
Semeling 08100

Dry Eye Symptoms





Comprehensive Dilated Eye Examination


Biomaterials for Healthcare Solutions
Scaffold
Injectable hydrogels
Micro/Nanoparticles
Our Approach
Applications
Bone Regeneration
(Ganguide et al. 2023)
3D Tumor Model
(Ganguide & Manchal, 2020; Roberto de Barros et al., 2023)
Fistula Treatment
(Ganguide et al. 2025, de Barros, Ganguide et al. 2023)
Hemorrhage Management
Localized Cancer Therapy
(Fiscorne et al., 2022; Ganguide et al., 2020; Ganguide & Manchal, 2019, 2020)
(Haghniaz, Ganguide et al., 2023)


Silk Fibroin Biomaterial
Silk Fibroin is a protein polymer that is spun into fibers by Lepidoptera larvae such as silkworms, spider scorpions, mites and flies
Silk as Biomaterial
Amino acid
Muga
Mori


NIR light and electric field responsive
NIR
Electric field
SWCNT-PA/DOX
Silk hydrogel

MEMORANDUM OF UNDERSTANDING (MoU)

BETWEEN

DYP DPU

School of Pharmacy & Research, Pimpri, Pune 18.

Formerly Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research,
Pimpri, Pune Maharashtra (India)

And

MANTHAN
FOUNDATION
•HEALTH •ENVIRONMENT •EDUCATION
Reg. No. Maha 590/2010/Pune

Manthan Foundation, Budhwar Peth,
Pune, Maharashtra, India

This Memorandum of Understanding (herein after referred to as "MoU") is entered into on this 22nd day of April 2025, by and between:

1. **Dr. D. Y. Patil Dnyan Prasad University's - School of Pharmacy and Research Pimpri, Pune, Maharashtra, India,** was established to impart quality pharmacy education and training to cater to the needs of the pharmacy profession and society at large (hereinafter referred to as "Institute").
2. **Manthan Foundation,** Budhwar Peth, Pune, Maharashtra, India, a non-governmental organization working towards maximizing social impact through sustainable development inclusive of addressing the needs ofcommunity development and society at large (hereinafter referred to as "Foundation").

1. Purpose

The purpose of this MoU is to establish a collaborative partnership between Institute and Foundation based on sustainable developmentapproaches, impartmeaningful collective actions&reflect upon social impact by implementingdiverse social development activities for the benefit of marginalized communities and society at large, inclusive of underserved or less privileged population segments or regions recording lower performance in the development priorities of central or state governments or global governance. A glimpse of primary focus areas, comprises of the following:

- Promoting education, employability and livelihood, empowerment and community welfare.
- Supporting innovation, incubators of Social Enterprises and promotion of financial inclusion.
- Promoting good healthcare and well-being, health care inclusive of mental healthcare, sanitation and safe drinking water.
- Promoting gender equality, empowerment of women and LGBTQIA+ communities. Also,promoting welfare of migrants and displaced persons
- Promoting livelihoods for rural and urban poor including enhancing income of small and marginal farmers and workers in the non-farm sector

- Ensuring environmental sustainability, addressing climate change including mitigation and adaptation, forest and wildlife conservation.
- Supporting other platforms that strengthen the non-profit ecosystem in capacity building and fundraising.
- Bridging the digital divide in internet and mobile phone access, addressing issues of misinformation and data protection.
- Creating a foundational ground towards strengthening the existing partnerships & investments network of the institute and foundation as well upscaling the scope to newer dimensions.
- Leveraging partnerships, investments, resources, expertise, and goodwill of both parties to contribute to the holistic development of society.
- Periodically reviewing, refining and updating this MOU towards appropriately catering and advancing Institute and Foundation objective, action, value and scope of relationships.

2. Scope of Collaboration

Understanding the immense potential of Institute and Foundation, both individually and collectively, the scope is likely to evolve over the coming years. The areas of mutual interest, but is not limited to, are outlined for the 1st year of engagement, expandable to subsequent years, are briefly outlined below:

A. Introductory social development actions	
1	Organize awareness programs, workshops, and training sessions on various social issues
2	Facilitate student participation in community service and social initiatives through volunteering, survey, fieldwork, internship, research, project and program assignments.
3	Be the gender champions, develop insights on prevailing issues for the appropriate responses.
4	Support the healthcare and well-being camps, and environmental awareness campaigns.
5	Participate in committees, forums, etc. to envisage potential risks towards mitigating them.
6	Work together to understand, empower women and children through targeted interventions
7	Actively pursue the awarded projects and volunteering actions for those who reached out
8	Be part of government, industry, institution, organization or individual's impact initiatives
9	Be proactive for being recognized, rewarded trophies, certificates across

Sohan

DYPDPU's School of Pharmacy & Research ★ Pimpri, Pune-18

MANTHAN FOUNDATION MH/580/2010/PN

	diverse touch points
10	Intrinsic drive and motivations through connections, coverage across diverse media platform
11	Take up any other mutually agreed upon initiatives to promote social development & impact.
B. Capacity and capability building programs	
1	Sphere ecosystem where innovative products, services &solutions incubate, strive and thrive.
2	Navigate social universe, be a researcher, a transformative leader, a pioneer behind major movements and an influential thought leader in shaping Science, Technology and Innovation.
3	Evolve and establish a governance Framework, realize value proposition for all stakeholders.
4	Support digital, technological backbone, sustenance, growth of exclusive inclusive movement
5	Expand network of partnerships and lay the foundation for path breaking business models
6	Pilot path breaking business models that in-road the product, services and solution offerings
7	Pioneer mass movement for inclusive growth through those shaping up STEM and innovation
8	Commitment towards formulating the structured pool for projects,volunteering and funding
9	Make available resources, facility
C. Leadership for change and social impact	
1	Drive cultural change by being drivers of change and be change leaders for the societal good
2	Introspect, understand intricacies, gain evolution journey insights so far & existing viewpoint
3	Gain knowledge of key stakeholders, participants, influencers and applicable binding thereof
4	Basic financial skeleton for linear continuity of projects, volunteering and day to day activities
5	Both institute and foundation will at best explore the potential and avenues of collaboration
6	Chart out short, medium as well long-term actions' visibility for spherical ultrasonic growth
7	On-board thought leaders, researchers and individuals those aspiring societal transformation
8	Revisit purpose of collaboration and establish the forward-looking mission, vision

Sohan

DYPDPU's School of Pharmacy & Research Pimpri, Pune-18

Bhatt

DHANVANTARI FOUNDATION

	and values
9	Position the drivers and owners for charting-out horizons of growth and realization thereof
10	Enhance social wellbeing thru making available affordable solutions, services and products.

In line with the scope definition, an action plan is charted as follows :

Sr. No.	ACTION	Sr. No.	ACTION
1	Internal Complaint Committee setup	2	Gender Champion and volunteering
3	Awareness, workshops and training	4	Education sessions for underprivileged
5	Health camp, Env-awareness campaigns	6	Women and children empowerment
7	Research and innovation programs	8	Project execution and realizations
9	Voluntary engagement (10 Hrs+)	10	Framework for experimentations
11	Module development (Med-Kits)	12	Pharmacy framework, execution
13	NGO-INS-IND bonds and connections	14	Internships, Trainings and Placements
15	Advancing rankings and recognitions	16	Domestic, International engagements
17	Organizing of Events and Conferences	18	Usage of Conference rooms, premises
19	Institutionalizing Rewards, Recognitions	20	Connect, facilitate Personalities/Alumni
21	Promote social development initiatives	22	Incubate STEM to innovate and disrupt
23	Create an ecosystem to serve purpose	24	Deriving the value creation approaches
25	Any other actions as may be deemed fit		

DYPDPU's School of Pharmacy & Research ★ Pimpri, Pune-18

MANTHAN FOUNDATION MH/590/2010/PN

Based on 1st year engagement and progress, MOU will undergo an iteration for its revision with potential advanced actions and social impacts for subsequent years of institute and foundation engagements in times to come.

3. Roles and Responsibilities

3.1 Dr. D. Y. Patil Dnyan Prasad University's - School of Pharmacy and Research agrees to:

- Provide necessary infrastructure, space, and resources for conducting joint activities, programs, and workshops.
- Encourage faculty and student involvement in social development programs organized by the Foundation.
- Integrate community development efforts with academic coursework and extracurricular activities where possible.
- Coordinate with Manthan Foundation to plan and execute joint social development projects.

3.2 **Manthan Foundation** agrees to:

- Develop and implement social development initiatives that align with the needs of the community and the expertise available at the College.
- Provide technical assistance, training, and guidance for conducting various social programs.
- Share best practices and resources with the College to enhance the quality and impact of community engagement activities.
- Mobilize community participants and oversee the execution of social programs in coordination with the College.

4. Financial Arrangements

Each party will bear its own costs unless otherwise agreed upon in writing for specific projects. Any project requiring financial contributions from both parties will be subject to a separate agreement detailing the funding arrangements.

5. Monitoring and Evaluation

Both parties will jointly monitor and evaluate the progress and impact of the social development programs. Regular meetings and progress reports will be exchanged to ensure transparency and effective implementation.

6. Duration and Termination

This MoU shall remain in effect for a period of 5 years, commencing from the date of signing. Either party may terminate this MoU by providing 30 days written notice to the other party.

DYPDPU's School of Pharmacy & Research Pimpri, Pune-18

MANTHAN FOUNDATION MH/590/ 2010/PN

7. Amendments

Any amendments to this MoU shall be made in writing and agreed upon by both parties.

8. Dispute Resolution

In case of any disputes arising out of or related to this MoU, the parties agree to resolve them amicably through mutual discussions. If the dispute cannot be resolved, it may be referred to an independent arbitrator whose decision shall be binding on both parties.

9. Legal Status

This MoU is not intended to create any legally binding obligations between the parties but serves as a mutual agreement to collaborate for social development. Any legally binding contracts or agreements for specific projects will be drafted separately.

Signed on 22nd of April 2025:

For Dr. D. Y. Patil Dnyan Prasad University's - School of Pharmacy and Research

Name : Dr. Sohan S. Chitlange

Designation : **Vice Chancellor (I/C) DYPDPU & Director, SPR**

Signature : Sohan Chitlange

Date : 22/04/2025

DYPDPU's School of Pharmacy & Research Pimpri, Pune-18

For Manthan Foundation, Pune, India:

Name : Mrs. Asha Bhatt

Designation : **President**

MANTHAN FOUNDATION MH/590/2010/PN

Signature : Bhatt

Date : 22nd Apr 2025

Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri, Pune- 411018

Date: 21/01/2025

Notice

All the students (Girls) of **F. Y. D. Pharm, F. Y. B. Pharm, F. Y. Pharm. D. and F. Y. M. Pharm** are hereby informed that the ICC cell of the Institute is organizing an expert session on **"Gender Sensitization"** by **Mrs. Asha Bhatt, President, Manthan Foundation, Pune** on **Wednesday, 22nd Jaunuary 2025** in **Seminar Hall** from **03:00 pm onwards.**

Dr. L. P. Kothapalli
(Presiding Officer)

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research * Pimpri, Pune-18.

Dr. S. S. Bhujbal
(Vice Principal)

Vision

To be recognized globally for its excellence in pursuit of newer horizons to build self-reliant pharmacist through quality pharmacy education.

Mission

To impart high-quality technical education and training that enables students to acquire in-depth knowledge and expertise in the field of pharmaceutical sciences to cater the needs of pharmacy profession and society at large.

Dr. D.Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research
Pimpri, Pune – 411018

Date: 28/01/2025

REPORT

Type of program	Guest Session
Resource person	Ms. Asha Bhat, President of the Manthan Foundation, Pune
Topic	Gender Sensitization
Date	22nd January 2025
Brief report	The ICC of DPU Pharmacy, Pune, organized a session on Gender Sensitization on 22nd January 2025. The session highlighted the importance of raising awareness about gender roles, stereotypes, and biases, emphasizing that gender equality is a universal concern. It clarified distinctions between biological differences (sex) and socially constructed roles (gender), with an inclusive approach to diverse identities like male, female, and non-binary. Common stereotypes, such as "women are emotional" or "men are breadwinners," were discussed for their role in reinforcing discrimination and limiting opportunities, perpetuating economic, educational, healthcare, and social inequalities. Ms. Bhat emphasized the significance of gender sensitization in fostering inclusivity, reducing gender-based violence, and creating equitable communities. Steps toward achieving this include education, open communication, advocating inclusive policies, and empowering individuals. Practical actions, such as supporting equal opportunities, using gender-neutral language, and challenging sexist remarks, were suggested. Institutions such as schools, workplaces, and media were identified as pivotal in driving change through gender-neutral curricula, fair pay, and inclusive representation. The session reinforced the need for collective efforts to build a respectful and equitable society.
POs Mapped	A, K

Dr. L.P. Kothapalli
(Incharge- ICC)

Dr. S. S. Bhujbal
(Vice Principal)


Gender
Sensitization
Understanding, Challenging, and
Promoting Gender Equality






Gender



SBM PharmaTech

DYP DPU

MEMORANDUM OF UNDERSTANDING

SBM PHARMATECH

&

Dr. D. Y. PATIL INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH, PIMPRI, PUNE

TRAINING AND RESEARCH COLLABORATIONS

MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding (hereinafter called as the 'MoU') is entered on 20th January 2025 between **SBM PharmaTech**, represented herein by Mr. Sujith Nair, hereinafter referred as 'First Party', the company whose expression, unless excluded by or repugnant to the subject or context shall include its successors – in-office, administrators and assigns.

AND

Dr. D. Y. Patil Unitech Society's, Dr. D. Y. Patil Institute Pharmaceutical Sciences and Research, Pimpri, Pune (DPU Pharmacy) and represented herein by Dr. Sohan Chitlange, hereinafter referred to as "Second Party", the institution whose expression, unless excluded by or repugnant to the subject or context shall include its successors --- in-office, administrators and assigns.

(First Party and Second Party are hereinafter jointly referred to as 'Parties' and individually as 'Party')

Sohan Chitlange

WHEREAS:

First Party- **SBM PharmaTech**, a company incorporated under the laws of India, having its registered place of business at Office No. 7, Radhika Avenue, Jagtap Dairy, Pimple Nilak, Pune-411027, India.

And

Second Party -Dr. D. Y. Patil Unitech Society's, Dr. D. Y. Patil Institute Pharmaceutical Sciences and Research, Pimpri, Pune (DPU Pharmacy) is a pioneer pharmacy institute in the country established in 1994. The institute offers Diploma in Pharmacy (D. Pharm), Bachelor of Pharmacy (B. Pharm), Masters of Pharmacy (M. Pharm in Pharmaceutics, Pharmaceutical Quality Assurance & Pharmacology), Doctor of Pharmacy (Pharm D), and also Doctorate (PhD) program in all 04 disciplines viz Pharmaceutics, Pharm. Chemistry, Pharmacology and Pharmacognosy. It is approved by AICTE, PCI, MSBTE and SavitribaiPhule Pune University, Pune. The Undergraduate program is reaccredited by National Board of Accreditation (NBA) New Delhi for the period of Five (05) years and accredited by National Assessment and Accreditation Council (NAAC), Bengaluru with 'A++' Grade (CGPA 3.77). The institute has been ranked amongst top 50 pharmacy institution in India consecutively for three years (2017-2022) by NIRF, Ministry of Human resource development, New Delhi and amongst Top 10 promising pharmacy colleges in India by Higher Education Review and by Academic Insights. The Institute is also recognized under section 2 (f) and 12 (b) from UGC, New Delhi and certified by ISO 9001:2008, 14001:2004.

B) First Party & Second Party believe that collaboration and co-operation between the organizations will promote more effective use of each of their resources, and provide each of them with enhanced opportunities.

C) The Parties intend to cooperate and focus their efforts on cooperation within areas of skill based training, education and research.

D) Both Parties, being legal entities in themselves desire to sign this MoU for advancing their mutual interests.

PURPOSE OF THE MoU

The purpose of this MOU is to establish a framework for Training and research collaboration between **SBM PharmaTech** and **DPU Pharmacy**. The areas of collaboration will include, but are not limited to, research collaboration, training for faculty and students, capacity building, and internship programs.

NOW THEREFORE, IN CONSIDERATION OF THE MUTUAL PROMISES SET FORTH IN THIS MoU, THE PARTIES HERE TO AGREE AS FOLLOWS:

Sohan Chitlange

CLAUSE 1

CO-OPERATION

1.1 Both Parties are united by common interests and objectives, and they shall establish channels of communication and co-operation that will promote and advance their respective operations within the Institution and its related wings. The Parties shall keep each other informed of potential opportunities and shall share all information that may be relevant to secure additional opportunities for one another.

1.2 First Party and Second Party co-operation will facilitate effective utilization of the intellectual capabilities of the personal of the First Party and Second Party in providing significant inputs in developing suitable research, and training systems.

1.3 The general terms of co-operation shall be governed by this MoU. The Parties shall cooperate with each other and shall, as promptly as is reasonably practical, enter into all relevant agreements, deeds and documents (the 'Definitive Documents') as may be required to give effect to the actions contemplated in terms of this MoU. The term of Definitive Documents shall be mutually decided between the Parties. Along with the Definitive Documents, this MoU shall represent the entire understanding as to the subject matter hereof and shall supersede any prior understanding between the Parties on the subject matter hereof.

CLAUSE 2

SCOPE OF THE MoU

2.1 Both parties believe that close co-operation between the two would be of major benefit to the student community to enhance their skills and knowledge.

2.2 Trainings and Internships
SBM PharmaTech will provide trainings in various areas of their expertise to the faculty and students of DPU Pharmacy. The financial involvements included in such training will be discussed and mutually agreed between the two parties as and when required.
Further, SBM PharmaTech will also provide internships to the students of DPU Pharmacy which may include training in specific departments of their company for a specified period of time in order to bridge the skill gap and make them industry ready.

2.3 Placement Drives and Industry Tie-ups: Both parties agree to organize campus recruitment drives by leveraging their network of partner companies and industry contacts. SBM PharmaTech will conduct pre-placement workshops and training sessions focused on key areas such as resume building, interview preparation, and corporate etiquette.

2.4 Research and Development: Both Parties may carry out the joint research activities in the field of Pharmaceutical Sciences on mutual acceptance. Collaboration will broadly include but not limited to: Joint research projects in areas of mutual interest, Co-publication of research

Sohan Chitlange

findings in academic journals, Joint organization of research conferences, workshops, and seminars. SBM PharmaTech will support for the commercialization of patents held by faculty members.

2.5 Promotion of facilities for consultancy activities: Both parties agree to collaborate in the development and promotion of state-of-the-art infrastructural and laboratory facilities to support consultancy activities. One party agrees to actively promote and facilitate the use of the facilities available at the other party's location to generate consultancy opportunities for them. The promoting party will encourage and connect potential clients with the available facilities, helping to generate consultancy engagements and foster business growth. Both parties will collaborate to ensure that the facilities remain up-to-date and suitable for the consultancy needs, thus driving effective and innovative solutions.

2.6 Short-Term Professional Courses: Both parties will design and deliver industry-relevant certificate courses in emerging fields, including pharmaceutical research and development, quality control, quality assurance, clinical research, pharmacovigilance, intellectual property rights, regulatory affairs, and computer system validation. These courses will be available to both in-house and external candidates, with SBM PharmaTech utilizing its skilled manpower to conduct and deliver the training.

2.7 Faculty-Led Projects: By fostering an environment of collaboration, this initiative will drive mutual growth, innovation, and the translation of academic research into practical, market-driven solutions. This approach will not only benefit faculty members but also contribute to the broader objectives of advancing technology and knowledge transfer.

2.8 Both Parties to obtain all internal approvals, consents and permissions of whatsoever nature required for offering any of the above mentioned components on the terms specified herein.

2.9 There is no financial commitment on both the parties. If there is any financial consideration, it will be dealt separately.

CLAUSE 3

INTELLECTUAL PROPERTY

3. 1 The intellectual property right of the Product jointly developed through this MoU, including the future advancements shall be jointly owned by Both Parties.

3. 2 The rights for IPs owned and independently developed by First Party and Second Party, but used in the development of Product shall rest with the original owner.

3. 3 Second Party will have the right for first refusal for the Products jointly developed through this engagement for commercialization purpose.

3. 4 No transfer of any ownership or license therein is made regarding any intellectual property of the same, including but not limited to the trademark, patent, trade secret, copyright etc. under this MoU, without the consent from both Parties.

Sohan Chitlange

CLAUSE 4

VALIDITY

4.1 This Agreement will be valid for a period of 5 years until it is expressly terminated by either Party on mutually agreed terms.
4.2 Both Parties may terminate this MoU upon 30 calendar days' notice in writing. In the event of Termination, both parties have to discharge their obligations.

CLAUSE 5

AMENDMENTS & CONFIDENTIALITY

This MOU may be amended by mutual written consent of the Parties. Any amendments will be documented in writing and signed by authorized representatives of both Parties.

The Parties agree to maintain the confidentiality of any proprietary or confidential information shared during the course of this collaboration, in accordance with their respective policies and procedures.

CLAUSE 6

RELATIONSHIP BETWEEN THE PARTIES

6.1 The Parties agree to designate coordinators to oversee the implementation of this MoU and to develop detailed plans for each area of collaboration. Regular meetings will be held to review progress and plan future activities.
6.2 It is expressly agreed that SBM PharmaTech and DPU Pharmacy are acting under this MoU as independent contractors, and the relationship established under this MoU shall not be construed as a partnership.
6.3 Neither Party is authorized to use the other Party's name in any way, to make any representations or create any obligation or liability, expressed or implied, on behalf of the other Party, without the prior written consent of the other Party.
6.4 Neither Party shall have, nor represent itself as having, any authority under the terms of this MoU to make agreements of any kind in the name of or binding upon the other Party, to pledge the other Party's credit, or to extend credit on behalf of the other Party.

Any divergence or difference derived from the interpretation or application of the MoU shall be resolved by arbitration between the parties as per the Arbitration Act, 1996. The place of the arbitration shall be at District Headquarters of either of the Party. This undertaking is to be construed in accordance with Indian Law with exclusive jurisdiction in the said parties.

IN WITNESS WHEREOF, the Parties have executed this MoU as of the day and year first above written.

Sohan Chitlange

AGREED:

For	For
SBM PharmaTech	**Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune-411018**
Authorized Signatory	**Authorized Signatory**
Mr. Sujith Nair, **Technical Lead,** SBM PharmaTech, Pune	**Dr. S. S. Chitlange,** **CEO,** Dr. D. Y. Patil Unitech Society and **Principal,** Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India
Witness 1: **Mr. Bhushan Tarwate** **SBM PharmaTech**	**Witness 1:** **Dr. A. B. Thomas** **Professor and Head-Pharm Chem,** **DPU Pharmacy, Pune**
Witness 2: **Mr. Aniket Joshi** **SBM PharmaTech**	**Witness 2:** **Dr. Rakesh Mishra** **Training and Placement Officer,** **DPU Pharmacy, Pune**

Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research,
Pimpri, Pune - 411018

Date: 04/02/2025

Type of Program	**Webinar**
Resource Person	Dr. Manoj Rawat, Project Leader, Novartis Healthcare Pvt. Ltd., India.
Topic	From Concept to Commercialization: The Phases of Pharmaceutical Formulation Development
Date	04/02/2025
Brief Report	On February 4, 2025, DYPDPU Pharmacy, in collaboration with SBM PharmaTech, organized a webinar titled "From Concept to Commercialization: The Phases of Pharmaceutical Formulation Development." The session was led by Dr. Manoj Rawat, Project Leader at Novartis Healthcare Pvt. Ltd., India. During the webinar, Dr. Rawat provided a comprehensive overview of the critical stages involved in pharmaceutical formulation development, highlighting the importance of each phase in ensuring the safety and efficacy of the final product. The discussion covered several key phases in the development process, including pre-formulation studies, where the physicochemical properties of active pharmaceutical ingredients (APIs) are evaluated, and formulation design, which focuses on creating stable and effective dosage forms. Dr. Rawat also elaborated on process development, which involves scaling up from laboratory research to commercial manufacturing, as well as the clinical trial phase, where safety and efficacy are tested in human subjects. The regulatory approval process was also discussed, shedding light on the necessary steps for bringing a drug to market. Throughout the webinar, Dr. Rawat shared insights into the challenges commonly encountered during formulation development, such as stability concerns, bioavailability issues, and manufacturing complexities. He offered solutions to these problems, emphasizing the role of advanced technologies and strict adherence to regulatory guidelines. This event underscored the importance of a structured, collaborative approach to pharmaceutical formulation development and highlighted the efforts required to bring safe and effective medications to market.
PO's Attained	A, C, D, F, I, K

Dr. A. B. Thomas
(Head, R&D)

Dr. S. S. Bhujbal
(Vice-Principal)


Akshit Chourasia
Asha Thomas
Pranali Jadhav
Tambare Ujwal
Concept to Commercialization: The Phases of NCE Formulation Development
Feb 2025
Manoj Rawat, PhD, PMP
Clinical Supply Project Lead
Novartis Healthcare Pvt Ltd India
"The views and opinions expressed in this presentation are those of the presenter and do not necessarily reflect the official policy or position of Novartis or any of its affiliates or officers"


Akshit Chourasia
Asha Thomas
Pranali Jadhav
Tambare Ujwal
QBD
Quality by design
Risk Assessment
Design of Experiments
Process Analytical Technology
Quality by Design
Risk Identification
Risk Analysis
Risk Evaluation
Wet Media Milling DoE
Spray Drying DoE
Formulation DoE
Particle Size
Total Product Yield
Stable Spray Dried Nanocrystalline Drug Products
Quality Risk Management
Design Space (Product and Process Design)
Critical Analysis and Process Validation
Control Strategy and Continuous Improvement
QBD:
FMEA
QBD
DOE protocol


Pranali Jadhav
Shrujal Mehta
Asmak's iPhone
Swati Dude
iPhone
Tambare Ujwal
iPhone
omkar Mali
Khushbu thakre
Sonal Gokule
Snehal Sawale
Ms Sayali

भारतीय गैर न्यायिक

भारत INDIA

रु. 500 FIVE HUNDRED RUPEES

पाँच सौ रुपये Rs. 500

सत्यमेव जयते

INDIA NON JUDICIAL

महाराष्ट्र MAHARASHTRA ◑ 2024 ◑ CT 307460

सह दुय्यम कोषागार अधिकारी पुणे

09 OCT 2024

प्रथम मुद्रांक लिपीक कोषागार पुणे करिता

NOTARY M. V. GOKHALE PIMPRI CHINCHWAD PUNE, MAHARASHTRA Reg. No. 4621 Exp. Dt. 17/09/2027 GOVERNMENT OF INDIA

The Pune Lawyers Consumers co-op Society Ltd. Pune 5

Memorandum of Understanding

This Agreement is made on the 01 st day of October, 2024

BETWEEN

Hindustan Antibiotics Limited is wholly owned Govt. of India, Public Sector Enterprise engaged in manufacturing of life saving drugs. It was established in 1954 with WHO/UNICEF assistance. It is pioneer manufacturer of Penicillin, Streptomycin, Tetracycline, Polyene antibiotics (Hamycin &

Aureofungin). It manufactures life saving drugs at affordable prices. In 1980, the company has diversified in the formulation manufacturing. The manufacturing facilities available are (a) Bulk (b) Formulations (c) Powder Injectables (d) Large Volume Parenteral drugs, Non-Parenteral drugs, agricultural facility. (Hereinafter referred to as "**H.A. Ltd**" which expression, unless repugnant to the subject or context therein, shall mean and include its affiliates, employees, assignees, subsidiaries, nominees, agents & successors-in-interest), of the FIRST PART.

AND

Dr. D. Y. Patil Unitech Society's Dr. D. Y. Patil Institute Pharmaceutical Sciences & Research, Pimpri, Pune is a pioneer pharmacy institute of Pimpri - chinchwad area established in 1994. The institute offers Diploma in Pharmacy (D. Pharm), Bachelor of Pharmacy (B. Pharm), Masters of Pharmacy (M. Pharm in Pharmaceutics, Pharmaceutical Quality Assurance & Pharmacology), Doctor of Pharmacy (Pharm D), and also, doctorate (PhD) in all 04 disciplines viz Pharmaceutics, Pharm. Chemistry, Pharmacology and Pharmacognosy. It is approved by AICTE, PCI, MSBTE and Savitribai Phule Pune University, Pune. (Hereinafter referred to as **DYPIPSR** which expression, unless repugnant to the subject or context therein, shall mean and include its affiliates, employees, assignees, subsidiaries, nominees, agents & successors-in-interest), of the SECOND PART.

H.A.Ltd and DYPIPSR shall hereinafter sometimes individually be referred to as the "Party" and collectively as the "Parties".

WHEREAS:-

The parties have discussed and deliberate on various items of mutual interest and benefits and have deemed expedient to execute this memorandum of understanding to mutually cooperate as per below:

A. DYPIPSR has animal house facility which is approved by Committee for the Purpose of Control and Supervision of Experiments on Animals (**CCSEA**) and expertise for day to day supervision of animals.

B. H. A. Ltd would like to utilize DYPIPSR's Animal House Facility to conduct **Systemic Injection (Intravenous) Test in mice as per Indian Pharmacopoeia for rubber stoppers, Leupolene granules.**
The details of our animal requirement are as follows:

No. of mice required	: 05 mice per test per sample + 05 Mice for control sample
Weight range	: Between 18 – 22 gms
Annual No. of mice required	: Approx. 250 per year
No. of samples	: Approx. 25 samples

For performing this test, H. A. Ltd. QCL staff will bring necessary material (sample) for testing along with the sterile syringes as per the requirement. H. A. Ltd. shall utilize Animals (mice), Animal house facility and experimental room available in DYPIPSR. H. A. Ltd. staff will visit for observation (72 hours) after the sample is injected.
Since, DYPIPSR does not have permission of CCSEA for breeding of animals, DYPIPSR will have to procure mice (in required weight range) for H. A. Ltd. H. A. Ltd. shall inform to DYPIPSR about requirement of mice well in advance.

C. For utilizing Animal House Facility of DYPIPSR for conducting **Systemic Injection (Intravenous) Test in mice as per Indian Pharmacopoeia for rubber stoppers & Leupolene granules,** H. A. Ltd will pay an amount of as per the quotation submitted by DYPIPSR dated 11.10.2024 for the period mentioned below :

No.	Period	Approx. Amount (Incl. 18 % GST)
1	01.10.2024 to 30.09.2025	Rs. 79650.00
2	01.10.2025 to 30.09.2026	Rs. 84960.00
3	01.10.2026 to 30.09.2027	Rs. 90270.00

Note:- (The total payable amount will vary depending upon actual numbers of animals used and number of days of study). As and when after utilizing Animal facility of DYPIPSR by H.A.Ltd for testing, the bill will be generated by DYPIPSR and the payment will be done by H.A.Ltd accordingly.

D. DYPIPSR and H. A. Ltd will not disclose any confidential and technical information of joint work with any other party, without consultation and written approval of each other.

1. <u>Arbitration:</u>
If any dispute arises between the parties about the interpretation or implementation of this agreement, or any clause of this agreement, the parties shall endeavor to settle such dispute amicably. In case of failure by the parties to resolve the dispute in the manner set out above within 60 (Sixty) days from the date when the dispute arose, the dispute shall be referred to arbitration of a sole arbitrator, having summery powers to be appointed by the statutory auditors of the company. The place of arbitration shall be at Pune. The arbitration proceeding shall be governed by the arbitration and conciliation act, 1996 as may be amended and modified from time to time.

2. <u>Governing Law and Jurisdiction:</u>
This Agreement shall be governed by and interpreted in all respects in accordance with the laws of India and the parties hereby submit to the exclusive jurisdiction of the Courts at Pune with respect to the subject

matter of this Agreement. Notwithstanding any other rights of either Party, either Party may seek injunctive relief in any court of competent jurisdiction against improper use.

3. **Authorization:**
The persons whose signatures appear below certify that they are authorized to enter this Agreement on behalf of the Party for whom they sign.

4. **Validity:**
This MoU will be valid for a period of Three years from the date **01.10.2024 to 30.09.2027** by both the parties as per mutually agreed terms and conditions. If the MoU is not extended after three years, then the ongoing activities will be completed and no further new activities will be initiated, till renewal. This shall be informed to CCSEA for their information.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective duly authorized representatives.

THIS AGREEMENT has been signed on the date first above written.

FOR AND ON BEHALF OF H.A.Ltd. - SIGNED BY

SIGNATURE: _____
NAME: **Mr.S.B.Mukherjee**
DESIGNATION: Assistant Manager (R & D / QAD / QCL / LRP)

S.B. MUKHERJEE
ASSISTANT MANAGER
(R&D / QAD / QCL / LRP)
HINDUSTAN ANTIBIOTICS LIMITED
Pimpri, Pune- 411018.

WITNESS :

SIGNATURE : _____
NAME: **Mr.Satish Kumar**
DESIGNATION: Company Secretary

SATISH KUMAR / सतिश कुमार
Company Secretary & Sr. Officer (Admin)
कंपनी सचिव और वरिष्ठ अधिकारी (प्रशासन)
Hindustan Antibiotics Limited
हिंदुस्तान एंटिबायोटिक्स लिमिटेड
Pimpri, Pune- 411018.
पिंपरी, पुणे- 411018.

FOR AND ON BEHALF OF DYPIPSR. - SIGNED BY

SIGNATURE: _____
NAME: **Dr. S. S. Chitlange**
DESIGNATION: Principal, Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Pune

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research, Pimpri, Pune-18.

WITNESS :

SIGNATURE: _____
NAME: **Dr. Vaishali R.Undale**
DESIGNATION: HOD (Pharmacology)

BEFORE ME
18/11/2024
MAKARAND V. GOKHALE
ADVOCATE & NOTARY (GOVT. OF INDIA)
2120, Sant Tukaram Nagar,
Pimpri, Pune- 411 018.
Maharashtra

NOTARIAL NOTARIAL NOTARIAL NOTARIAL NOTARIAL

Noted and Registered at Serial No. 62/2024
'18 NOV 2024

भारतीय गैर न्यायिक

भारत INDIA

रु. 500 FIVE HUNDRED RUPEES

पाँच सौ रुपये Rs. 500

सत्यमेव जयते

INDIA NON JUDICIAL

महाराष्ट्र MAHARASHTRA ◐ 2023 ◐ CN 477923

ज्या कारणासाठी जास्त मुद्रांक घेतले ते स्पष्ट करणेसाठी.

मुद्रांक खरेदी करणाऱ्यांची नोंदणीकृत दस्तऐवजाशी संबंधकारक नाही.

अनु.क्र. 3315 दि. 11-7-2024 मु.शु.रक्कम 500/-

दस्ताचा प्रकार करारनामा

दस्त नोंदणी करणार आहेत का ? होय/नाही.

मिळकतीचे वर्णन

मुद्रांक विक्रेता इंडस बायोटेक लिमिटेड

पत्ता सांगवी विश्व पुणे

दुय्यम दस्ताचा क्रमांक

इतर तपशील राशीन गायकवाड - पुणे

मुद्रांक विकत घेणाऱ्याची सही

डॉ. दिपक किसन पाटणे
प्रॉक्सी ऑफिसर
परवाना क्र. २३८१००१
२३३ वानवडी, रामटेकडी, पुणे

दस्तिक कोषागार अधिकारी पुणे

03 JUL 2024

प्रथम मुद्रांक लिपीक कोषागार पुणे करिता

MASTER SERVICE AGREEMENT

This Stamp Paper forms an integral part of the Master Service Agreement executed on 17th July 2024 between Indus Biotech Limited and Dr D.Y. Patil Institute of Pharmaceutical Sciences and Research

Dr. D.Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

MASTER SERVICES AGREEMENT

This Master Services Agreement (**"Agreement"**) is made effective as of the 17th day of July, 2024 (**"Effective Date"**) by and between

INDUS BIOTECH LIMITED, a company incorporated under the laws of India and having its registered office at 1, Rahul Residency, Plot nos. 6 & 7, Off Salunke Vihar Road, Kondhwa, Pune, Maharashtra, India (hereinafter referred to as the "**Indus**"), (which expression shall unless repugnant to the meaning or context thereof, be deemed to mean and include its successors and assigns) of the **FIRST PART**

AND

Dr D. Y. Patil Unitech Society's, Dr D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, 411018 (hereinafter referred to as the **"INSTITUTE"**), (which expression shall unless repugnant to the meaning or context thereof, be deemed to mean and include its successors and assigns) of the **SECOND PART**

Indus and INSTITUTE, wherever the context so requires, hereinafter referred to individually as the "Party" and collectively as the "Parties"

WHEREAS:

a. Indus is engaged in the business of inter-alia researching, developing and manufacturing ethical formulations for chronic indications from botanical sources as well as functional ingredients from natural resources

b. The INSTITUTE is a pioneer pharmacy institute of Pimpri Chinchwad area established in 1994. The institute offers Bachelor of Pharmacy (B. Pharm), Master of Pharmacy (M. Pharm in Pharmaceutics, Pharmaceutical Quality Assurance & Pharmacology), Doctor of Pharmacy (Pharm D) and also, doctorate (PhD) in all 04 disciplines viz Pharmaceutics, Pharm. Chemistry, Pharmacology and Pharmacognosy. It is approved by AICTE, PCI and Savitribai Phule Pune University, Pune and accredited by NBA and NAAC. The institute is engaged in academic and research activity.

c. Indus wishes to engage the services of the INSTITUTE in the areas of "Contract Services for Research and development in the Interest of Indus Products and allied fields".

d. The Parties wish to contract with each other, subject to and in accordance with the terms and conditions detailed herein.

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

Indus	INSTITUTE

NOW IT IS HEREBY AGREED BY THE PARTIES AS FOLLOWS:

1. Purpose of the Agreement and Project; Nature of Services.

1.1 Project

The Project includes services which the INSTITUTE will perform including and related to scientific studies, payment schedules and milestones, project reports, associated data and documents and any additional terms and conditions as applicable to the INSTITUTE's provision of services to Indus which upon signature and execution by both Parties shall be deemed incorporated herein **("Project")**

1.2 Services

The services shall be in the fields of Contract Services for Research and development in the interest of Indus products and allied fields and shall specifically comprise those detailed in such protocol, reports, data and other associated documents in a timely manner as agreed, including preparation and submission of a final report in a mutually agreed format to Indus along with necessary appendices, to enable Indus to understand and use such information described therein on its own. **(collectively, the "Services").**

a) If any provision of a project shall conflict with a provision of this Agreement, the provisions within this Agreement shall govern, unless specifically stated otherwise within the Project.

b) Any changes to the Services shall be subject to a mutual agreement by the Parties. The details of such changes (e.g. budget impact, scope of services changes, etc.) shall be agreed upon in writing and memorialized via an amendment to the applicable Project.

2. Delivery of Services.

(a) The **INSTITUTE** performs and warrants that it will provide, the Services: (i) in accordance with the terms of the project included in or referenced in the applicable project; (ii) to the best of its ability in a professional manner consistent with industry standards; (iii) in accordance with the standard of care customarily observed with regard to such services in the **INSTITUTE**'s field of expertise; (iv) in accordance with the **INSTITUTE**'s standard operating procedures as such relate to the Services; (v) in a timely and efficient manner.

(b) In the event of a breach by **INSTITUTE** of its warranties and/ or representations and/or undertakings in Sections 2 (a) or other breach of the Agreement, the **INSTITUTE** shall, at Indus's option and as Indus's sole remedy, either: (i) repeat the Services at the **INSTITUTE's** own cost, including the costs of any materials required to repeat the Services, including Materials; or (ii) where possible, take corrective action, at the **INSTITUTE**'s own cost, to remedy the breach to Indus's satisfaction; or (iii) refund to Indus the contract price paid for the Services plus the cost of any materials, including Materials, provided by Indus to the **INSTITUTE**.

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

Indus	INSTITUTE

(c) The **INSTITUTE** will prepare and maintain complete and accurate records and data for the Services and will maintain such records and data with respect to a project, including the raw data both in digital and physical format for three (3) years (or less upon Indus's request) after completion of the Services. All records related to the project will be transferred to Indus three (3) years after completion of the Services or earlier if requested by Indus. After such transfer, the **INSTITUTE** shall have no further obligation under this Section 2(c).

(d) Upon reasonable notice and at reasonable times or as required by applicable law or regulation, the **INSTITUTE** will permit Indus or its representatives, any regulatory agency of applicable jurisdiction (**"Regulatory Agency"**) to access to the records maintained pursuant to this Section 2 for purposes of source data verification, auditing or inspection. Where any Regulatory Agency notifies the **INSTITUTE** that it will inspect the **INSTITUTE**'s records, facilities, equipment or procedures, or otherwise take action related to this Agreement or any project related document then the **INSTITUTE** shall: (i) immediately notify Indus of such; (ii) allow the Regulatory Agency to conduct such inspection or take other action; (iii) allow Indus to be present at such inspection (where time and the relevant Regulatory Agency permit); (iv) allow Indus to participate in any response to the Regulatory Agency; and (v) provide Indus with copies of any reports or correspondence issued by the Regulatory Agency relating to this Agreement or Protocol or which may impact performance of the Services being provided hereunder, together with the **INSTITUTE**'s proposed response, for Indus's review and prior approval (such approval not to be unreasonably withheld).

3. **Materials.**

(a) Indus will provide the **INSTITUTE** with sufficient amounts of all Indus proprietary materials, or other substances with which to perform the Services, as specified in the applicable Protocol (**"Materials"**), as well as such sufficient and comprehensive data as may be reasonably required by the **INSTITUTE** concerning the stability of the Materials, storage and safety requirements, including a Material Safety Data Sheet as required by applicable law.

(b) The **INSTITUTE** will use the Materials only in the performance of the Services as specified in the applicable Protocol. The **INSTITUTE** shall not, and shall not permit the use of, either the Materials or any other biological materials treated therewith in human beings, or in any other studies unless specifically included in the Protocol.

(c) The **INSTITUTE** shall not distribute or release Materials to any person or institution other than those under the direct supervision and responsibility of the **INSTITUTE** and shall ensure that no one will be allowed to take or send Materials to any other location, unless specifically written in the Protocol.

(d) The **INSTITUTE** shall not provide or permit the provision of Materials to any person or institution that has not entered into a written agreement with the **INSTITUTE** that permits the **INSTITUTE** and Indus to enforce the restrictions contained in this

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

Indus	INSTITUTE

Agreement against such person or institution. The **INSTITUTE** agrees to comply with all laws and regulations applicable to the handling and use of the Material in the course of rendering the Services.

(e) Indus retains all rights, title and interest in and to the Materials. Nothing in this Agreement shall be construed to grant or imply any right or license to use, make or sell the Materials or any Indus patents or patent applications for any purpose other than as expressly permitted herein. Indus shall be free without restriction to distribute the Materials to others and use them for its own purposes. In accordance with Indus's instructions, the **INSTITUTE** will promptly return to Indus or otherwise dispose of any quantities of the Materials remaining after completion of the Services and will certify such disposition in writing.

(f) Indus provides all Materials and Confidential Information "as is" with no warranty, express, implied or statutory, including without limitation warranties of merchantability, title, non-infringement, exclusivity, or fitness for a particular purpose.

(g) The **INSTITUTE** warrants that the Material shall not be:
- (i) used in research that is subject to consulting or licensing obligations of any third party.
- (ii) modified in any way, reverse engineered or used for reproduction.
- (iii) Used in any manner which infringes upon or violates the intellectual property rights of any third party.

4. Compensation.

Indus shall compensate the INSTITUTE for services rendered in accordance with the agreed milestones and budget as listed in the protocol attached to this agreement including expenses at actuals and pass-through costs (subject to Indus's prior written approval). Unless otherwise agreed in particular, the following shall apply:

(a) Institute will invoice Indus for the fees, expenses at actuals and pass-through costs incurred in performing the Services as per the project milestone; The payments shall be disbursed only when the documentation is received as per the milestones specified in the project

(b) Indus shall pay each invoice within thirty (30) days from the date of receipt of the invoice. If any portion of an invoice is disputed, then the Indus shall pay the undisputed amounts as set forth in the preceding sentence and the Parties shall use good faith efforts to reconcile the disputed amount as soon as practicable.

(c) Unless otherwise indicated in the respective project, all budgets, invoices and payments under this Agreement will be in Indian currency and shall be deemed to include deduction of applicable taxes

(d) Payee Name: Dr. D.Y. Patil Institute of Pharmaceutical Sciences & Research

Dr. D.Y. Patil Inst. of Pharm. Sci & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

Indus	INSTITUTE

Bank Name: Bank of Maharashtra
Account No: 60102689281
IFSC Code: MAHB0001280
E-mail ID: sanjeevani.deshkar@dypvp.edu.in, pharmacy.accounts@dypvp.edu.in
Contact Name and No: Dr. Sanjeevani Deshkar, 9850547454
Mob: 9850547454

5. Confidentiality.

(a) **"Confidential Information"** means confidential or proprietary information of Indus either disclosed orally or in writing to or otherwise learned by the INSTITUTE under this Agreement that should reasonably be known to be confidential or proprietary to Indus, including but not limited to information relating to Indus's: research, development, preclinical and clinical programs, data and results; pharmaceutical or biologic or any other candidates and products; inventions, works of authorship, trade secrets, processes, conceptions, formulas, patents, patent applications, and licenses; IP Rights (as defined in Section 6); business, product, marketing, sales, scientific and technical strategies, programs and results, including costs and prices; suppliers, manufacturers, customers, market data, personnel, and consultants; and other confidential matters related to Indus.

(b) Subject to Section 5(a), until ten (10) years after the expiration or termination of this Agreement, the INSTITUTE:

(i) shall not use Confidential Information except for the purpose of performing Services;
(ii) will hold Confidential Information in strictest confidence and shall not disclose Confidential Information to others, except for its employees or agents who require Confidential Information for the purpose of performing Services and who are subject to binding obligations of confidentiality and restricted use at least as protective as those of this Agreement;
(iii) will protect the confidentiality of Confidential Information using at least the same level of efforts and measures used to protect its own confidential information, and at least commercially reasonable efforts and measures, including without limitation limiting access to Confidential Information commensurate with performance of the Services and keeping adequate records of those with access to Confidential Information and of all uses or dispositions of Confidential Information; and
(iv) will notify Indus as promptly as practicable of any unauthorized use or disclosure of Confidential Information;

(c) The INSTITUTE's obligations under Section 5(b) shall not apply to any Confidential Information that:
(i) The INSTITUTE knew prior to learning it under this Agreement, as demonstrated by written records predating the date it was learned under this Agreement;

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

Indus	INSTITUTE

(ii) is now, or becomes in the future, publicly available other than by an act or omission of the INSTITUTE;

(iii) a third party discloses to the INSTITUTE as a matter of right, without any restriction on disclosure, and without any breach of any direct or indirect obligation of confidentiality to Indus, as shown by the INSTITUTE's written records contemporaneous with such third party disclosure; or

(iv) the INSTITUTE independently develops without use of or reference to Confidential Information, as demonstrated by the INSTITUTE's independent written records contemporaneous with such development.

(d) Notwithstanding other provisions of this Agreement, the INSTITUTE may disclose Confidential Information to the extent and to the persons or entities required under applicable governmental law, rule, regulation or order, provided that the INSTITUTE: (i) first gives prompt notice of such disclosure requirement to Indus so as to enable Indus to seek any limitations on or exemptions from such disclosure requirement; and (ii) reasonably cooperates at Indus's request in any such efforts by Indus.

(e) Upon the earlier of the completion of a Project or termination of this Agreement or Indus's request for any reason, the INSTITUTE will: (i) immediately cease all use of all Confidential Information disclosed hereunder; and (ii) promptly, at Indus's instruction, either return to Indus or destroy all Confidential Information disclosed thereunder, including any copies, extracts, summaries, or derivative works thereof, and certify in writing to Indus the completion of such return and/or destruction, *provided, however,* that the INSTITUTE may retain one copy solely for archival purposes.

(f) Indus retains all right, title and interest in and to Confidential Information. This Agreement gives the INSTITUTE no right or license to any Confidential Information or any intellectual property or other rights owned by or licensed to Indus, by implication or otherwise, except the right to use Confidential Information solely for performance of the applicable Services. Indus may freely transfer, disclose and/or use Confidential Information for its or others' purposes.

(g) The INSTITUTE acknowledges that any actual or threatened breach of this Section 5 will cause Indus immediate and irreparable harm that cannot be adequately compensated by monetary damages, and it therefore agrees that Indus shall have the right to secure equitable and injunctive relief under this Agreement in addition to any other remedies that may be legally available.

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

Indus	INSTITUTE

6. **Intellectual Property.**

(a) The INSTITUTE hereby acknowledges that Indus owns all right, title and interest to and in any intellectual property disclosed to the INSTITUTE in the course of performance of the Services hereunder, including Materials and confidential and/or proprietary information.

(b) The INSTITUTE hereby agrees that Indus is and shall be the sole owner of all documents, data and intellectual property rights created in the course of performance of the Services hereunder and the INSTITUTE hereby assigns to Indus all of the INSTITUTE's right, title and interest in and to any intellectual property rights arising from inventions, software programs, databases, or other discoveries made, conceived, reduced to practice, authored or otherwise developed solely or jointly by the INSTITUTE or any of the INSTITUTE's employees or agents in whole or in part through the course of performance of the Services hereunder and/ or the use of Confidential Information (**"IP Rights"**), together with the right to sue for damages for infringement or misuse.

(c) The INSTITUTE will promptly notify Indus of any IP Rights promptly upon learning of them and fully disclose the details of such. The INSTITUTE will promptly execute all/any patent and copyright applications or other such documents required to protect, enforce or perfect Indus's right, title and interest in and to such IP Rights, as may be required under the law of any country. The INSTITUTE hereby grants Indus an irrevocable power of attorney to execute on the INSTITUTE's behalf, if the INSTITUTE does not promptly do so, patent and copyright applications or other such documents required to protect, enforce or perfect Indus's right, title and interest in and to such IP Rights.

(d) It is acknowledged by Indus that the INSTITUTE, as at the Effective Date, possesses certain intellectual property rights that were created by the INSTITUTE, are its property and are used by the INSTITUTE in its business and do not relate to Indus or its Confidential Information or Materials ("the INSTITUTE's **Background IP**"). Indus agrees that any modifications and/or improvements to the INSTITUTE Background IP which are made during the course of the Services and are unrelated to Indus or its Confidential Information or Materials, shall be the property of the INSTITUTE. The INSTITUTE grants Indus an irrevocable, non-exclusive, worldwide, perpetual, royalty-free license to use any the INSTITUTE's Background IP for the sole purpose of use and/or interpretation of the results, data and information generated from the Services.

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

Indus	INSTITUTE

7. **Representation and Warranties.**

The INSTITUTE represents and warrants to Indus that:

(a) The INSTITUTE has the full right, power and authority to enter into this Agreement and perform its obligations hereunder without the consent of any third party and without breach of any agreements with or obligations to any third party;

(b) The INSTITUTE will not grant, transfer, assign or convey, directly or indirectly, any right, title or interest in or to any IP Rights to any third party;

(c) The INSTITUTE shall require its employees, officers, directors, agents and subcontractors ("**Representatives**") in connection with this Agreement and any Protocol to comply with the obligations herein and shall be responsible for all acts of Representatives as if such were its own; and

(d) The INSTITUTE has not entered and will not enter into any agreement with or obligation to a third party inconsistent, incompatible, or conflicting with its obligations under this Agreement.

8. **Indemnification.**

(a) Each Party will defend, indemnify and hold harmless the other Party, its officers, directors, employees, sublicenses, customers and agents from and against any and all losses, liabilities, damages, expenses and costs (including reasonable attorney's fees) ("**Losses**") resulting from third party claims, demands, suits or proceedings arising out of the first Party's actual or alleged material breach of this Agreement or its negligence, recklessness or willful misconduct in the course of activities carried out in connection with this Agreement *provided that* each Party shall not be required to indemnify the other Party where, and to the extent that, Losses arose from the negligence, recklessness or willful misconduct of the Party seeking indemnification. Each Party will notify the other Party promptly upon learning of a claim, demand, suit, or proceeding that might give rise to a Loss, and the potentially indemnifying Party may control defense and settlement thereof provided it does so diligently, in good faith, and using reasonably experienced counsel with expertise in the relevant field. The potentially indemnified Party will reasonably cooperate in such defense and/or settlement at the potentially indemnifying Party's request and expense and may participate at its own expense using its own counsel.

(b) The rights and obligations of the Parties under this Section shall not be limited by the provisions regarding limitation of liability as set forth in Section 2(d) hereof.

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

Indus	INSTITUTE

9. **Term and Termination.**

(a) The initial term of this Agreement shall commence on the Effective Date and expire Ten (10) years therefrom, unless earlier terminated under this Section 9. Expiration of this Agreement shall not terminate any Protocols then in effect, which shall continue to be governed by the terms of this Agreement.

(b) Either Party may terminate this Agreement for a material breach by the other Party upon thirty (30) days written notice specifying the breach unless such breach is cured within such thirty (30) day period. Each Party may terminate a project for a material breach by the other Party upon thirty (30) days written notice specifying the breach unless such breach is cured within such thirty (30) day period.

(c) Either Party may terminate this Agreement at any time upon sixty (60) days written notice, but such termination shall not terminate any project then in effect, which shall continue to be governed by the terms of this Agreement.

(d) Indus may terminate any project upon sixty (60) days written notice on the basis of business, financial, scientific, technical or regulatory conditions pertaining to Indus or its product(s) or program(s) that are the subject of the Services.

(e) In the event of any early termination, any properly and necessarily incurred but unpaid fees relating to a completed or ongoing project shall be paid by Indus provided that a valid invoice is presented within thirty (30) days of termination and the termination was not by Indus for cause or by the INSTITUTE at will. In the event of any sums prepaid by Indus in respect of Services not completed, the INSTITUTE shall promptly reimburse such prepaid sums in full.

(f) Expiration or termination of this Agreement shall not affect accrued rights or obligations of the Parties. Sections 2(d), 2(e), 3(c), 3(d), 5, 6, 7(b), 7(c), 7(d), 7(e), 8, 9(e), 10 and 11 shall survive termination or expiration of this Agreement.

10. **Publication.**

Publication includes but is not limited to Books, Book Chapters, Journal Articles, Conference Papers, Reference Work, Computer Software, Inventions, Creative Work, Reports, Translations, Legal Case, Map, Newspaper/Magazine Articles, Thesis and Audio-visual material. **("Publication")**

a. **Promotional Activities:** Indus reserves all rights to conduct and manage any and all promotional activities related to the project.

b. **Journal Articles:** Either Party shall provide thirty (30) days written notice to the other Party prior to submitting any journal article relating to the services, materials, confidential information, or IP rights arising from this project. During this period, the

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

Indus	INSTITUTE

other Party shall have the opportunity to review the proposed article to protect its interests and rights. In the event of a journal article being rejected for publication, or one and a half years after the completion of the project (i.e. receipt of the final report) Indus shall have the sole right to its publication.

c. **Thesis:** In the event that a work related to project is allotted to a student at the Institute as part of fulfillment of their degree program, the Institute agrees to provide the Company with the following information in writing:

   i) Name of the Student
   ii) Title of the Thesis
   iii) Expected Timeframe for Completion and such other relevant information as may be necessary.

The Institute will seek and obtain written permission from Indus prior to the initiation of the thesis project. The project will not commence until such written permission is granted.

d. **Other Publications**: For any publications other than journal articles, Indus reserves all rights to its publications.

e. **Consent to Publication:** The Company may withhold its consent to any publication for appropriate business reasons. The determination of what constitutes an appropriate business reason shall be at the sole discretion of Indus.

11. Relationship

This Agreement creates no relationship of joint ventures, partners, and associates or of principal and agent between the parties hereto. The INSTITUTE shall not incur any obligation or commitment, whether express or implied on behalf of the Indus. It is further agreed by the Parties that each party is responsible for all of its employees and agents and its labor costs and expenses.

12. Counterparts

This Agreement may be executed simultaneously in any number of counterparts, each of which when executed and delivered will be deemed an original, but all of which will constitute one and the same instrument and any Party may execute this Agreement by signing any one or more of such originals or counterparts.

13. General

(a) This Agreement shall be interpreted and enforced in accordance with the laws of India. The Parties will submit any dispute or claim arising under this Agreement to the exclusive jurisdiction of the Pune Court, and the Parties hereby submit to, and waive any objection to, personal jurisdiction and venue in such courts for such purpose. The language of the proceedings shall be in English.

D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

Indus	INSTITUTE

(b) Any purported assignment or delegation by the INSTITUTE of this Agreement in whole or in part without the prior written consent of Indus shall be void. Indus has the unconditional right to assign this Agreement if there is no resulting material change in the scope of the Services. This Agreement shall be binding upon the Parties, their successors and their permitted assigns.

(c) All notices under this Agreement shall be in writing and shall be deemed given upon personal delivery, facsimile transmission with electronic confirmation of transmission, delivery by internationally- or nationally-recognized bonded courier service, or seven (7) days after sending by certified or registered mail, postage prepaid and return receipt requested, to the following addresses or facsimile numbers of the respective Parties or such other address or facsimile number as given by notice under this Section 11(c):

Indus:	Indus Biotech Limited At the address set forth at the beginning of the Agreement Attention: Dr. Prasad Thakurdesai Telephone: +91 020 64785063
THE INSTITUTE:	The INSTITUTE At the address set forth at the beginning of the Agreement. Attention: Dr. Sohan chitlange Telephone: 9850547454

(d) If either Party is affected by a force majeure event (namely, a civil commotion, embargo, governmental legislation or regulation, riot, invasion, war, threat of or preparation for war, fire, explosion, storm, flood, earthquake, subsidence, epidemic or other natural physical disaster or such like), it shall immediately notify the other Party in writing of the matter constituting the force majeure event and shall keep the other Party fully informed of its continuance or relevant change in circumstance. The force majeure event shall not entitle either Party to terminate this Agreement unless such event subsists for a period of three (3) months or more, in which event the terminating Party shall notify the other Party in writing. Prior to such event subsisting for three (3) months or more, neither Party shall be deemed in breach of this Agreement by reason of delay in performance of its obligations hereunder due to such event.

(e) This Agreement sets forth the complete, final and exclusive agreement between the Parties and supersedes and terminates all prior agreements and understandings between the Parties. No amendment to, or waiver of right under, this Agreement is effective unless in writing signed by authorized representatives of the Parties. No waiver by a Party of any breach of this Agreement shall be a waiver of any preceding or succeeding breach. No waiver by a Party of any right under this Agreement shall be construed as a waiver of any other right. If any provision of this Agreement is judicially or administratively determined to be unenforceable, the provision will be reformed to most nearly approximate the Parties' original intent, but otherwise this Agreement will continue in full force and effect.

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Indus Biotech Limited Pune

Indus	INSTITUTE

(f) No person who is not a Party (including any officer, employee, agent, representative or subcontractor of either Party) shall have the right to enforce any provision of this Agreement or a Project which expressly or by implication confers a benefit on that person without the express prior written agreement of the Parties, which agreement must refer to this Section.

The Parties have entered into this Agreement as of the Effective Date by their duly authorized representatives.

INDUS BIOTECH LIMITED

Indus Biotech Limited Pune

By:
Name: Dr. Prasad Thakurdesai

Title: Chief Scientific Officer

Witness:

1. Pallavi Deshpande Pdeshpande
2. Ajinkya Deosthali Deosthali

Dr D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri.

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

By:
Name: Dr. Sohan chitlange

Title: Principal, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pune & CEO Administration, Dr. D. Y. Patil Unitech Society, Pune

Witness:

1. Dr. Sanjeevani S. Deshkar Deshkar
2. Dr. Vinita Patole VPatole

Indus	INSTITUTE

Date: 30/09/2024

To,

Dr. Sanjeevani Deshkar

Professor and Head

Department of Pharmaceutics

Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,

Pimpri, Pune-411018

Subject: Acceptance of Budget Proposal of the project Development of a Fenugreek seed derived exosome-based product for Cosmetic applications

Dear Ma'am,

We accept enclosed budget proposal reference no. DPU/Pharmacy/1115A/2024 dated 27th September 2024 for Development of a Fenugreek seed derived exosome-based product for Cosmetic applications.

Enclosure: DPU/Pharmacy/1115A/2024

For INDUS BIOTECH LIMITED

Indus Biotech Limited Pune

Authorized signatory

Indus Biotech Limited

(Formerly known as Indus Biotech Private Limited)

Registered Office

1, Rahul Residency, Plot No. 6 & 7, Off. Salunke Vihar Road, Kondhwa, Pune - 411 048, Maharashtra, INDIA

Tel : +91 20 26851239 / 26852139 | Email : Info@indusbiotech.com | www.indusbiotech.com

Company Identification Number : U24231MH1995PLC085656

Dr. D. Y. Patil Unitech Society's

DPU

DR. D. Y. PATIL INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH, PUNE

(Affiliated to Savitribai Phule Pune University ID No. PU/PN/Pharm/104/94)

(Approved by Pharmacy Council of India)

NAAC Accredited 2nd Cycle ('A++' Grade with 3.77 CGPA) | AISHE CODE C-41223

Ranked amongst top 50 Pharmacy Colleges by NIRF, New Delhi | Mentor - Industry Linked Institute AICTE-CII | Recipient of 'Best College Award' by Savitribai Phule Pune University

Dr. P. D. Patil, Chairman | Dr. (Mrs.) Bhagyashree Patil, Vice Chairperson | Dr. Somnath Patil, Secretary | Dr. Sohan Chitlange, Principal

Ref. No. : DPU/Pharmacy/1115A/2024 Date : 27/09/2024

Budget Proposal of the project for Indus biotech Ltd. (2024-2025)

Title of project: Development of a fenugreek seed-derived exosome-based product for cosmetic applications

Investigators: Dr. Sanjeevani Deshkar, Dr. Asha Thomas

Objective-wise activities, milestones, approx. cost and timeline of project

Ob No.	Activity	Milestone payments and Document List	Approx. Cost (Rs.)	Duration of objective
OB1	**Preparation of exosome-rich extract from IND seeds and evaluation of exosome dispersion**	**1st instalment** after submission of signed project synopsis with protocol, Master agreement, CDA etc.	Rs. 1,62,500/- + 29,250/- (GST) to institute A/c = Rs. **191750/-**	2 months
OB2	**Conversion of exosomes dispersion to powder by a suitable technique**	**2nd instalment** after signed Report of OB1 and detailed protocol of OB2 and OB3	Rs. 3,32,500/- + Rs.59,850/-(GST) to institute A/c = **392350/-** Rs. 30,000/- to PI A/c	2 months
OB3	**Cell viability and anti-senescence effect (To be given to DPU Regenerative lab)**	**3rd instalment** after signed report OB2 and protocol of OB4	Rs. 1,25,000/- + Rs.22500/-(GST) to institute A/c = Rs. **1,47,500/-**	1 month
OB4	**Evaluation for efficacy: anti-aging activity**	**4th instalment** after signed report OB3 and OB4 and protocol of OB5	Rs. 1,15,000/- + Rs.20700/-(GST) to institute A/c = **135700/-**	2 months
OB5	**Development of Prototype formulation**	**5th Instalment** After signed report OB5 and submission of project completion documents	Rs. 82,000/-+ Rs.14,760/-(GST) to institute A/c = **96760/-**	1 month
		Total Approx amount	**Rs. 8, 47, 000/- + 1,47,060/- (GST)= Rs. 9,94,060/-**	**8 months**

Dr. S. S. Deshkar
HOD, P'ceutics

Dr. A. B. Thomas
HOD, P'chemistry

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research, Pimpri, Pune-18.

Dr. S. S. Chitlange
Principal

Date: 23/01/2025

To,

Dr. Sanjeevani Deshkar

Professor and Head

Department of Pharmaceutics

Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,

Pimpri, Pune-411018

Subject: Acceptance of Budget Proposal of the project titled, "*In vitro* simulated digestion, fermentation and bioassay for defatted fenugreek seed flakes (Fenuflakes)."

Dear Ma'am,

We accept the enclosed budget proposal, reference no. DPU/Pharmacy/1307/2025, dated 21 January 2025, for the above-mentioned project.

Enclosure: DPU/Pharmacy/1307/2025

For INDUS BIOTECH LIMITED

Authorized signatory

(Dr. Prasad Thakurdesai)

Indus Biotech Limited

(Formerly known as Indus Biotech Private Limited)

Registered Office

1, Rahul Residency, Plot No. 6 & 7, Off. Salunke Vihar Road, Kondhwa, Pune - 411 048, Maharashtra, INDIA

Tel : +91 20 26851239 / 26852139 | Email : Info@indusbiotech.com | www.indusbiotech.com

Company Identification Number : U24231MH1995PLC085656

Dr. D. Y. Patil Unitech Society's
DPU
DR. D. Y. PATIL INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH, PUNE
(Affiliated to Savitribai Phule Pune University ID No. PU/PN/Pharm/104/94)
(Approved by Pharmacy Council of India)
NAAC Accredited 2nd Cycle ('A++' Grade with 3.77 CGPA) | AISHE CODE C-41223

Ranked amongst top 50 Pharmacy Colleges by NIRF, New Delhi | Mentor - Industry Linked Institute AICTE-CII | Recipient of 'Best College Award' by Savitribai Phule Pune University

Dr. P. D. Patil, Chairman | Dr. (Mrs.) Bhagyashree Patil, Vice Chairperson | Dr. Somnath Patil, Secretary | Dr. Sohan Chitlange, Principal

Ref. No. : DPU/Pharmacy/1301/2025 Date : 21/01/2025

Budget Proposal of the project for Indus biotech Ltd. (2024-2025)

Title of project: *In vitro* simulated digestion, fermentation and bioassay for defatted fenugreek seed flakes (Fenuflakes)

Investigators: Dr. Sanjeevani Deshkar, Dr. Asha Thomas, Dr. Vaishali Undale

Objective-wise activities, milestones, approx. cost and timeline of project

Ob No.	Activity	Milestone payments and Document List	Approx. Cost (Rs.)	Duration of objective
OB1 & OB2	To perform *in-vitro* digestion and fermentation of fenuflakes by simulating gastrointestinal conditions utilizing enzymatic and pH modifications & To perform Cell viability studies for assessing safety of digested and fermented fenuflakes	1st advanced installment after submission of signed project synopsis with protocol (This will include material cost for initiating objective 1 to 5)	Rs. 3,00,000/- + 54,000/- (GST) to institute A/c Rs. 40,000/- to PI A/c	0 to 2 months
OB 3, OB 4 & OB 5	To determine the inhibition of alpha-amylase, alpha-glucosidase and lipase by digested and fermented fenuflakes	2nd installment after signed Report of OB1 and OB2 and detailed protocol of OB3, OB4, and OB5	Rs. 1,35,000/- + Rs.24300/-(GST) to institute A/c	2 to 5 months
--	Report preparation	3rd installment after signed report OB3, OB 4 and OB5	Rs. 1,25,000/- + Rs.19750/-(GST) to institute A/c	6th month
		Total Approx amount	**Rs. 6,00,000/- + 98050/- (GST)= Rs. 6,98,050/-**	**6 months**

Dr. S. S. Deshkar
HOD, P'ceutics

Dr. A. B. Thomas
HOD, P'Chemistry

Dr. S. S. Chitlange
Principal

Sant Tukaram Nagar, Pimpri, Pune - 411018, Maharashtra (India)
Tel. : +91-20-67116417, 27805292 / 93 • Email : info.pharmacy@dypvp.edu.in • Website : pharmacy.dypvp.edu.in
dpu.pharmacy | DPU Pharmacy | dpu.pharmacy | #DPU Pharmacy

dypvp.edu.in

Account Details for the institute:

Name of Bank: Bank of Maharashtra
Branch Name: D. Y. Patil College of Engg
Address of the Bank: Sant Tukaram Nagar, Pimpri Pune 411018
Telephone No of the Bank: 020-27420181
Name of the A/C Holder: Dr. D.Y. Patil Institute of Pharmaceutical Sciences & Research
Account Number: 60102689281
IFSC Code: MAHB0001280

Account Details for the PI:

Name of Bank: HDFC
Branch Name: Anand Park, Aundh Branch
Name of the A/C Holder: Sanjeevani Deshkar
Account Number: 50100171251902
IFSC Code: HDFC0000052

Ғылым және білім беру қызметтерін көрсету саласында өзара ынтымақтастық туралы
КЕЛІСІМ-ШАРТ

Қарағанды қ. «16» 04 2021

«Академик Е.А. Бөкетов атындағы Қарағанды университеті» КеАҚ (Қазақстан Республикасы), Басқарма төрағасы – ректор, профессор Дулатбеков Нұрлан Орынбасарұлы, бірінші тараптан және д-р Д. Ы. Патил, фармацевтикалық ғылымдар институты, Пимпри қ., Пуна ауданы (Индия), директор (институт басшысы) атынан д-р Сохан С. Читланджи мен доцент д-р Бхоле Р. П., екінші тараптан бұдан әрі – «Келісуші тараптар», білім және ғылым саласындағы өзара тиімді ынтымақтастықты жалғастыру мақсатында келесі келісім шарт жасасты.

1. Келісім-шарт мәні

1.1 Осы Шарттың мәні – университет өмірінің әр түрлі салаларында тең құқылық пен өзара тиімділік негізінде даму.

2. Келісуші Тараптардың міндеттері

2.1. Келісуші тараптар ынтымақтастық шеңберінде келесі міндеттемелерді қабылдайды:

– өзара келісілген тақырыптар бойынша бірлескен ғылыми зерттеулерді ұйымдастыру, ғалымдармен, оның ішінде Хирш индексі жоғары ғалымдармен алмасу және бірлескен ғылыми еңбектер шығару, кафедралар, зертханалар және басқа ғылыми бөлімдер арасындағы байланысты дамыту және қолдау;

– ақпаратпен, басылымдармен және басқа да ғылыми және ғылыми-әдістемелік материалдармен үнемі алмасуға, әр университетте өткізілетін ғылыми іс-шаралар туралы бір-біріне хабарлауға және басқа тарап өкілдерін осы іс-шараларға қатысуға шақыруға;

– студенттермен, ғылыми қызметкерлермен және академиялық құраммен алмасуды жүзеге асырады, оларға теориялық және практикалық білімді кеңейту үшін барлық жағдайларды жасайды, сондай-ақ белгіленген тәртіппен жатақханаларға орналастырады;

– бірлескен білім беру бағдарламаларын дамыту;

–тараптардың біреуі өткізетін ғылыми конференцияларға, семинарларға өзара негізде қатысуға және ғылыми зерттеулердің нәтижелерін Тараптардың мерзімді және ғылыми басылымдарында ұсынуға;

– бірлескен білім беру және мәдени бағдарламалар, семинарлар, тренингтер, конкурстар мен конференциялар өткізуге;

– магистратура және докторантура бағдарламалары бойынша студенттердің оқу жетістіктерімен транскрипт (сертификат) бере отырып, магистратура мен докторантура бойынша толық немесе ішінара оқу мүмкіндігін қамтамасыз

CONTRACT
on Mutual Cooperation in the Provision of Educational and Scientific Services

c. Karagandy «16» 04 2021

NLC "Karagandy University of the name of academician E. A. Buketov" (the Republic of Kazakhstan) on behalf of the Chairman of the Board – Rector, Professor Dulatbekov Nurlan Orynbasarovich, from the one side, and Dr. D. Y. Patil Instituteof Pharmaceutical Sciences, Pimpri, Pune (India), on behalf of Principal (Head of the Institute) Dr. Sohan S. Chitlange and Dr. R. P. Bhole Associate Professor, from the other side, hereinafter mentioned as "Agreeing parties", concluded following agreement with the aim of mutually beneficial cooperation continuation in education and science sphere.

1. Object of Agreement

1.1 Object of Agreement is development on the basis of equal rights possession and mutually profitable cooperation in different spheres of university life.

2. Obligations of Agreeing Parties

2.1. Agreeing parties in frames of cooperation accept following obligations:

– to cooperate in the field of scientific work through the organization of joint scientific research on mutually agreed topics, the exchange of scientists, including those with a high Hirsch index, and the publication of joint scientific works, developing and maintaining contacts between departments, laboratories and other scientific departments;

– to exchange regularly with information, publications and other scientific and scientific-methodical materials, to inform each other about scientific activities being held at each university, and to invite representatives of other side to take part in this activities;

– to perform the exchange of students, scientific workers and academic staff, rendering them all necessary conditions for enlarging theoretical and practical knowledge, and also provide with placements in dormitories in established order;

– to develop joint educational programs;

– to take part on mutually bases in scientific conferences, seminars, that are held by one of the sides, and to represent results of scientific research in periodical and scientific publications of Sides;

– to carry out joint educational and cultural programs, seminars, trainings, contests and conferences;

– to provide opportunity of full or partial (during one academic period) study on master and doctorate training programs with issuance of transcript (certificate) with academic achievements of student and rendering the opportunity of defense of results of scientific research and gaining of academic degrees on specialties offered at appropriate institution;

– to provide with assistance in vocational training of academic teaching staff through courses of vocational

ету және ғылыми зерттеу нәтижелерін қорғау және тиісті оқу орнында ұсынылатын мамандықтар бойынша ғылыми дәрежелер алу мүмкіндігі;
– тиісті оқу орнында ұсынылатын мамандықтар бойынша докторантура, пост-докторантура және магистрді кәсіби даярлау курстары арқылы академиялық педагогикалық кадрларды кәсіптік даярлауға көмек көрсету;
– оқытушыларға, қызметкерлерге және студенттерге тиісті мекемеде ұсынылатын мамандықтар бойынша ғылыми және/немесе кәсіби практика (тағылымдама) мүмкіндігін беру;
– студенттер мен оқытушылар құрамының ғылыми-әдістемелік жұмыстарына өзара шолу жасау;
– ұлттық заңнамаларға сәйкес ғалымдардың Тараптардың диссертациялық кеңестерінің жұмысына қатысуын жеңілдету;
– Тараптардың студенттері, оқытушылары мен қызметкерлерінің жақын және алыс шет елдердің университеттерімен және ғылыми орталықтарымен академиялық ұтқырлығын дамытуға көмек көрсету, басқа Тараптың халықаралық ынтымақтастығын кеңейтуге ықпал ету;
– монографияларды, ғылыми зерттеулерді, ғылыми жинақтарды басып шығару жоспарлары жайлы бір-біріне хабарлауға;
– білім берудің прогрессивті әдістерін дамыту және кредиттік аудару жүйесін енгізу бойынша тәжірибе алмасу;
2.2. Университет саясаты мен әкімшілігі саласында келіссөз жүргізуші тараптардың өзара іс-қимылы тәжірибе алмасу және жоғары оқу орындары арасындағы ынтымақтастықтың нәтижелерін шығару үшін осы қызмет саласындағы қызметкерлердің алмасуымен ұйымдастырылуы мүмкін екендігі жоқ емес.

3. Өзге жағдайлар

3.1. Осы Келісім тараптардың біреуінің бастамасы бойынша талқылауға ұсынылу мүмкіндігі бар ынтымақтастықтың басқа түрлерін жоққа шығармайды, сондай-ақ жазбаша түрде толтырылуы және өзгертілуі және өкілдердің қол қоюы мүмкін.
3.2. Осы Келісімнің мәлімдемелерін жүзеге асыру үшін келісуші тараптар нақты жұмыс формаларын, ғылыми тақырыптарын, ынтымақтастық шарттары мен квоталарын, сондай-ақ оны ұйымдастырудың және қаржыландырудың тәртібі мен шарты болуы мүмкін ынтымақтастықтың жаңа жұмыс бағдарламаларын әзірлеп, мақұлдай алады.

4. Қорытынды мәлімдемелер

4.1. Осы Келісім-шарт Тараптармен қол қойылған кезден бастап күшіне енеді және 5 (бес) жыл бойы дәл 2026 жылдың_____ наурызына дейін әрекет етеді.
4.2. Тараптар басқа Тарапты мүдделері туралы

training of doctorate, post-doctorate and master on specialties offered at appropriate institution;
– to provide the opportunity of scientific and/or professional practice (internship) to teachers, staff and students on specialties offered at appropriate institution;
– to carry out mutual reviewing of scientific and methodical work of students and academic teaching staff;
– to facilitate the participation of scientists in work of dissertation councils of Sides in accordance with national legislation;
– to provide assistance in development of academic mobility of students, teachers and staff of Sides with universities and scientific centers of countries of near and far foreign countries, to facilitate enlarging of international cooperation of another Side;
– to inform each other with plans of publishing monographs, scientific research creations, scientific collections;
– to exchange experience in development of progressive methods of education and implementation of system of credit-transfer system.
2.2. It is not excluded that cooperation of Agreeing parties can be arranged in sphere of university policy and administration by organization staff exchange in this activity sphere for experience exchange and interuniversity cooperation results summing up.

3. Other Conditions

3.1. Present Agreement doesn't exclude other forms of cooperation that can be proposed for discussion by initiative of one of the parties, and also might be completed and changed in written form and signed by representatives.
3.2. For realization of statements of present Agreement Agreeing parties can develop and approve new Work programs of cooperation, in which there might be pointed concrete forms, scientific topics, terms and quota of cooperation, and also order and condition of its organization and financing.

4. Conclusive Statements

4.1. Present Agreement will come into force from the Parties signing day and will operate during 5 (five) years, precisely till March 15, 2026.
4.2. Parties can dissolve present Agreement at pre-term period, informing in written form about their intensions

жазбаша түрде хабардар ете отырып, бірақ осы Келісімнің аяқталу күніне дейін үш айдан кешіктірмей осы келісімді бұза алады.
4.3. Кез-келген қызметте туындаған кез-келген дау-дамай жағдайында оны екі тарап та тиісті елдердің белгіленген заңдарын сақтай отырып шешеді.
4.4. Осы Шарт қазақ және ағылшын тілдерінде, Тараптардың әрқайсысы үшін бір (1) данадан бірдей заңды күшке ие екі (2) данада жасалды.

other Party, but not later than before three months till present Agreement expiry date.
4.3. In case of any dispute arising in any of activity it will be solved mutually by both of the parties in adherence of the prescribed laws of respective countries.
4.4. This Agreement is made in both Kazakh and English languages in two (2) copies, possessing equal legal power, one (1) copy for each Party.

5. Тараптардың заңды мекенжайлары

Д-р Д. Ы. Патил Unitech Қоғамы
Д-р Д. Ы. Патил фармацевтикалық ғылымдар және зерттеулер институты, Пимпри, Пуна, Үндістан – 411018
Тел.: 02067116417/02027805292/02027805293

Институт директоры – дәр Сохан С. Читландж

16/04 2021

Доцент – д-р Р. П.Бхоле

16/04/ 2021

«Академик Е.А. Бөкетов атындағы Қарағанды университеті» КЕ АҚ
Қазақстан Республикасы,
100024, Қарағанды,
Университет көшесі, 28-үй
тел: +7 7212 356412
факс: +7 7212 356398
E-mail: office@ksu.kz
Сайт: www.buketov.edu.kz
Басқарма төрағасы – ректоры

Дулатбеков Нұрлан

2021

5. Legal Addresses of Parties

Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India – 411018
Phone: 02067116417/02027805292/02027805293

Principal of the Institute – Dr. Sohan S. Chitlange

16/04/ 2021

Associate Professor – Dr. R. P. Bhole

16/04/ 2021

NPLC «Karagandy University of the name of Academician E. A. Buketov»
Republic of Kazakhstan,
100024, Karaganda,
28, Universitetskaya str.
tel.: +7 7212 356412
fax: +7 7212 356398
E-mail: office@ksu.kz
Сайт: www.buketov.edu.kz
Chairman of the Board – Rector

Nurlan Dulatbekov

2021

भारतीय गैर न्यायिक

भारत INDIA

रु. 500 FIVE HUNDRED RUPEES

पाँच सौ रुपये Rs. 500

सत्यमेव जयते

INDIA NON JUDICIAL

महाराष्ट्र MAHARASHTRA 13 FEB 2025 2024 CZ 822917

अनु.क्र.: 14312 दि.: मुल्य.: 500/-

१) दस्ताचा प्रकार : MOU

२) दस्त नोंदणी करणार आहेत का ?:- होय/नाही

३) मिळकतीचे वर्णन :

४) मुद्रांक विक्रत घेणाऱ्याचे नांव : WhiteLeaf

५) पत्ता : 44 Wanwadi Pune.

६) हस्ते व्यक्तीचे नांव : Akshay Mehta

७) पत्ता : Pune.

८) दुसऱ्या मुल्यांकनाचे नांव : D.Y.P.O.P.U.

Mehta

मुद्रांक घेणाऱ्याची सही

विजय सखाराम भालेकर
परवाना क्र. २२०१०२७
७५/५९०, महर्षिनगर, पुणे-३७

मुद्रांक कोषागार अधिकारी पुणे

31 JAN 2025

प्रथम मुद्रांक लिपीक कोषागार पुणे करिता

MEMORANDUM OF UNDERSTANDING (MOU)

This Memorandum of Understanding (MOU) is made and entered into on this **13th day** of **February 2025** (the "Effective Date"),

BY AND BETWEEN:

Klyntra E-Commerce Ventures Private Limited, Super Tabs Innovations Private Limited AND H2h Global Media Tech Private Limited, companies incorporated under the provisions of the Companies Act, 2013 having its Registered office at 44,Wanwadi Bazaar Pune-411040, having Ms. Veenu Mehta and Mr. Akshay Mehta as Founders & Directors hereinafter referred to as **"WhiteLeaf"**

WHITELEAF

VeMehta

Sohan Chitlange

(which expression shall, unless repugnant to the context hereof, mean the Companies –Klyntra E-Commerce Ventures Private Limited, SuperTabs Innovations Private Limited, H2H Global Media Tech Private Limited and include its Directors, Founders, it's successors in office and permitted assigns and any brands from these companies) of the One Part.

AND

School of Pharmacy and Research, constituent unit of Dr. D. Y. Patil Unitech Society's, DR. D. Y. PATIL DNYAN PRASAD UNIVERSITY, Pune, Maharashtra, India, a private university established under Maharashtra Private Universities (Establishment and regulations) (Amendment) Act 2024 (Mah. Act No. 20 of 2024). The school is highly committed to providing excellence in education and research in the Pharmaceutical Sciences and is accredited and recognized by apex bodies like NAAC (A++ Grade), NBA, NIRF (hereinafter referred to as "**DYP-DPU SPR**") (which expression shall, unless repugnant to the context thereof, mean and include its directors, faculty members, staff, and students, and their successors in office and permitted assigns), of the Other Part.

WHEREAS, WhiteLeaf and **DYP-DPU SPR** have expressed their interest in collaborating on specific technology and development projects and research activities, trials and other activities as required for specific projects carried out by interns/students/faculties guided by Leadership Faculty from its institution to work on the said project as per the project scope and timeline as outlined in the email communication exchanged between the Parties from time to time;

AND WHEREAS, **DYP-DPU SPR** will provide assistance in carrying out research, trials and other activities required for specific projects carried out by interns/students/faculties guided by Leadership Faculty from its institution to work on the said projects as per the project scope and timeline mentioned in the email communication;

AND WHEREAS, the Parties have executed a Confidentiality, Non-Disclosure, and Non-Compete Agreement (NDA) to protect the trade secrets and confidential information of WhiteLeaf;

NOW, THEREFORE, the Parties agree as follows:

TELE

VPMehta

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Sohan Chillarge

1.Project Scope: The scope of each project, including specific tasks, deliverables, and objectives, shall be mutually agreed upon in writing via email between the Parties.

2. Research and Development: DYP-DPU SPR will engage in the R and D activities for projects of WhiteLeaf as per the requirement of the party. The institute will appoint a PI and research students who will work on the projects. The PI in consultation with White Leaf will prepare a budget for the execution of project which will include charges for the resources at actual, including the consultancy and student remuneration charges. Upon mutual agreement by both parties the project will be taken ahead for execution.

3. Trainings and Internships

WhiteLeaf will provide trainings in various areas of their expertise to the faculty and students of DYP-DPU SPR. The financial involvements included in such training will be discussed and mutually agreed between the two parties as and when required.

4. Stipend/Compensation: The stipend or compensation for the projects assigned shall be mutually agreed upon by WhiteLeaf and DYP-DPU SPR on a project-by-project basis. The details of the stipend/compensation, including payment terms and frequency, shall be outlined in a separate agreement or as mutually agreed upon by WhiteLeaf and DYP-DPU SPR.

5.Project Execution Timeline: The timeline for each project, including start and end dates, milestones, and key deliverable dates, shall be mutually agreed upon in writing between the Parties.

6.Confidentiality: The Parties shall adhere to the terms and obligations of the Confidentiality, Non-Disclosure, and Non-Compete Agreement (NDA) previously executed between DYP-DPU SPR and WhiteLeaf. The NDA shall remain in full force and effect during the course of the projects and beyond, as per the terms specified therein.

7. Termination: The initial term of this Agreement shall commence on the Effective Date and expire Ten (10) years therefrom, unless earlier terminated. Expiration of this Agreement shall not terminate any Protocols then in effect, which shall continue to be governed by the terms of this Agreement. Either Party may terminate this MOU with 30 days prior written notice to the other Party in case of material br[illegible]erformance, or as mutually agreed upon by the

WHITELEAF

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research Pimpri, Pune-18.

Parties. The binding of the CONFIDENTIALITY, NON-DISCLOSURE, AND NON-COMPETE AGREEMENT shall persist even after termination of the MOU.

8.Governing Law and Jurisdiction: This MOU shall be governed by and construed in accordance with the laws of India. Any disputes arising out of or in connection with this MOU shall be subject to the exclusive jurisdiction of the courts of Pune.

IN WITNESS WHEREOF, the authorized representatives of the Parties have executed this MOU as of the Effective Date.

For, WhiteLeaf **By:** Ms.Veenu Mehta **Designation:** Director **Klyntra E-commerce Ventures Private Limited** **SuperTabs Innovations Private Limited** **H2H Global Media Tech Private Limited** Date:13-02-2025 Place: Pune **Witness:** Name: Mr. Akshay Mehta Place: Pune	For, **Dr. D. Y. Patil Dnyan Prasad University's, School of Pharmacy and Research, Pimpri, Pune** **By: Dr. Sohan Chitlange** **Designation**: Principal **Dr. D. Y. Patil Dnyan Prasad University's, School of Pharmacy and Research, Pimpri, Pune** Date:13-02-2025 Place: Pune **Witness:** Name: Dr. Asha Thomas Place: Pune

(1) LEIUTIS PHARMACEUTICALS LLP, HYDERABAD

(2) DEPARTMENT OF PHARMACOLOGY, DR. D.Y. PATIL INSTITUTEOFPHARMACEUTICALSCIENCES AND RESEARCH, PIMPRI, PUNE

CONFIDENTIALITY AGREEMENT

THIS AGREEMENT is made on 29th June 2023

BETWEEN

(1) **Leiutis Pharmaceuticals LLP,** incorporated and registered in Hyderabad, Telangana; as **Disclosing Party**and

(2) **Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Pune(DPU Pharmacy)** and registered in Maharashtra as **Recipient Party**

BACKGROUND

(A) Leiutis and Department of Pharmacology, Dr DY Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Punehave entered into discussions for research collaboration, project execution, and preclinical *In-vivo/In-vitro* studies(as defined herein).

(B) Each party wishes to disclose to the other, and wishes to ensure that the recipient maintains the confidentiality of Confidential Information (as defined herein) for the limited purpose as set out in this agreement.

(C) In consideration of the benefits to the parties of disclosing and receiving the Confidential Information, the parties have agreed to comply with the following terms in connection with the use and disclosure of Confidential Information.

OPERATIVE CLAUSES

1. <u>Definitions and interpretation</u>

1.1 The following definitions and rules of interpretation in this clause apply in this agreement:

Affiliate — any company or other business entity, which, directly or indirectly, controls, is controlled by or is under common control with a party. For the purpose of this agreement, "control" means the power to direct or cause the direction of the management or policies of the other entity, whether through ownership of voting securities, contract or otherwise.

Confidential Information — all confidential information and data (however recorded or preserved) disclosed or made available, directly or indirectly, by the Disclosing Party (or any of its Affiliates or Representatives) to the Recipient Group and its Representatives including but not limited to:

a. products, data, services, clients, customers,

suppliers, specifications, formulae, processes, know-how, intellectual property, trade secrets, inventions, methodology, samples, procedures and techniques, and all business, financial, commercial, technical, operational, organisational, legal, regulatory, administrative, management and marketing information;

b. the fact that discussions and negotiations are taking place concerning the Purpose and the status of those discussions and negotiations;
c. any information that would be regarded as confidential by a reasonable business person relating to the business, affairs, plans, intentions, or market opportunities of the Disclosing Party or of the Disclosing Party's Group, and
d. any information or analysis derived from the Confidential Information;

but not including any information that:

e. is or becomes generally available to the public (other than as a result of its disclosure by the Recipient Group or its Representatives in breach of this agreement), (except that any compilation of otherwise public information in a form not publicly known shall nevertheless be treated as Confidential Information); or
f. was lawfully in the possession of the Recipient Group before the information was disclosed to it by the Disclosing Party as evidenced by written records; or
g. the parties agree in writing is not confidential or may be disclosed.

All tangible media or material containing Confidential Information (including any product samples and packaging, raw data, data generated in any study performed and emails) shall be and remain the property of the Disclosing Party;

Disclosing Party — the party to this agreement disclosing Confidential Information;

Effective Date — the [specify date] or [date of execution of this agreement (being the date of signature of the last to sign of the parties)].

Group — in relation to a party, that party and each and any Affiliate from time to time;

Purpose	*"discussing and evaluating each party's respective interest in making appropriate commercial arrangements with the other party"*
Recipient	the party to this agreement or any member of its Group who receives, the Confidential Information;
Representatives	includes directors, officers, employees, advisers, agents, sub-contractors and other representatives of a party or members of that party's Group.
Term	5 years commencing on the Effective Date.

1.2 Clause, schedule and paragraph headings shall not affect the interpretation of this agreement.

1.3 A **person** includes a natural person, corporate or unincorporated body (whether or not having separate legal personality).

1.4 Unless the context otherwise requires, words in the singular shall include the plural and in the plural include the singular.

1.5 In this agreement (unless otherwise specified) a reference to a law or legislation is to that law or legislation as amended, extended, supplanted, re-enacted or replaced from time to time and includes all subordinate legislation made under it, all legislation replacing or superseding legislation that formerly implemented any European Union legislation (notwithstanding that such new legislation may no longer implement any European Union legislation) and all legislation replacing or superseding European Union legislation that formerly had direct effect in the United Kingdom (or relevant part thereof).

1.6 References to clauses and schedules are to the clauses and schedules of this agreement.

1.7 Any words following the terms including, includes, in particular, for example or any similar expression shall be construed as illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding those terms

2. Obligations of the Recipient

2.1 With effect from the Effective Date, the Recipient shall keep, and shall procure that other members of its Group shall keep, the Disclosing Party's (and its Group's) Confidential Information confidential and, except with the prior written consent of the Disclosing Party, shall not:

2.1.1 use or exploit the Confidential Information in any way except for the Purpose; or

2.1.2 disclose, transfer or make available the Confidential Information in whole or in part to any third party, except as expressly permitted by this agreement; or copy, reduce to writing or otherwise record

the Confidential Information except as strictly necessary for the Purpose (and any such copies, reductions to writing, records and any reports or analyses containing or referring to Confidential Information shall be the property of the Disclosing Party).

2.2 The Recipient and members of its Group may disclose the Disclosing Party's Confidential Information to those of its Representatives who need to know this Confidential Information for the Purpose, provided that:

2.2.1 it informs the Representatives of the confidential nature of the Confidential Information before disclosure; and

2.2.2 it procures that the Representatives shall, in relation to any Confidential Information disclosed to them, comply with this agreement as if they were the Recipient and, if the Disclosing Party so requests, procure that any relevant Representative enters into a confidentiality agreement with the Disclosing Party on terms equivalent to those contained in this agreement;

and it shall at all times be liable for the failure of any Representative to comply with the terms of this agreement.

2.3 The Recipient and members of its Group may disclose Confidential Information only to the extent required by law, by any governmental or other regulatory authority or by a court or other authority of competent jurisdiction provided that, to the extent it is legally permitted to do so, it gives the Disclosing Party as much notice of such disclosure as possible.

3. Return of information and announcements

3.1 No party shall make, or permit any person to make, any public announcement concerning this agreement without the prior written consent of the other party (such consent not to be unreasonably withheld or delayed) except as required by law or any governmental or regulatory authority (including, without limitation, any relevant securities exchange), or by any court or other authority of competent jurisdiction.

3.2 The Recipient shall upon receipt of a written demand from the Disclosing party to do so, and in event within 7 days of the termination of this agreement and at its own expense, return all Confidential Information to the Recipient, or, if the Disclosing Party so requests, provide evidence to the Disclosing Party's reasonable satisfaction that the Confidential Information has been destroyed or deleted.

4. Reservation of rights and acknowledgement

4.1 The Disclosing Party reserves all rights in its Confidential Information. No rights in respect of the Disclosing Party's Confidential Information are granted to the Recipient and no obligations are imposed on the Disclosing Party other than those expressly stated in this agreement. In particular, nothing in this agreement shall be construed or implied as obliging the Disclosing Party to disclose any specific type of information under this agreement, whether Confidential Information or not.

4.2 Except as expressly stated in this agreement, the Disclosing Party does not make any express or implied warranty or representation concerning its Confidential Information, or the accuracy or completeness of the Confidential Information.

4.3 The disclosure of Confidential Information by the Disclosing Party shall not form any offer by, or representation or warranty on the part of, the Disclosing Party to enter into any further agreement.

4.4 The Recipient acknowledges that damages alone would not be an adequate remedy for the breach of any of the provisions of this agreement. Accordingly, without prejudice to any other rights and remedies it may have, the Disclosing Party shall (where permitted by applicable law) be entitled to the granting of equitable relief (including injunctive relief) concerning any threatened or actual breach of any of the provisions of this agreement.

5. Entire agreement and variation

5.1 This agreement constitutes the entire agreement between the parties and supersedes and extinguishes all previous drafts, agreements, arrangements and understandings between them, whether written or oral, relating to its subject matter.

5.2 Each party agrees that it shall have no remedies in respect of any representation or warranty (whether made innocently or negligently) that is not set out in this agreement. Each party agrees that its only liability in respect of those representations and warranties that are set out in this agreement (whether made innocently or negligently) shall be for breach of contract.

5.3 No variation of this agreement shall be effective unless it is in writing and signed by on behalf of each of the parties by their authorised representatives.

5.4 The rights of the parties under this agreement are in addition to and not exclusive of rights under the general law.

5.5 Delay in exercising or non-exercise of any right under this agreement is not a waiver of that or any other right, partial exercise of any right under this agreement shall not preclude any further or other exercise of that right or any other right under this Agreement and waiver of a breach of any term of this agreement shall not operate as a waiver of breach of any other term or any subsequent breach of that term.

6. No waiver

6.1 Failure to exercise, or any delay in exercising, any right or remedy provided under this agreement or by law shall not constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict any further exercise of that or any other right or remedy.

6.2 No single or partial exercise of any right or remedy provided under this agreement or by law shall preclude or restrict the further exercise of that or any other right or remedy.

7. Assignment

7.1 Except as otherwise provided in this agreement, no party may assign, sub-contract or deal in any way with, any of its rights or obligations under this agreement or any document referred to in it, save that the Disclosing Party may assign its rights under this agreement to any entity in its Group on prior written notice to the Recipient.

8. Notices

8.1 Any notice required to be given under this agreement, shall be in writing and shall be delivered personally, or sent by pre-paid first class post or recorded delivery or by commercial courier, to each party required to receive the notice at its address as set out below:

8.1.1 **Party 1:**

8.1.1.1 K Chandrasekar, CEO

8.1.1.2 Leiutis Pharmaceuticals LLP

8.1.2 **Party 2**:

8.1.2.1 Dr. Sohan Chitlange

8.1.2.2 Dr DY Patil Inst of Pharm. Sci& Research, Pimpri, Pune

or as otherwise specified by the relevant party by notice in writing to each other party.

8.2 Any notice shall be deemed to have been duly received:

8.2.1 if delivered personally, when left at the address and for the contact referred to in this clause; or

if sent by pre-paid air mail post or recorded delivery, at 9.00 am at the place of delivery on the fifth Business Day after posting; or

8.2.2 if delivered by commercial courier, on the date and at the time that the courier's delivery receipt is signed.

8.3 A notice required to be given under this agreement shall not be validly given if sent by e-mail.

9. No partnership

9.1 Nothing in this agreement is intended to, or shall be deemed to, establish any partnership or joint venture between any of the parties, constitute any party the agent of another party, nor authorise any party to make or enter into any commitments for or on behalf of any other party.

10. Third party rights

10.1 Except as provided in this clause 10, this agreement is made for the benefit of the parties to it and their successors and permitted assigns and is not intended to benefit, or be enforceable by, anyone else.

10.2 This agreement is made for the benefit of the Disclosing Party and its Group from time to time, and any entity in the Disclosing Party's Group may enforce this agreement as if they were the Disclosing Party and a party to this agreement.

10.3 The parties may terminate, rescind or vary this agreement without the consent of any person who is not a party to this agreement.

11. Term

11.1 This agreement shall apply from the Effective Date and shall continue for the duration of the Term. The obligations of the Recipient, in respect of Confidential Information disclosed or supplied to it under this agreement, shall however survive termination or expiry of this agreement and remain in full force and effect for a period of 5 years thereafter.

12. Governing law and jurisdiction

12.1 This agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the law of India.

12.2 The parties irrevocably agree that the courts of India shall have non-exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this agreement or its subject matter or formation (including non-contractual disputes or claims).

This agreement has been entered into on the date stated at the beginning of it.

Signed by

1. .....
K Chandrasekar
for & on behalf of
Leiutis
CEO

Signed by

1. .....
Dr Sohan Chitlange
CEO, Administration,
DPU Unitech Society &
Principal DPU Pharmacy

2. .....
Dr. V. Addepalli
Dept of Pharmacology
Dr DY Patil Inst. of
Pharm. Science &
Research.

Witness: 1. ----------

Mr B Nagaraju, VP Leiutis Pharma LLP
Hyderabad

2. ----------

Dr. V. R. Undale
Dept of Pharmacology, Dr. D.Y .Patil
Inst. of Pharm Sc. & Res
Pune

Dr. D. Y. Patil Inst. of Pharm. Sci. & Research
Pimpri,
Pune-18.

AGREEMENT FOR SPONSORED RESEARCH

C. 1 THE AGREEMENT

C.1.1. This AGREEMENT made and entered into on this day of 14th July 2023 between **Dr. Vaishali Undale (Project Coordinator), Head of the Department of Pharmacology (DOP), Dr. D.Y. Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Pune** (here in after called First Party which expression shall where the context so admits include its successors and permitted assigns) of the one part.

C.1.2. **Mr K Chandrasekhar, CEO, Leiutis Pharmaceuticals LLP,** a company with registered office at Hyderabad, India (herein after called the Second Party which expression shall where the context so admits include its successors and permitted assigns) of the other part.

C.2 PREAMBLE

C.2.1 Whereas the first party at its Department, having CCSEA (Committee for Control and Supervision of Experiments on Animals) approved Animal House, has expertise in the animal experiments, pre-clinical studies of various drugs and drug combinations, in vitro studies and has been approached by the second party for carrying out certain animal experiments and pre-clinical studies.

C.2.2 Where as the second party is engaged in the R & D work, novel formulation development and marketing and has agreed for the sponsorship of the below mentioned project and to carry out part or full work and the required trials and animal testing of specific API and its' designed formulation of specific drug or combination of drugs.

C.3 SCOPE OF THE AGREEMENT

C.3.1 The agreement details the terms and conditions for first party undertaking the studies, design, execution for the project sponsored by second party, the financial arrangements, rights and obligations of the parties hereto, pertaining to the project, which is elaborated in the Annexure-I (Project Title: "Preclinical Study for treatment of Major Depressive Disorder of Selective Novel Formulations in Swiss Albino or C57/6 Mice (as per Annexure 1). Further, this

agreement may cover any other projects for any API or new formulations for study of CNS activities in animal model or in in vitro cell line on specified mutually agreed conditions and at agreed cost. For future projects simple communications will suffice under stipulated conditions of this agreement.

C.4 FINANCIAL ARRANGEMENT

C.4.1 In consideration of first party at its laboratory undertaking the study project for animal studies and pre-clinical studies, the second party shall pay first party Rs. 1.46 lac (Rupees one lac and forty six thousand only) for the purpose mentioned in the annexure 1: This fee shall be paid in two stages, Rs 80000/ (Rs. eighty thousand only) at the time of signing, and remaining Rs. 66000/ (Rs sixty six thousand only) after completion of experiments and submission of final report, as per proposal for small animals and maintenance, uses of equipment, consumables/contingencies, IAEC/scientific charges, etc.

C.5 RESPONSIBILITY OF THE FIRST PARTY

only

C.5.1 The first party through its animal house and laboratory shall undertake the studies after CCSEA approval in accordance with the scope of work detailed in Annexure-I to this agreement.

C.5.2 The duration of the projects is two and half months as specified in project details in Annexure – 1.

C.5.3 The period for completion of studies could however be extended to such further period as may be required and mutually agreed between the parties with or without any liability on either of the parties on mutual consent.

C.5.4 The first party through its Laboratory shall submit/present (interim/progress) reports after six weeks, and a detailed Final Report on the completion of assigned study (mile stone to be achieved at different time are mentioned in Annexure-1).

C.5.5 The First party shall handover to Second party the complete details of the experiments, outcome of pre-clinical studies and knowledge developed and will be covered by the Confidential Agreement signed already.

C. 6 OPERATIONAL RESPONSIBILITIES OF PARTY

C.6.1 The first party shall be responsible for all procedural, operational, and other matters pertaining to the project.

C.7 EFFECTIVE DATE, DURATRION AND TERMINATION OF AGREEMENT

C. 7.1 The agreement shall be effective from the date mentioned above or date of signing (whichever later) and shall remain in force for the period of two and half months from the effective date. However, first party may plan to start earlier if possible.

C.7.2 During the tenure of the agreement parties hereto can terminate the agreement after agreeing on it mutually.

C.8 SETTLEMENTS

C.8.1 In the event of termination of the agreement vide C.7.2, the rights and obligations of the parties hereto shall be settled by mutual decisions.

C.9 CONFIDENTIALITY

C.9.1 During the tenure of the agreement and 5 years there after (as signed by Confidential Agreement) both the parties undertake on their behalf and on behalf of their subcontractors / employees / representatives / associates to maintain strict confidentiality and prevent disclosure thereof of all the information and data exchanged/generated pertaining to work under this agreement for any purposes other than in accordance with this agreement.

C.10. COMPLETION OF THE PROJECT

C.10.1 The project shall be deemed to have successfully completed on submission of the Final Report as stated herein by the first party to the second party, to their expectation.

C.11 PUBLICATIONS

C.11.1 First party shall not publish anything out the project. The second party at its discretion may publish the results in journals or use the data as needed. The second party may discuss with first party any publications in journals and at its discretion may include investigators from the

first party. It will be duly acknowledged that the work is being carried out by the first party under a sponsorship assignment from the second party.

C.12 PATENTS

C.12.1 First party is prohibited to file any patent based on the work done and out of any outcome of this sponsored project. Any patents resulting out of the above sponsored project, if at all, will be submitted by only Leiutis and will be owned by it.

C.13 FORCE MAJEURE

C.13.1 Neither party shall be held responsible for non - fulfillment of their respective obligations under this agreement due to the exigency of one or more of the force majeure events such as but not limited to Acts of God, war, Flood, earthquakes, strike, lockouts, epidemics, riots, civil commotion, etc. provided in the occurrence and cessation of any such events, the party affected thereby shall give a notice in writing to the other party within seven days of such occurrence or cessation, if the force-majeure conditions continued beyond two months, the parties shall then mutually decide about the future course of action.

C.14 NOTICES

C.14.1 All notices and other communications required to be served on the either party under the terms of this agreement shall be considered to be duly served if the same shall have been delivered by email or by post or left with or posted by registered mail to their last known address of business.

C.15 AMENDMENTS TO THE AGREEMENT

C.15.1 No amendment or modification of this agreement shall be valid unless the same is made in writing by both the parties or their authorized representatives and specifically stating the same to be an amendment of this agreement. The modifications/charges shall be effective from the date on which they are made /executed, unless otherwise agreed.

C.16 ARBITRATION

C.16.1 Except as herein before provided, any dispute arising out of this Agreement, the same shall be referred to the arbitration of two arbitrators, one to be appointed by each party to the dispute and incase of difference of opinion between them, an umpire appointed by the said two arbitrators before entering on the reference and the decision of such arbitrators or umpire, as the case may be, shall be final and binding on both parties, The venue of arbitration shall be at such place as may be fixed by such arbitration or umpire and the arbitration proceedings shall take place under the Indian Arbitration Act, 1940.

C.17. ASSIGNMENT OF THE AGREEMENT

C.17.1 The Rights and/or liability arising to any party to this agreement shall not be assigned, except with the written consent of the parties and subject to such terms and conditions as may be mutually agreed upon.

SEAL OF PARTIES

In witness whereof, the parties hereto have signed this agreement on the day, month and year mentioned herein before.

For and on behalf of first party	For and on behalf of second party,
DOP, Dr DYP Inst. of Pharm. Sc. & Res. Pune	Leiutis Pharmaceuticals LLP, Hyderabad
Signature:	Signature:
Name: Dr. Vaishali Undale	Mr K Chandrasekar
Designation: Head of Department of Pharmacology	Designation: CEO
Seal: Pimpri, Pune-18.	Seal:
Witness : Dr. Addepalli Veeranjaneyulu Director, Research	Witness (Name & Address)

MEMORANDUM OF UNDERSTANDING

(for Academic/R&D Strategic Partners of TechEx.in)

This Memorandum of Understanding is made on the 8th day of April 2024.

BETWEEN

Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, hereinafter referred to as **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** and being represented by Dr. Sohan Chitlange, Principal of Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune.

AND

Entrepreneurship Development Center, an Indian Non-profit Company registered under section 8 of The Companies Act- 1956, having its registered office at 100, NCL Innovation Park, CSIR-NCL Campus, Dr. Homi Bhabha Road, Pune-411008, Maharashtra, India, hereinafter referred to as **Venture Center**, which expression shall unless repugnant to context include its successors, executors and assignees,

Both hereinafter referred to as the "Parties" collectively, or "Party" individually.

1. PREAMBLE

For Venture Center	*For Institution*

WHEREAS Venture Center is a non-profit technology business incubator (TBI) hosted by CSIR-National Chemical Laboratory, Pune specializing in science and technology based startups in a wide array of market sectors and scientific disciplines. Venture Center is a TBI created under a scheme of CSIR (Government of India), approved by DST-NSTEDB (MoS&T, Govt of India). Venture Center is recognized as a NIDHI-Center of Excellence by DST-NSTEDB. Venture Center is also a BIRAC (Department of Biotechnology, Govt of India) supported bioincubator that is nurturing several biotech/biomed startups and innovators. BIRAC has selected Venture Center to host the BIRAC Regional Bioinnovation Center and the Center for Biopharma Analysis. Venture Center has been awarded the National Award for Technology Business Incubators from the President of India on 11 May 2016, the AABI (Asian) Incubator of the Year 2018 and National Entrepreneurship Award under the Ecosystem Builder Category 2019 and National Award for best Incubator for nurturing IP 2021-22.

WHEREAS Venture Center has formed a technology transfer hub - TechEx.in with support from the National Biopharma Mission (NBM) – an initiative of Biotechnology Industry Research Assistance Council (BIRAC) and Department of Biotechnology (Government of India), to help and assist inventors and technology developers seek formal IP protection, market their technologies, help technology developers and technology commercialization entities find each other, forge partnerships and advance the technology closer to the market in a win-win partnership.

WHEREAS The Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, situated in Pimpri, Pune (DPU Pharmacy), stands as a premier institution in India. Established in 1994, its primary objective is to provide high-quality education and training in pharmacy to meet the demands of the profession and society at large. All programs offered by the institute are recognized by the Pharmacy Council of India (PCI) and approved by the All India Council for Technical Education (AICTE). The institute has received accreditation from the National Assessment and Accreditation Council (NAAC) during its 2nd cycle, achieving an 'A++' Grade with a CGPA of 3.77. Notably, it has consistently ranked among the top 50 institutions in India according to the National Institutional Ranking Framework (NIRF) under the Ministry of Education, Government of India, from 2017 to 2023. Furthermore, it has been recognized as a Mentor Industry-Linked Institute and has received the Best Industry-Linked National Award from AICTE-CII in 2019, 2020, and 2021. In addition, the institute has been

honored with the Utkrisht Sansthan Vishwakarma Award in 2020 (Third Position) by AICTE, New Delhi, the Best College Award in 2018 from Savitribai Phule Pune University, Pune, and the Chatra Vishwakarma Award in 2019 from AICTE, New Delhi. It is duly Recognized Under Section 2 (f) and 12 (B) by the University Grants Commission (UGC), New Delhi. Moreover, the institute holds ISO 9001:2015 and ISO 14001:2015 certifications, further attesting to its commitment to excellence and quality assurance. **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** has plans to strengthen its innovation promotion, IP protection and technology commercialization capabilities and has expressed an interest in engaging with partners with complementing activities and interests.

WHEREAS, given the commonality of objectives, Venture Center has agreed to make accessible its various TechEx.in services to **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** as mentioned in Appendix 1.

Given the complementarities of their objectives and aligned interests, the Parties therefore decided to enter into a MoU to secure those objectives by mutual cooperation.

2. INTERPRETATION AND DEFINITIONS

Subject to the context hereof the following words and expressions shall be construed and interpreted so as to have the following meaning.

2.1 **Effective Date**: shall mean the date of signing of this agreement by both parties.

2.2 **Technology**: shall mean **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** technical knowhow, technical knowledge and information, and/or patents and patent applications.

2.3 **IP:** Intellectual Property shall mean Knowhow, confidential information, Patents, trademarks, Industrial Designs and IC Layout Designs and Copyrights if any.

3. TERM OF MOU

3.1 This MoU shall remain in force for a period 12 months from the Effective date.

3.2 The term of the MoU as specified in 3.1 may be extended to such further terms as mutually decided by the parties in consultation with each other.

4. SCOPE OF MOU

4.1 Venture Center agrees to partner with **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** and **Dr. D.Y. Patil Institute of**

Pharmaceutical Sciences and Research, Pimpri, Pune agrees to accept Venture Center as a partner.

4.2 Both Venture Center and **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** agree to designate one nodal person from each side to coordinate and facilitate implementation of this MoU. On behalf of **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** Mrs Shweta Mishra will be the nodal person as point of contact. On behalf of Venture Center, Dr. Kavita Parekh will be the nodal person as point of contact. The relationship under this MoU shall be mutually non-exclusive.

4.3 **Responsibilities of Venture Center**

4.3.1 Venture Center agrees to invite **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** for all the open Talks, seminars and events.

4.3.2 Venture Center will arrange and announce free of cost mentoring and advisory clinics open to all its Strategic Partners including the **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune.** The mentoring clinics will be held roughly once a month. **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** will be required to sign up for the above clinics and book the slots on a first come as per availability.

4.3.3 Venture Center agrees to make accessible discounted TechEx.in services (as listed in the Appendix 1) to **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** subject to a) availability, b) **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** agreeing to all terms & conditions applicable to specific services and c) payment of applicable fees. The **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** may or may not choose to avail of these services as per requirement and as allowed by its rules.

4.3.4 Venture Center will provide access to occasional funding support for patent filing and/or tech transfer training announced by NBM-BIRAC as and when available.

4.4 **Responsibilities of Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune**

4.4.1 **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** shall identify a single point contact at **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune**

4.4.2 **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** shall acknowledge and credit Venture Center (a registered Service mark of Entrepreneurship Development Center) as Innovation Management Support provided by TechEx.in, the RTTO supported by Venture Center and National Biopharma Mission wherever applicable.

4.4.3 In order to reduce any misunderstandings or duplication of work, the **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** shall inform Venture Center of any parallel efforts by other partners/ service providers with regards to services offered by Venture Center.

4.5 Each Party will be responsible for its own costs in connection with all matters relating to collaborations under this MOU.

5. CONFIDENTIALITY

5.1 Parties shall initiate discussions by sharing non-confidential information first.

5.2 Venture Center shall at all time act with the utmost good faith and a spirit of co-operation and shall ensure that confidential information if any disclosed to it by the **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** will be kept confidential.

6. NON-SOLICITATION

Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune agrees that during the period of this MoU and 6 months after that, it will not hire, contract or take away or cause to be hired, contracted or taken away any employee or independent contractor of Venture Center.

7. AMENDMENTS

7.1 This MoU is the sole repository of the mutually agreed covenants between the parties. The MoU may be amended by mutual consent and the amendments shall be applicable from the date of such amendments unless agreed to contrary.

7.2 Any matter not provided for in this MoU may be discussed and any agreement on such matter may be added in this MoU as addendum by reducing such agreement in

writing. Any such addendum shall be deemed to be an integral part of the MoU.

8. TERMINATION

The parties have the option to withdraw from any or all areas of cooperation covered by this MoU by giving a notice of not less than 10 days in writing to the other party, informing the cause(s) for termination. However, the provisions of confidentiality shall bind both parties.

9. NOTICES

The parties establish the following contact addresses for the provision of serving notices under this MoU:

For Dr. D.Y. Patil Institute of Pharmaceutical
Sciences and Research, Pimpri, Pune
Dr. Sohan Chitlange
Principal, DPU-Pharmacy and CEO, DPU Unitech
Society, Sant Tukaram Nagar, Pimpri, Pune, 411018
9175950217
principal.pharmacy@dypvp.edu.in

For Venture Center
COO & General Manager
Entrepreneurship Development Center
Venture Center, 100, NCL Innovation Park,
Dr. Homi Bhabha Road, Pune - 411008
Email: gm@venturecenter.co.in

10. INDEMNIFICATION

Each Party shall indemnify, defend and hold harmless the other Party, its officers, agents, volunteers, contractors, and employees from any and all liability, loss, expense (including reasonable attorneys' fees and other defense costs), or claims imposed for damages of any nature whatsoever, including but not limited to, bodily injury, death, personal injury, or property damage arising out of willful misconduct or gross negligent acts or omissions on the part of the Party's own officers, agents, contractors, or employees under or in connection with any obligation under this MOU

For Venture Center	*For Institution*

Agreement. This indemnity shall survive termination of this MOU Agreement.

11. RESOLUTION OF DISPUTES

The Parties will attempt in good faith to resolve any dispute or claim arising out of or in relation to this MOU or the subject matter hereof through consultation and negotiation in good faith in a spirit of mutual cooperation. Such matters will be initially addressed by the Nodal officers of each party who shall use reasonable efforts to attempt to resolve the dispute through good faith negotiations. If they fail to resolve the dispute within thirty (30) days after either party notifies the other of the dispute, then the matter will be escalated to the Directors/Heads of Organizations or their designees of each party for resolution and in the event of any persistent disagreement; the parties shall appoint neutral and otherwise qualified third party mediator. The mediator fees shall be shared equally between both parties.

12. NO LIABILITIES

Neither party shall make a claim against or be liable to, the other party or its affiliates or agents for any damages, including (without limitation) lost profits or injury to business reputation, resulting from the continuation or abandonment of negotiations.

13. GOVERNING LAW

13.1 The validity, construction and performance of this MOU and the rights and obligations of the Parties hereunder shall be governed by and interpreted in accordance with the laws of the Union of India applicable to contracts made and to be wholly performed within India, without giving effect to any principles of conflict of law provisions thereof.

13.2 The Parties hereto unequivocally and expressly agree that any disputes or differences arising out of or in relation to this MOU, including the interpretation thereof, shall be subject to the exclusive jurisdiction of the courts of Pune only.

14. FORCE MAJEURE

Neither party shall be held responsible for non-fulfillment of their respective obligations under this MOU due to the exigency of one or more of the force majeure events such as but not limited to acts of God, war, flood, earthquakes, strike, lockouts, epidemics, riots, civil commotion, etc. provided on the occurrence and

cessation of any such events, the party affected thereby shall give a notice in writing to the other party within one week of such occurrence or cessation. If the force majeure conditions continued beyond one month, the parties shall then mutually decide about the future course of action.

15. HEADINGS

The section headings contained in this Agreement are set forth for the convenience of the parties only, do not form a part of this Agreement and are not to be considered a part hereof for the purpose of construction or interpretation hereof, or otherwise.

16. ENTIRE AGREEMENT

This Agreement, together with any other materials referenced in or expressly made a part of the Agreement, constitutes the final and entire Agreement between Venture Center and **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune** and supersedes all prior and contemporary agreements, oral or written.

17. NO WAIVER OR ASSIGNMENT

The failure of either party to exercise any of its rights under this Agreement for a breach thereof shall not be deemed to be a waiver of such rights, and no waiver by either party, whether written or oral, express or implied, of any rights under or arising from this Agreement shall be binding on any subsequent occasion; and no concession by either party shall be treated as an implied modification of the Agreement unless specifically agreed in writing. This Agreement, or any part thereof, may not be assigned or transferred without the prior written consent of the other party.

18. SEVERABILITY

If any provision hereof is held unenforceable or void, the remaining provisions shall be enforced in accordance with their terms.

In witness whereof, the parties hereto have caused their authorized representatives to sign this Memorandum of Understanding on the date mentioned hereinabove.

For Venture Center	*For Institution*

For and on-behalf of Venture Center

Dr Manisha Premnath, COO & GM
Venture Center,
100, NCL Innovation Park,
Dr. Homi Bhabha Road,
Pune - 411008.
Phone: +91-9172232215
Email: gm@venturecenter.co.in

For and on-behalf of **Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune**

Dr. Sohan Chitlange
Principal, DPU-Pharmacy and CEO, DPU
Unitech Society, Sant Tukaram Nagar, Pimpri,
Pune, 411018
9175950217
principal.pharmacy@dypvp.edu.in

Witnesses:

1. ..... (Dr. Mugdha Lele, Venture Center)
2. ..... (Dr. Kavita Parekh)

Witnesses:

1. ..... (Dr. Vidyadhar)
2. ..... (Dr. R. P. Bhole)

Date:

Place: Pune

For Venture Center	*For Institution*

APPENDIX- 1

TechEx.in services relevant to Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune and the terms at which they shall be available:

Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune will be able to avail of services of TechEx.in at the following deep discount:

Category	Description	Discount
Strategic Partners	Applicable on all TechEx.in services	30%

List of TechEx.in services: (More information latest Term Sheet, please see http://www.techex.in/services/)

- Designing and drafting institutional policies for innovation management
- IP protection and data management
- Agreement structuring and drafting
- Technology marketing and lead management
- Technology transfer-deal structuring, IP valuation and contract management
- Spin off and new venture creation
- IP Analytics: reports and opinions
- Technology and IP audits and due diligence
- Awareness & training for faculties, inventors, students etc.
- Training of in-house IP/TT staff
- Any other technology and innovation management services announced by TechEx.in.

For Venture Center	*For Institution*

WELLCRAFT INFRAPROJECTS
PRIVATE LIMITED

Memorandum of Understanding (MoU) **10/12/25**
Between
DPGU School for Hospitality and Tourism, Dnyaan Prasad Global University
and
DoubleTree by Hilton Chinchwad

This Memorandum of Understanding (MoU) is entered into by and between **Dnyaan Prasad Global University, School for Hospitality & Tourism by Dr. D.Y. Patil Unitech,** and **DoubleTree by Hilton Chinchwad**, with a shared commitment to foster academic–industry collaboration and enhance exposure, learning, and career opportunities for students pursuing hospitality education.

Both parties agree that this collaboration will contribute significant value, supporting the development of skilled and industry-ready hospitality professionals and fostering mutual benefit for the students and the organization.

Areas of Collaboration

As part of this MoU, the following areas of collaboration are agreed upon by both parties:

1. Internship Support & ODC Assistance

- Placement of students for internship training at the organization.
- The university will support Outdoor Catering (ODC) manpower requirements when requested.

2. Placement Priority

- Priority consideration for students during annual or ongoing placement drives.

3. Expert Mentorship & Guest Engagement

- Inviting industry experts from the organization for guest lectures, workshops, skill sessions, and mentorship programs.

4. Industrial Visits & Experiential Learning

- Organizing structured industrial and field visits to the organization to provide students with real-time operational exposure.

5. Faculty Development Support

- Providing collaborative training opportunities for faculty to align with current industry standards, skills, and best practices.

6. Training Workshops

- Conducting periodic expert workshops or training sessions for trainees at the hotel property.

7. Academic Contribution

- Guest lectures or knowledge-exchange sessions by university faculty to support operational learning and industry alignment.
- Additionally, the university agrees to recommend the organization as a preferred hospitality industry partner for future institutional events, training initiatives, and collaborative engagements to strengthen mutual value.

- **Term and Validity**
- This Memorandum of Understanding shall remain valid for a period of **Three (3) years from the date of signing**, unless extended or terminated earlier by mutual written consent of both parties.

- **Signatories**
- This MoU is signed in good faith and with mutual agreement on this ___ day of _____, 2025.

For DPGU School for Hospitality and Tourism	**For DoubleTree by Hilton Chinchwad**
Dr. Pradyuman Rathore	**Mr. Khizer Khan**
Director	Hotel Manager
DPGU School for Hospitality and Tourism	DoubleTree by Hilton Chinchwad
Signature: _____	Signature: _____

Memorandum of Understanding (MoU) Date **10/12/25**

Between

DPGU School for Hospitality and Tourism, Dnyaan Prasad Global University

and

DoubleTree by Hilton Chinchwad

This Memorandum of Understanding (MoU) is entered into by and between **Dnyaan Prasad Global University, School for Hospitality & Tourism by Dr. D.Y. Patil Unitech**, and **DoubleTree by Hilton Chinchwad**, with a shared commitment to foster academic–industry collaboration and enhance exposure, learning, and career opportunities for students pursuing hospitality education.

Both parties agree that this collaboration will contribute significant value, supporting the development of skilled and industry-ready hospitality professionals and fostering mutual benefit for the students and the organization.

Areas of Collaboration

As part of this MoU, the following areas of collaboration are agreed upon by both parties:

1. Internship Support & ODC Assistance

- Placement of students for internship training at the organization.
- The university will support Outdoor Catering (ODC) manpower requirements when requested.

2. Placement Priority

- Priority consideration for students during annual or ongoing placement drives.

3. Expert Mentorship & Guest Engagement

- Inviting industry experts from the organization for guest lectures, workshops, skill sessions, and mentorship programs.

4. Industrial Visits & Experiential Learning

- Organizing structured industrial and field visits to the organization to provide students with real-time operational exposure.

Date.:

5. Faculty Development Support

- Providing collaborative training opportunities for faculty to align with current industry standards, skills, and best practices.

6. Training Workshops

- Conducting periodic expert workshops or training sessions for trainees at the hotel property.

7. Academic Contribution

- Guest lectures or knowledge-exchange sessions by university faculty to support operational learning and industry alignment.
- Additionally, the university agrees to recommend the organization as a preferred hospitality industry partner for future institutional events, training initiatives, and collaborative engagements to strengthen mutual value.

- **Term and Validity**
- This Memorandum of Understanding shall remain valid for a period of **Three (3) years from the date of signing**, unless extended or terminated earlier by mutual written consent of both parties.

- **Signatories**
- This MoU is signed in good faith and with mutual agreement on this ___ day of _____, 2025.

For DPGU School for Hospitality and Tourism
Dr. Pradyuman Rathore
Director
DPGU School for Hospitality and Tourism

Signature: _____

For DoubleTree by Hilton Chinchwad
Mr. Khizer Khan
Hotel Manager
DoubleTree by Hilton Chinchwad

Signature: _____

MOU

DNYAN PRASAD GLOBAL UNIVERSITY

AND

PUNE MANAGEMENT ASSOCIATION

2025-26

COPY FOR CONSULTANCIES

MEMORANDUM OF UNDERSTANDING (MoU)

BETWEEN

PUNE MANAGEMENT ASSOCIATION
1332, Shivajinagar, 1st Floor, JM Road, Institution of Engineers Building, Adjacent to COEP Ground, Opp Modern Cafe, PUNE 411005

AND

DNYAAN PRASAD GLOBAL UNIVERSITY'S SCHOOL OF MANAGEMENT & RESEARCH
Tathawade, Pune, Maharashtra 411 033.

This **Memorandum of Understanding** is intended to promote interaction between **PUNE MANAGEMENT ASSOCIATION, PUNE** and **DNYAAN PRASAD GLOBAL UNIVERSITY'S SCHOOL OF MANAGEMENT & RESEARCH.**

A. **Purpose of the MoU:** This Memorandum of Understanding (MoU) is established to foster collaboration between **Pune Management Association (PMA)** and **DNYAAN PRASAD GLOBAL UNIVERSITY'S SCHOOL OF MANAGEMENT & RESEARCH (DPGU SMR)** with the objective of bridging the skill gap between academia and industry. Both institutions acknowledge their shared responsibility in preparing students to meet real-world demands by enhancing business management and professional education, particularly in domains such as Business Administration, General Management, and allied fields. PMA shall primarily serve as a Knowledge and Resource Partner in this endeavour.

B. **Areas of Collaboration:** The Key areas of Cooperation under this MoU include, but are not limited to:
   a. **Mentorship Programs:** PMA professionals will mentor selected faculty and students from the DPGU SMR It is preferable that the students and Faculty members shall be the members of the PMA.
   b. **Student Chapter Formation:** Establishment of a PMA Student Chapter at the DPGU SMR to promote student engagement and development of managerial competencies. Activities will be governed by the PMA, as per guidelines separately given.
   c. **Entrepreneurship Development Cell (ED Cell):** Conducting entrepreneurial initiatives like business idea incubation, mentorship, training, and funding guidance.
   d. **Mock Interviews:** Organizing industry-led mock interviews for students.
   e. **Workshops & Joint Certifications:** Conducting expert-led workshops on current topics with options for joint certification.
   f. **Joint Research Initiatives:** Co-authoring papers, reports, and studies on mutually agreed topics.
   g. **Case Study Development:** Collaborative development of case studies based on real industry scenarios.
   h. **Curriculum Enrichment:** Jointly reviewing and upgrading the curriculum; PMA to nominate experts for academic boards if required.
   Faculty Development Programs: Conducting Faculty and Management Development Programs.



j. **Faculty Internship Programs (FIP):** Facilitating faculty internships in industry sectors aligned with their specialization.
k. **Live Projects:** Enabling live and summer project opportunities via the PMA network.
l. **Consultancy Assignments:** Offering consultancy projects based on faculty expertise through PMA affiliations.
m. **Learner Evaluation:** Involving PMA experts in evaluation activities like project viva, etc.
n. **Expert Lectures:** Inviting PMA experts for lectures, seminars, inductions, and keynotes.
o. **Conference Support:** PMA to support organization of national/international conferences and workshops.
p. **Industrial Visits:** Facilitating student and faculty visits to industrial establishments.

C. **Implementation:**
   a. All collaborative activities will be jointly planned and approved in writing.
   b. Each organization will appoint a coordinator to manage and execute agreed activities.
   c. Financial responsibilities for any activity lie solely with the initiating organization unless agreed otherwise in writing.
   d. This MoU entails no financial obligations or student placement commitments on PMA.
   e. The DPGU SMR shall actively participate in PMA-led initiatives.

D. **Intellectual Property**: All research outputs and publications from joint activities will be shared between both parties.

E. **Duration and Renewal:** This MoU is valid for a period of two (2) years from the date of signing and may be renewed or modified by mutual written consent.

F. **Amendments:** Any amendments must be made through a written agreement signed by authorized representatives. In the event of disagreements, both parties commit to resolving issues amicably.

G. **PMA Membership**: All the activities mentioned above shall be exclusively for PMA Members. The DPGU SMR is expected to:
   a. Obtain Institutional Membership of PMA and/or establish the PMA Student Branch at the DPGU SMR Campus.
   b. DPGU SMR is nominating its Department of Consultancy, MDP and Applied Research through Dr. Dhananjay Pingale to oversee MoU activities.
   c. Encourage faculty and students to join PMA and actively participate in the Student Chapter.

H. **Termination:** This MoU may be terminated at any point by either party with prior one month's written notice. Any ongoing activity at the time of termination shall be completed as agreed.

PUNE MANAGEMENT ASSOCIATION PMA F1011

I. **Publicity and Promotion:** Both parties agree to promote events, programs, and collaborations through their respective communication channels including social media and websites.

J. **Signatories:** In witness whereof, the representatives of both organizations affix their signatures to this agreement:

Organization	Pune Management Association	DPGU SMR, Pune
Signature		
Name	Mr. Pradeep Tupe	Dr. Vishal Wadajkar
Designation	Vice-President	Director
Date	14/10/2025	14/10/2025

K. **Witnesses:**

Organization	Pune Management Association	a. DPGU SMR
Signature		
Name	Sunil R. Harpude	Dr. Dhananjay Pingale
Designation	Jt. Secretary.	Associate Professor
Date	14/10/2025	14/10/2025

Sr.no	Name	Designation	email-id	Contact details
01	Rahul Joshi	PMA Coordinator	rahul@smjc.co.in	9823534191
02	Dr. Dhananjay Pingale	Associate Professor	dhananjay.pingale@dypdpu.edu.in	9921791252

Date & Place: 14/10/**2025, Pune, India**



MOU

DNYAN PRASAD GLOBAL UNIVERSITY

AND

INDIAN SOCIETY FOR TRAINING AND DEVELOPMENT

2025-26

Memorandum of Understanding

On

"Industry Academia Linkage"

Between

ISTD (Pune)

and

DPGU SMR, Pune.

1st Sept. 2025

Memorandum of Understanding on "Industry Academia Linkage" With ISTD Pune Chapter and Dnyaan Prasad Global University's School of Management & Research, Tathawade, Pune

ISTD Pune Chapter and DPGU

This agreement is made on 1st Sept. 2025

BETWEEN

Dnyaan Prasad Global University's School of Management & Research, Tathawade, Pune is a private university with UGC approved programs, having its campus at Survey No. 138, Jeevan Nagar, Tathawade, Pune, Maharashtra, India. **Dr. Vishal Wadajkar**, **Director, DPGU SMR** is duly authorized to sign and execute this agreement on behalf of DPGU SMR. Though, Dr. Dhananjay Pingale, Head-Consultancy, MDP and Applied Research will be the single point of contact for execution of this MoU.

AND

Indian Society of Training & Development, Pune Chapter (hereinafter referred to as ISTD), established in April 1970, a national level professional & non-profit society registered under the Societies Registration Act, 1860 and represented through **Mr. Ravindra Baviskar**, **Chairman, ISTD Pune Chapter**, who is duly authorized to sign and execute this Agreement on behalf of ISTD, Pune chapter.

The Indian Society for Training & Development, established in April 1970, a national level professional & non-profit society registered under the Societies Registration Act, 1860. It has a large membership of individuals and institutions involved in the area of training and development of Human Resource from Government, Public and Private Sector Organizations &Enterprises, Educational and Training Institutions and other Professional Bodies. The Society is affiliated to the International Federation of Training and Development Organizations (IFTDO), Geneva and Asian Regional Training and Development Organizations (ARTDO), Manila. The Indian Society for Training & Development Organizes Training Programs, all over the country both at Chapter and National Levels. The programs cover selected areas of HRD with special emphasis on Training of Trainers, Training Goals & Objectives and Training tools & Technologies. A very large number of Public & Private Sector Organizations, Training Institutions Central and State Government Participate in these programs, some of which have been held in collaboration with Planning Commission, Bureau of Public Enterprises and the Training Division of Department of Personnel, Government Of India.

Dnyaan Prasad Global University's School of Management & Research:

Dnyaan Prasad Global University's School of Management and Research (DPGU SMR) is committed to revolutionize management education in India, with a strategic vision to emerge as a premier business Institute. As an integral constituent of the esteemed DPGU, the institute synergizes academic meticulousness with a dynamic learning ecosystem to cultivate future leaders who can navigate the complexities of the global business landscape. Whereas, the institute boasts state-of-the-art infrastructure and a distinguished faculty comprising accomplished scholars and industry practitioners, who collectively strive to deliver innovative and industry-relevant management programmes that align with the evolving needs of the corporate world. By emphasizing experiential learning, the institute enables students to acquire practical insights and develop strategic thinking skills, thereby empowering them to tackle complex business challenges effectively.

The Department of Consultancy, MDP and Applied Research at Dnyaan Prasad Global University's School of Management and Research is a strategic hub for business innovation, policy advocacy, and academic-industry collaboration. It drives impactful research and consultancy projects across sectors such as healthcare, education, skill development, and corporate strategy. Also the department has completed projects with the United Nations Agencies like ILO and UNICEF. Through its MDP initiatives, the department empowers professionals with industry-relevant training, offering 42 specialized modules co-designed with ISTD and industry leaders. Applied research efforts include policy briefs, interdisciplinary studies and CSR implementations, contributing to national development agendas and institutional growth. The department also hosts Technical Experience Centre (TEC), a cutting-edge facility offering immersive, hands-on training in Blockchain, Internet of Things (IoT) and Cyber Security, anchored by industry-grade labs and professional tools. TEC features India's first fully functional Blockchain lab in higher education, 39,000+ IoT devices, and over 90 advanced forensic kits for cyber-crime investigation and secure data recovery.

DPGU SMR wishes to be an "Academic Partner" of ISTD with mutually beneficial association by way of signing this MOU in the areas of their interests.

The following are the areas of mutual cooperation:

1. **Academic Participation**: ISTD will work with DPGU SMR, Pune in designing practical sessions as per the syllabus and industry preferences related to case study orientations and simulation processes etc. ISTD will nominate interested and competent Industry professionals to work closely with academic staff members of DPGU SMR.

2. **Research and live Projects**: ISTD will endeavour to outsource the Industry based Projects in areas like HR, Marketing, Finance and General Management

to DPGU SMR. Also, DPGU SMR Faculty members and students will take up the respective Projects in collaboration with ISTD.

3. **Joint Research initiatives:** DPGU SMR and ISTD would take up Joint Research initiatives in areas of mutual interest. These initiatives may take the form of Literature review / white papers / position papers / review papers / empirical research / policy briefs on areas of relevance. The same may be published by DPGU SMR.

4. **Mentoring:** DPGU SMR welcomes industry professionals from ISTD to mentor DPGU SMR students on an ongoing basis or one a one-off basis

5. ISTD will arrange Corporate Lectures, Short duration Programmes, Grooming Sessions for the DPGU SMR Students and Faculty Development Programmes, Train the Trainer workshop for the DPGU SMR Faculty members and students. Such sessions will be aimed to bridge the gap between the Classroom training and the Corporate requirements.

6. ISTD will also provide exposure to the faculties of DPGU SMR in ISTD-led corporate training. This will not be based on commercials but to provide exposure to the faculties. On the mutual understanding of both the parties DPGU SMR seeks support from ISTD in the various verticals of DPGU SMR such as, corporate consultancy, MDP, applied research, Technical Experience Center, Public Policy Analysis etc. This collaboration will be discussed and decided with mutual consultations considering a case by case approach.

7. **Faculty Development Programmes**: ISTD and DPGU SMR shall jointly organize faculty development programmes.

8. **Corporate Interviewing Activity:** ISTD will help in organizing interviews to be conducted by the students guided by the faculty members, with CEO's or Senior Management personnel. The corporate interview activity helps the students to appreciate and understand the role of a senior manager in the industry, study the career graph of an individual, understand the workplace responsibilities, commitments, and thus helps in bridging the institute industry gap. This activity also helps in motivating the students to excel and to become successful leaders. These interviews can be published in the form of an interview. DPGU SMR seeks support from ISTD in this activity

9. **Summer Projects:** Students of Management Course need to undergo at least two months summer training with an organization. This gives the students actual know-how of the industry and thus provides practical exposure. DPGU SMR would like to explore such opportunities with ISTD or through a network of ISTD members / professionals.

10. **Guest Lectures:** DPGU SMR would like to invite experts from ISTD for guest lectures to share their experiences with students; which would help them understand the expectations of industry from the management graduates. DPGU SMR would also like to invite such experts from ISTD as keynote speakers for induction, seminars and other institutional activities. This will be free of cost, intellectual interaction and exchange of resource persons.

11. **Industry Visits:** DPGU SMR would like to organize industry visits for students and faculty to get an exposure to real life industry practices. ISTD can support DPGU SMR in such activities.

12. DPGU SMR shall provide its infrastructure free of cost for pre-identified joint events and access to ISTD members to its library and IT resources, when not in college use.

13. DPGU SMR shall provide its students as volunteers free of cost for pre-identified ISTD events.

14. The duration of the MOU between ISTD and DPGU SMR is for three years from the date of signing. This agreement can be further renewed by the consent of both the parties. Need based editions and alterations in this MoU are desirable. These future changes will be made as an addendum to this MoU and will be treated as an official part of this MoU.

Signed on this Wednesday 1st Sept. 2025 at Pune.

For the DPGU SMR

Sign:
Name: Dr. Vishal Wadajkar
Designation: Director, DPGU-SMR
Dean-Faculty of Commerce
& Management

Witness

Sign:
Name: Dr. Dhananjay Pingale
Designation: Associate Professor
Head-Consultancy, MDP &
Applied Research

For the ISTD:

Sign:
Name: Mr Ravindra Baviskar

Designation: Chairperson ISTD, Pune

Witness

Sign:
Name: Dr Rashmi Hebalkar,
Head, MoU Committee, ISTD Pune
Designation: National Council Member,
STD PUNE chapter
Diploma In charge, ISTD Pune centre

DYP DPU Dr. D. Y. Patil Dnyan Prasad University's
School of Management and Research, Pune

ISRN

MEMORANDUM OF UNDERSTANDING (MoU)

BETWEEN

DNYAAN PRASAD GLOBAL UNIVERSITY's

SCHOOL OF MANAGEMENT & RESEARCH

AND

INDIAN SOCIAL RESPONSIBILITY NETWORK

This Memorandum of Understanding (MoU) is entered into on Dated: 01st October 2025 (hereinafter referred to as the "MoU') made between

Dnyaan Prasad Global University's School of Management & Research, a post graduate management education institute working under the Dr. D. Y. Patil Unitech Society and having its campus at Survey No. 138, Jeevan Nagar, Tathawade, Pune- 411 038 (hereinafter referred to as the "DPGU SMR", which expression shall unless repugnant to the context or meaning thereof mean and include its successors and permitted assigns) of the FIRST PART.

AND

Indian Social Responsibility Network , a a non-profit organization registered under the Indian Trust Act in July 2014, having its Head Office A-85, Ground Floor, East of Kailash, New Delhi - 110065, (hereinafter referred to as the **"ISRN"**, which expression shall, unless repugnant to the context or meaning thereof, mean and include its successors and permitted assigns) of the SECOND PART.

WHEREAS:

A. DPGU SMR and ISRN are referred to individually as **"PARTY"** and collectively as **"PARTIES"**.

B. DPGU SMR Dnyaan Prasad Global University's School of Management and Research (DPGU SMR) is committed to revolutionize management education in India, with a strategic vision to emerge as a premier business Institute. As an integral constituent of the esteemed DPGU, the institute synergizes academic meticulousness with a dynamic learning ecosystem to cultivate future leaders who can navigate the complexities of the global business landscape. Whereas, the institute boasts state-of-the-art infrastructure and a distinguished faculty comprising accomplished scholars and industry practitioners, who collectively strive to deliver innovative and industry-relevant management programmes that align with the evolving needs of the corporate world. By emphasizing experiential learning, the institute enables students to acquire practical insights and develop strategic thinking skills, thereby empowering them to tackle complex business challenges effectively.

The Department of Consultancy, MDP and Applied Research at Dnyaan Prasad Global University's School of Management & Research is a strategic hub for business innovation, policy advocacy, and academic-industry collaboration. It drives impactful research and consultancy projects across sectors such as healthcare, education, skill development, and corporate strategy. Also the department has completed projects with the United Nations Agencies like ILO and UNICEF. Through its MDP initiatives, the department empowers professionals with industry-relevant training, offering 42 specialized modules co-designed with ISTD and industry leaders. Applied research efforts include policy briefs, interdisciplinary studies and CSR implementations, contributing to national development agendas and institutional growth. The department also hosts Technical Experience Centre (TEC), a cutting-edge facility offering immersive, hands-on training in Blockchain, Internet of Things (IoT) and Cyber Security, anchored by industry-grade labs and professional tools. TEC features India's first fully functional blockchain lab in higher education, 39,000+ IoT devices, and over 90 advanced forensic kits for cyber-crime investigation and secure data recovery.

C. ISRN is established in 2014, is a multi-dimensional facilitation network with over 800 member organizations, engaged with sustainable development programs with a vision to level up India into a developed nation through a participatory approach for the holistic development of rural and sub-urban communities. ISRN has been able to deliver on the lines of the Sustainable Development Goals and have initiated result-oriented impactful sustainable solutions in the sectors of Capacity Building, Research & Development and Model Project Implementation including Education, Health and Agriculture.

D. The Parties are desirous to collaborate to initiate and complete projects that included but are not limited to work on broader perspective of nation building through, joint research, policy briefs, workshops, etc. in any suitable sector, as per the mutual discussion. The specifics of the collaboration are mentioned in the proposal, hereinafter referred to as the Project in **Annexure A**.

E. The Parties shall adhere to the Standard Terms as listed in **Annexure B**.

NOW THIS MOU WITNESSETH AND IT IS HEREBY AGREED BY AND BETWEEN THE PARTIES AS FOLLOWS:

1. **BACKGROUND AND PURPOSE**

DPGU SMR and ISRN have decided to work together to initiate and complete projects that include but are not limited to work on a broader perspective of nation building through joint research, policy briefs, workshops, etc. in any suitable sector, as per mutual discussion. Each party will contribute towards this Project as defined and agreed roles and responsibilities set out in the joint proposal attached as **Annexure A**.

2. **GOVERNANCE MECHANISM**

2.1. Both Parties shall constitute an appropriate mechanism for mutual governance and control of the Purpose through **Dr. Vishal Wadajkar, Director and Dr. Dhananjay Pingale, Associate Professor (DPGU SMR)** or his designee, and **Mr. Santosh Gupta (ISRN)** or his designee. Such committees will meet periodically or need a basis at mutual consent.

2.2. Both Parties will meet periodically to review, monitor, and comment on key activities and deliverables. The committee will undertake joint progress review as a part of experience sharing and further planning, on a quarterly basis and on need basis at mutual consent.

2.3. Both Parties shall provide access to each other's staff and keep informed of any material developments or proposals in relation to the business or operations of any Party and its subsidiaries that may have any effect on the partnership.

3. **DURATION OF THE MOU**

The terms of the MoU, unless mutually terminated, shall be from the effective date, i.e., the date of signing and up to a period of two (2) years and extendable as per the project requirements and as per the understanding and agreement between the Parties with written consent by each party.

4. **INTELLECTUAL PROPERTY RIGHTS**

Both Parties agree that any intellectual property which is jointly developed through activities covered under this MoU can be used by either Party. This association will not affect the IPR ownership of pre-existing materials, and each Party will continue to have ownership of its pre-existing materials, with no claim by the other Party.

5. **BRANDING, MARKS AND LOGO**

Both Parties agrees that it shall not:

i. represent, or permit the representation of, the other Party's views without other Party's prior written consent; or

ii. use, or permit the use of the other Party's name, marks or logos in any advertisements, promotional literature or information without other Party's prior written consent, and if such other Party does so consent, it shall use the name, marks and logos strictly in accordance with the permission provided and with the insertion of such disclaimers as the permitting Party shall request.

IN WITNESS THEREOF, all PARTIES have affixed their signatures hereto as of the day and year first written above.

SIGNED ON BEHALF OF DNYAAN PRASAD GLOBAL UNIVERSITY'S SCHOOL OF MANAGEMENT & RESEARCH

NAME: Dr. VISHAL WADAJKAR

DESIGNATION: DIRECTOR

DATE: 01st October 2025

SIGNED ON BEHALF OF INDIAN SOCIAL RESPONSIBILITY NETWORK



NAME: Mr. SANTOSH GUPTA

DESIGNATION: CHIEF EXECUTIVE OFFICER

DATE: 01st October 2025

ANNEXURE A: BROAD SCOPE OF WORK

For the proposed partnership of DPGU SMR with ISRN, the Parties agreed to leverage the expertise and experience of the Parties and thereby benefit from the collaboration. The understanding between the two parties:

a) The collaboration will include, but will not be limited to, co-hosting events, participation in grand challenges and request for proposals (RFP), technology and innovation evaluations, end-user feedback and knowledge sharing, knowledge management, thought leadership, publications, contribution of problem statements to source the right interventions.

b) The Parties will also work towards promoting and supporting startups to distribute their solutions and technologies via each other's platform and network.

c) The parties will share their Expert Connects and market reach opportunities as per the mandate of the respective organizations.

d) Both parties' processes and guidelines remain paramount, and nothing under this MOU shall supersede those provisions.

e) Both Parties acknowledge and agree that it is not the purpose of this MoU to create a partnership, joint venture, or similar arrangement whereby the Parties could be held jointly liable vis-a-vis third parties or for any other purposes.

f) Nothing herein shall constitute a commitment by either Party to provide the other Party or parties with financing in respect of the Project or otherwise.

g) Each party will recognize the other as a technical/ ecosystem partner, subject to prior approval, and must obtain explicit consent before displaying the partner's logo on any platform.

Both ISRN and DPGU SMR agree to collaborate in the following broad areas of work, recognizing that activities may evolve based on emerging opportunities and mutual agreement:

Role of DPGU SMR

1. Share updated portfolio of solutions supported under DPGU SMR for exploring potential funder profiles.
2. Facilitate timely availability of proposals, concept notes, or other documents required for advancing fundraising leads.
3. Share and pursue collaboratively with ISRN, keeping ISRN informed.
4. Sharing of financial resources & payments with ISRN as per the agreed terms and conditions
5. Invite ISRN to relevant DPGU SMR events for participation, speaker opportunities and collaboration.
6. Include ISRN as an implementing agency in proposals where suitable, depending on team presence, geography and capabilities and accordingly facilitate financial engagement towards the same.

Role of ISRN

1. Partner with DPGU SMR as an implementing and fund-sourcing agency for projects and technologies supported under DPGU SMR.
2. Co-create implementation plans for rolling out/piloting DPGU SMR supported products/technologies in communities/public health facilities.
3. Generate leads and follow up with corporate donors, CSR foundations, philanthropies and HNIs.
4. Facilitate meetings with relevant government stakeholders at national, state, and district levels.
5. Share and pursue collaboratively with DPGU SMR, keeping DPGU SMR informed.
6. Explore opportunities to include DPGU SMR supported solutions in ongoing ISRN projects.
7. Provide relevant capacity-building support during implementation.
8. Invite DPGU SMR to relevant ISRN events for participation, speaking opportunities and collaboration.

Joint Deliverables

1. Jointly co-create and pursue fundraising proposals and ensure branding of both the organizations.
2. Co-host or collaborate in relevant events, consultations and workshops.
3. Engage in joint advocacy with stakeholders.
4. Share knowledge, case studies, and best practices for wider dissemination and impact.
5. For each of the successful proposals ISRN will help in implementing the project depending on its capacity of execution or any alternative mutually agreed; DPGU SMR will provide technology, research and technical support also will help in implementing projects. This aspect will be pre-decided based on mutual understanding at the time of preparing proposals before submitting it.
6. This Memorandum of Understanding outlines the broad areas of collaboration; however each specific projectshall be independently negotiated between the parties with respect to its scope of work, deliverables and financial terms.
7. Both parties shall retain the freedom to undertake and execute independent projects outside the scope of this MoU, without any obligation to the other party.



ANNEXURE B: STANDARD TERMS OF THE MoU

1. **AUTHORIZATIONS**

Both Parties shall obtain and maintain, in effect at all times, all governmental, administrative, and other authorizations necessary for the implementation of this Agreement.

2. **REPORTS AND DOCUMENTS**

All reports and documents prepared by or with any of the Party's assistance may be distributed by other Party as needed among its staff, and officers. The Distributing Party shall acknowledge the Contributing Party in such publication.

3. **DISCLAIMERS AND INDEMNITY**

Neither Party shall make any express or implied representation or warranty as to the accuracy, completeness or sufficiency of any reports, analyses or memoranda prepared by, or with the assistance of, such Party.

In case of any breach of any terms and conditions or any and all liabilities, claims, lawsuits, including any and all awards and/or judgments to which it may become subject, insofar as said liabilities, claims and lawsuits (including costs, expenses, awards and/or judgments) arising by virtue of performance of this MoU unless a court of competent jurisdiction determines by final judgment that such loss, damage or liability was the result of gross negligence or willful misconduct on the part of such Party, each Party agrees to indemnify and hold each other harmless against any and all liabilities, losses, costs, claims, expenses or damages suffered or incurred by the Parties at any time which arise directly or indirectly from any such actions.

4. **DELAYS IN PROJECT IMPLEMENTATION**

Under the terms of this Agreement, neither Party shall be liable to the other for any delay or failure to fulfill its obligations under this MoU to the extent that any such delay or failure arises from causes beyond its control, including but not limited to, fire, floods, acts of God, acts or regulations of any governmental or supranational authority, war, riot, strike, lockout or industrial disputes.

5. **CONFIDENTIALITY**

Either Party, their staff, employees and advisers will treat Information provided to them by the other Party as confidential subject to the following terms. "Information" refers to any and all non-public financial, technical, strategic, commercial or other information concerning the business and affairs of any of the Parties (whether prepared by the Party, its advisers or otherwise) that is provided by or on behalf of the Party, on or after the date hereof, but does not include (a) information which was already in the other PARTY's possession prior to the date hereof; (b) information which is or hereafter becomes generally available to the public other than as a result of a disclosure by any of the PARTIES in violation of the MoU; or (c) information obtained from a third PARTY which to the best of knowledge and after due inquiry was not provided in breach of the third PARTY's confidentiality obligations.

Notwithstanding anything to the contrary contained herein, it is understood that Parties may disclose the Information or portions thereof (a) at the request of any regulatory, supervisory or governmental authority, institution or department; or (b) under court process or pursuant to any statutory

requirement; or (c) to auditors, external counsel or accountants but subject to such recipients agreeing to keep such Information confidential.

6. **COMMUNICATION AND PUBLICITY**

Both Parties agree that there will be publicity opportunities to help multiple audiences better understand the issue associated with the project. The same may be communicated and publicized to the relevant audience through events, conferences, workshops, meetings, advertisements, word of mouth, emails, social media etc. Towards the same communication materials may be built to effectively reach the target audience vide PPT, press releases as appropriate, fact sheets, and success stories. The Distributing Party shall acknowledge the Contributing Party in such communication where applicable.

7. **NO PARTNERSHIP, JOINT VENTURE OR INVESTMENT COMMITMENT**

Both Parties acknowledge and agree that it is not the purpose of this MoU to create a partnership, joint venture or similar arrangement whereby the Parties could be held jointly liable vis-a-vis third parties or for any other purposes.

Nothing herein shall constitute a commitment by either Party to provide the other Party with financing in respect of the Project or otherwise.

Both Parties agrees that they shall not engage in (or authorize or permit any person or entity acting on its behalf to engage in) any corrupt, fraudulent, coercive, collusive or obstructive practices with respect to the Project or any transaction contemplated by this MoU.

8. **SETTLEMENT OF DISPUTES**

This MoU is governed by and shall be construed in accordance with the laws of India.

The Parties undertake to endeavor in good faith to resolve any differences and disputes arising under, or in connection with, this Agreement by amicable settlement.

Absent amicable settlement, all disputes arising out of or in connection with this Agreement shall be finally settled under the Rules of Delhi High Court (the "Rules") by one or more arbitrators appointed in accordance with the Rules. The place of arbitration shall be Delhi, and the language of the arbitration shall be English.

Both Parties acknowledge and agree that no provision of this MoU or of the Rules, nor the submission to arbitration by the Parties, in any way constitutes or implies a waiver, renunciation, termination, or modification of any of the Parties' privileges, immunities or exemptions granted in the Parties' Articles of Agreement, or under any applicable law.

Both Parties irrevocably waive any immunity they may have or become entitled to from any judicial proceedings, in any jurisdiction whatsoever, brought for the purpose of enforcing this agreement to arbitrate or any award issued pursuant thereto, or of securing the issuance of any provisional or interim remedy, including but not limited to injunction, attachment or sequestration, or of effecting execution of any such award, and further waives any immunity they might otherwise have or enjoy from any order or judgment imposing any such remedy or effecting such execution.

9. **AMENDMENTS**

Any amendment or waiver of, or any consent given under, any provision of this MoU shall be in writing and, in the case of an amendment, shall be effective only if signed by all Parties.

10. **SUCCESSORS AND ASSIGNEES**

This MoU binds and benefits the respective successors and assignees of the Parties, provided that no Party may assign this MoU as a whole or in part without the prior written consent of the other.

11. **FORMAL COMMUNICATIONS**

Any notice, request or other formal communication to be given or made under this MoU shall be in writing and shall be deemed to have been duly given when delivered by hand, airmail, established courier service, or facsimile to the recipient at the respective addresses listed below, or at such other address as designated by a subsequent notice in writing. All further correspondence regarding the implementation of this MoU should be addressed to:

FOR ON BEHALF OF DNYAAN PRASAD GLOBAL UNIVERSITY'S SCHOOL OF MANAGEMENT & RESEARCH:

Attention: **DR. VISHAL WADAJKAR, DIRECTOR** at **SCHOOL OF MANAGEMENT & RESEARCH**; **Contact No.**: 9881377547;

FOR ON BEHALF OF INDIAN SOCIAL RESPONSIBILITY NETWORK:

Attention: **Mr. SANTOSH GUPTA, CHIEF EXECUTIVE OFFICER** at **INDIAN SOCIAL RESPONSIBILITY NETWORK (ISRN)**; **Contact No.**: 9711522271

12. **TERMINATION**

Each of the Parties shall have the right to terminate this MoU without cause, by giving the other Party written notice at least thirty (30) calendar days prior to the effective date of termination.

Notwithstanding anything herein or elsewhere in this MoU, the provisions of the following Sections shall survive the termination of this Agreement: Intellectual Property Rights, Branding, Marks and Logo, Reports and Documents, Disclaimers and Indemnity, Confidentiality, Communication and Publicity.

13. **ENTIRE AGREEMENT AND COUNTERPARTS**

This MoU, together with all its Annexes, constitutes the entire agreement between the Parties and supersedes any and all prior agreements, understandings and arrangements, oral or written, between them with respect to the subject matter hereof. If any provision of this MoU shall be held to be invalid, illegal or unenforceable, the validity of all other provisions hereof shall in no way be affected thereby, and this MoU shall be construed and be enforceable as if such invalid, illegal or unenforceable provision had not been included in this MoU.

This MoU may be executed in several counterparts, each of which is original but all of which constitute the same agreement.



MOU

DNYAN PRASAD GLOBAL UNIVERSITY

AND

DISTRICT INDUSTRIES CENTRE PUNE

2025-26

MEMORANDUM OF UNDERSTANDING (MoU)

BETWEEN

District Industries Centre Pune
Agriculture College Campus Shivajinagar
Pune, Maharashtra, 411005.

&

Dnyaan Prasad Global University's
School of Management & Research
Survey No. 138, Jeevan Nagar, Tathawade, Pune-411033

FOR

Agriculture and Non- Agriculture One District One Product Branding and Promotion and Geographical Indication

MEMORANDUM OF UNDERSTANDING

This **Memorandum of Understanding** (hereinafter called as the 'MOU') is entered into on this the 01 day of Oct. 2025, for organizing the entrepreneurship development activities by and between

District Industries Centre (DIC) Pune represented herein by its **General Manager** (hereinafter referred as **"First Party"**, the institution which expression, unless excluded by or repugnant to the subject or context shall include its successors – in-office, administrators and assigns).

AND

Dnyaan Prasad Global University's School of Management & Research, Survey No. 138, Jeevan Nagar, Tathawade, Pune - 411 033 and represented herein by its- **Director** (hereinafter referred to as, organization which expression, unless excluded by or repugnant to the subject or context shall include its successors – in-office, administrators and assigns).

(First Party and Second Party are hereinafter jointly referred to as 'Parties' and individually as 'Party')

WHEREAS:

A) First Party is a District Level Government Body: **District Industries Centre, Pune.**

B) **District Industries Centre (DIC) Pune & Dnyaan Prasad Global University's School of Management & Research, Tathawade, Pune** believe that collaboration and co-operation between them will promote more effective use of each of their resources, and provide each of them with enhanced opportunities.

C) The Parties intend to cooperate and focus their efforts on cooperation within the area of One District One Product branding and promotion.

D) Both Parties, being legal entities in themselves desire to sign this MOU for advancing their mutual interests.

E) **Dnyaan Prasad Global University's School of Management & Research, Tathawade**, and the Second Party committed to revolutionizing management education in India, with a strategic vision to emerge as a premier business school. As an integral constituent of the esteemed DYPDPU, the institute synergizes academic meticulousness with a dynamic learning ecosystem to cultivate future leaders who can navigate the complexities of the global business landscape.

NOW THEREFORE, IN CONSIDERATION OF THE MUTUAL PROMISES SET FORTH IN THIS MOU, THE PARTIES HERE TO AGREE AS FOLLOWS:

CLAUSE 1 CO-OPERATION

1.1 Both Parties are united by common interests and objectives, and they shall establish channels of communication and co-operation that will promote and advance their respective operations within the **Institution** and its related wings. The Parties shall keep each other informed of potential opportunities and shall share all information that may be relevant to secure additional opportunities for one another.

1.2 First Party and Second Party co-operation will facilitate effective utilization of the intellectual capabilities of the faculty of First Party providing significant inputs to them in branding and promotion of One District One Product (ODOP) of Pune District developing awareness about ODOP among students and giving projects related to ODOP to students for developing innovative and entrepreneurial side.

1.3 The general terms of co-operation shall be governed by this MOU. The Parties shall cooperate with each other and shall, as promptly as is reasonably practical, enter into all relevant agreements, deeds and documents (the 'Definitive Documents') as may be required to give effect to the actions contemplated in terms of this MOU. The term of Definitive Documents shall be mutually decided between the Parties. Along with the Definitive Documents, this MOU shall represent the entire understanding as to the subject matter hereof and shall supersede any prior understanding between the Parties on the subject matter hereof.

CLAUSE 2 SCOPE OF THE MoU

2.1 The budding graduates from the institutions could play a key role in branding and promoting One District One Product of the District. Both parties believe that close co-operation between the two would be of major benefit to the student community to enhance their skills and knowledge.

2.2 **ODOP products and GI products of Pune District:** As per the Industries department is concerned there is one Agriculture and Non-Agriculture ODOP product for a district. In Pune the Agriculture ODOP product is Frozen Food and Non-Agriculture ODOP product is engineering goods and Geographical Indication products are Purandar Fig, Puneri Pagadi and Ambemohar Rice. Second Party's students will get an opportunity to work on both Agriculture and Non- Agriculture ODOP and Geographical products projects and do branding and promotion of the same

2.3 **Awareness program:** First Party will give valuable input to the Second Party in designing an awareness program about ODOP and DIC scheme so that the students do various projects on ODOP along with the branding and promotion for the same.

2.4 **Industry Visits:** With the intervention of General Manager DIC Pune the students of Second Party can visit various industries, industries clusters of the district, meet industry experts pertaining to the projects of ODOP and other projects.

2.5 **Research and Development:** Both Parties have agreed to carry out the joint research activities in the fields of **branding and promotion of ODOP.**

CLAUSE 3 INTELLECTUAL PROPERTY

Nothing contained in this MOU shall, by express grant, implication, Estoppel or otherwise, create in either Party any right, title, interest, or license in or to the intellectual property (including but not limited to know-how, inventions, patents, copy rights and designs) of the other Party.

CLAUSE 4 VALIDITY

4.1 This Agreement will be valid until it is expressly terminated by either Party on mutually agreed terms, during which period **DIC**, the First Party, as the case may be, will take effective steps for implementation of this MOU. Any act on the part of Dnyaan Prasad Global University's School of Management & Research the Second Party after termination of this Agreement by way of communication, correspondence etc., shall not be construed as an extension of this MOU

4.2 Both Parties may terminate this MOU upon 30 calendar days' notice in writing. In the event of Termination, both parties have to discharge their obligations.

CLAUSE 5 RELATIONSHIP BETWEEN THE PARTIES

5.1 It is expressly agreed that District Industries Centre Pune and Dnyaan Prasad Global University's School of Management & Research are acting under this MOU as independent contractors, and the relationship established under this MOU shall not be construed as a partnership. Neither Party is authorized to use the other Party's name in any way, to make any representations or create any obligation or liability, expressed or implied, on behalf of the other Party, without the prior written consent of the other Party. Neither Party shall have, nor represent itself as having, any authority under the terms of this MOU to make agreements of any kind in the name of or binding upon the other Party, to pledge the other Party's credit, or to extend credit on behalf of the other Party.

District Industries Centre Pune
First Party

Dnyaan Prasad Global University's School of Management & Research
Second Party

Any divergence or difference derived from the interpretation or application of the MoU shall be resolved by arbitration between the parties as per the Arbitration Act, 1996. The place of the arbitration shall be at District Head Quarters of the First Party. This undertaking is to be construed in accordance with Indian Law with exclusive jurisdiction in the Courts of **Mumbai.**

AGREED:

For, **District Industries Centre Pune**

7/10/2025

Authorized Signatory

Archana Kothari

For, **Dnyaan Prasad Global University's School of Management & Research**

Authorized Signatory

Dr. Vishal Wadajkar, Director

District Industries Centre Satara Pune	**Dnyaan Prasad Global University's School of Management & Research**
Agriculture College Shivajinagar Pune -411005	Survey No. 138, Jeevan Nagar, Tathawade, Pune- 411038.
Contact Details: 7620293491	Contact Details: 9921791252
E-mail: didic.pune@maharashtra.gov.in	E-mail: dhananjay.pingale@dypdpu.edu.in
Web: www.di.maharashtra.gov.in	Web: https://smr.dypdpu.edu.in/

Witness 1:

Shri. Yashwant Gaikwad
Manager DIC, Pune

Witness 2:

Dr. Kiran Kale,
Head-Management Studies

Witness 3:

Srijeet R Nair, EY LLP

Witness 4:

Dr. Dhananjay Pingale
Head-Consultancy, MDP, Applied Research

Dnyaan Prasad Global University's School of Management & Research Survey No. 138, Jeevan Nagar, Tathawade, Pune - 411033	**BRANDTOUCH & ANALYTICS PRIVATE LIMITED,** **N.M. Joshi Marg, Lower Parel (West), Mumbai 400013**

MEMORANDUM OF UNDERSTANDING

BETWEEN

Dnyaan Prasad Global University's
School of Management & Research

AND

BRANDTOUCH & ANALYTICS PRIVATE LIMITED

For

Business Development and Marketing Promotional Consultancy

About Dnyaan Prasad Global University's School of Management & Research

DPGU SMR is committed to revolutionizing management education in India, with a strategic vision to emerge as a premier business institute. As an integral constituent of the esteemed Dnyaan Prasad Global University, the institute synergizes academic rigor with a dynamic learning ecosystem to cultivate future leaders capable of navigating the complexities of the global business landscape.

The institute boasts state-of-the-art infrastructure and a distinguished faculty comprising accomplished scholars and industry practitioners. Together, they strive to deliver innovative and industry-relevant management programs that align with the evolving needs of the corporate world. By emphasizing experiential learning, the institute enables students to acquire practical insights and develop strategic thinking skills, thereby empowering them to tackle complex business challenges effectively.

Department of Consultancy, MDP and Applied Research

The Department of Consultancy, MDP and Applied Research at Dnyaan Prasad Global University's School of Management & Research serves as a strategic hub for business innovation, policy advocacy, and academic–industry collaboration. It drives impactful research and consultancy projects across sectors such as healthcare, education, skill development, and corporate strategy.

The department has successfully completed projects with United Nations agencies such as the International Labour Organization (ILO) and UNICEF. Through its Management Development Programme (MDP) initiatives, the department empowers professionals with industry-relevant training, offering 42 specialized modules co-designed with ISTD and leading industry experts.

Applied research efforts include policy briefs, interdisciplinary studies, and CSR implementations that contribute to national development agendas and institutional growth.

The department also hosts the Technical Experience Centre (TEC) — a cutting-edge facility offering immersive, hands-on training in Blockchain, Internet of Things (IoT), and Cyber Security, supported by industry-grade labs and professional tools. TEC features India's first fully functional blockchain lab in higher education, over 39,000 IoT devices, and more than 90 advanced forensic kits for cyber-crime investigation and secure data recovery.

About

BRANDTOUCH & ANALYTICS PRIVATE LIMITED

BRANDTOUCH & ANALYTICS PRIVATE LIMITED, a company registered under the Indian Companies Act, 2013 bearing CIN no. U93000MH2015PTC266534 having its registered office at 107, SunMill Compound, N.M. Joshi Marg, Lower Parel (West), Mumbai 400013 (herein referred to as "BrandTouch" / "BTA" which expression shall, unless repugnant to the subject or context thereof shall mean and include its affiliates and associates and permitted substitutes or assigns and group companies, incorporated or to be incorporated) of the ONE PART.

MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding (hereinafter called as the 'MOU') will be effective from 7th Day of November Two Thousand and Twenty-Five (07/11/2025) to financial year ending i.e. 31st march 2028, by and between

Dnyaan Prasad Global University's

School of Management & Research, Pune

(Hereinafter referred as 'INSTITUTE')

AND

BRANDTOUCH & ANALYTICS PRIVATE LIMITED

(Hereinafter referred as 'CLIENT')

(Institute and CLIENT are hereinafter jointly referred to as 'Parties'.)

WHEREAS:

A) **The INSTITUTE** agrees to provide consultancy support and professional services to the **CLIENT** for the development, promotion, and strategic positioning of its BRANDTOUCH & ANALYTICS PRIVATE LIMITED promotional assignment. This Memorandum of Understanding (MoU) outlines the scope of consultancy to be rendered by the INSTITUTE to the CLIENT across multiple functional domains, as detailed below.

B) **Purpose**

1. Client is in the business of providing Campus engagement activities including but not limited to Soft Skill Trainings, Technical Trainings, Sponsorships, Events and more. Such programs may be BTA's proprietary programs, brand-sponsored programs, or programs jointly developed by BTA and the Institute, Designed to benefit students from other colleges across Pune, this promotional activity aims to enhance their knowledge by creating awareness about health and hygiene.
2. The purpose of this MoU is to promote health awareness among students through campaign activities
3. The purpose of this MoU is to established a mutual understanding regarding sponsorship support by Brandtouch & Analytics in return for students registration facilitated by DPGU School of Management & Research.

C) **Objective:**

1. Students of the Institute shall actively be engaged in the promotion of brands through various campaigns, events, and registration drives conducted under the scope of this MOU.

2. This Memorandum of Understanding (MOU) is specifically intended for Brand Promotion and Commercial engagement between the Parties.

D) Commercial Aspect of strategic partnership The Parties agree that sponsorships which shall be calculated as the annexure mentioned below.

Slabs	Rs per Registrations	Total Amount	Working	Criteria
0 to 15000 Registrations	10	150000	Total Amount Considered as Example for 10 x 15000	Speaker and promoter to be managed by brandtouch
15001 to 50000 Registrations	15	525000	Total Amount Considered as Example for 15 x 35000	Speaker and promoter to be managed by brandtouch
50001 and Above Registrations	20	1100000	Total Amount Considered as Example for 20 x 55000	Speaker and promoter to be managed by brandtouch

The above annexure is applicable until 28th February 2026.

E) Payment timeline: Payments will be processed at the end of each month, subject to receipt and verification of the agreed registrations.

F) Term and Termination: The term of this engagement under the MOU will be upto 31st march 2028 from the Effective Date, ("7th November 2025"). The MOU may be extended for the said date on mutual agreement beyond the Initial Term.

G) The INSTITUTE will take care of all the required human resource for attaining the objectives as mentioned above.

H) Either party may use the other's logo (subject to adhering to the brand manual guidelines) or branding materials for promotional purposes, only with mutual consent

The authorized representative of the "INSTITUTE" will be the **Director**, ***Dr. Vishal Wadajkar,*** and the point of contact on behalf of the INSTITUTE will be ***Dr. Dhananjay Pingale, Associate Professor, Head Consultancy, MDP & Applied Research.***

- Any dispute between the parties shall always be resolved by mutual consultation without any resort to arbitration or other form of legal remedy including resort to court of law.
- This Memorandum of Understanding will be effective up to from the date of signing this agreement. Either party may terminate the MOU by serving prior written notice of 30 days to the other party without assigning any reasons thereof.
- Any notice, or communications required to be given by the parties shall be addressed to the parties at the address specified at the first page of this MoU.

Terms and Conditions:

1. If any project results in proprietary outputs (such as client-specific methodologies, custom research frameworks, or sensitive business insights), the rights to such outcomes, including intellectual property and commercialization, shall be mutually discussed and finalized on a case-by-case basis.
2. All data, reports, and deliverables developed under this collaboration shall remain confidential and should be shared by BTA for some more research and consultancy purposes.

3. Neither party shall disclose or publish client information or work developed under this MoU without the written consent of the other party.
4. Any rights regarding intellectual property, licensing, publications, and financial benefits derived from jointly executed client work will be mutually agreed upon.
5. During the tenure of this MoU, both parties agree to maintain strict confidentiality of client details, research data, financial transactions, and project methodologies shared under this collaboration.
6. Both parties shall ensure that their respective teams and personnel do not disclose or misuse any information received under the scope of this MoU, except with prior written consent from the originating party.
7. Any amendment and/or addenda to this MoU shall be made in writing and duly signed by both parties.
8. This collaboration can be terminated by either party with a 30 days prior written notice. In case of ongoing project(s) at the end of this notice period, the MoU will be terminated only after completion of ongoing project(s) and honuring full and final financial settlements. A mutually agreed / signed written communication to that effect will be the instrument marking closure of collaboration.
9. Both parties commit to working in full coordination to ensure smooth and successful execution of all projects under this MoU.
10. In case of any dispute or difference arising out of or in connection with this MoU, both parties shall resolve the matter amicably through mutual consultation only.
11. After completion of the MoU term, the CLIENT shall have the **right to continue operating independently in the same domain,** and renewal of collaboration with the INSTITUTE may be discussed based on mutual interest.

In written, where both parties have set and signed the precept under this MoU under their respective seal of the parties on the day Month and year mentioned.

On behalf of

Dnyaan Prasad Global University's

School of Management & Research , Pune-411033

Name : Dr. Vishal Wadajkar

Designation : Director

Date: 10/11/2025

Dnyaan Prasad Global University's School of Management & Research, Survey No. 138, Jeevan Nagar, Tathawade, Pune-411033

Email : director.smr@dypdpu.edu.in

Website : https://smr.dypdpu.edu.in/

In Presence of:

Name : Dr. Kiran Kale

Designation : Head Management Program

Email : kiran.kale@dypdpu.edu.in

Date -10/11/2025

Name : Dr. Dhananjay Pingale

Designation : Head Consultancy, MDP & Applied Research

Email: dhananjay.pingale@dypdpu.edu.in

Date : 07/11/2025

On behalf of

BRANDTOUCH & ANALYTICS PRIVATE LIMITED

BrandTouch & Analytics Private Limited

Authorised Signatory

Name: Suresh Pradhan

Designation: Head of Operations

Date: 10/11/2025

Email: suresh.p@brandtouchindia.com

Website: https://brandtouchindia.com/

In Presence of:

Name: Sharvin Chaubal

Designation: Alliance Manager

Email: sharvin.c@brandtouchindia.com

Date: 10/11/2025